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Abstract 
Synthesis and Applications of Dirhodium Metallopeptides 
by 
Alexander Nikolaevich Zaykov 
The work describes the development of a new class of synthetic 
metallopeptides that features a dirhodium metal center. Combination of 
peptide and dirhodium properties leads to unique effects on peptide 
structure, peptide-protein interactions, and metal catalytic activity aimed at 
small molecule as well as protein substrates. Dirhodium is directly bound to 
carboxylate side chains of aspartate or glutamate yielding kinetically inert 
coordination complexes. This improves stability, allows purification and 
provides enhanced biocompatibility. Bridging of two side chains in the same 
sequence enables control of the peptide secondary structure. Dirhodium 
metallopeptides are applied to regulate coiled coil dimerization, stabilize and 
induce helical secondary structure, catalyze enantioselective organometallic 
transformation, and serve as ligands for proteins. These results lead to the 
development of hybrid organic-inorganic therapeutic agents, biological 
probes for study of protein-protein interactions, and enantioselective 
metallopeptide catalysis. 
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Chapter 1 
Thesis overview 
 Chapter 2 provides a brief overview of the design principles and 
peptide structural elements that are utilized in the engineering of 
metallopeptides and covers important functional applications that have been 
developed with metallopeptides structures. Examples are presented of the 
well-folded, metal-containing architectures with peptide structures spanning 
from the simple "-helix or !-hairpin motifs to the more complex multi-
peptide assemblies. Bringing a metal complex and a peptide into a single 
structure results in functions that can both be analogous and entirely unique 
to the functions of natural metalloproteins. The incorporation of redox-active 
metallocenters into a peptide scaffold was used to create systems capable of 
the electron transfer; short peptide tags that can bind luminescent lanthanide 
ions were utilized for imaging applications and protein structure 
characterization; and the selectivity of the catalytic metal centers was altered 
with peptides serving as the chiral ligands. 
Chapter 3 introduces dirhodium metal complexes, their structure, 
synthesis and applications. The catalytic properties of dirhodium are of 
particular interest because of their efficiency in the chemistry of diazo-
compounds. A number of synthetically useful transformations can be 
accomplished, such as C–H and X–H insertion (X = heteroatom), 
cycloaddition to the unsaturated bonds and ylide formation with electron 
rich atoms. The development of chiral dirhodium complexes ensured their 
utility in asymmetric organic synthesis. Dirhodium reactivity was also 
applied in the site-selective modification of protein substrates, selectively 
  2 
targeting exposed tryptophan residues on the protein surface. In addition to 
the applications of catalytic function, dirhodium complexes have shown the 
potential to be used as antitumor agents. The antitumor activity of dirhodium 
is similar to the cisplatin drug, proceeding through metal binding to a DNA 
strand.  A series of intercalating dirhodium complexes were also developed 
that are capable of cleaving DNA upon photoexcitation. 
The development of techniques allowing the attachment of a 
dirhodium metallocenter to peptide side-chain carboxylates is described in 
Chapter 4.1 Because typical methods for the synthesis of dirhodium 
complexes require high temperatures and organic solvents, a new approach 
had to be developed to be more compatible with peptide chemistry. 
Metallopeptides can be synthesized in mild aqueous conditions and high 
yields, employing dirhodium complexes with trifluoroacetate ligands as 
precursors. To eliminate the problem of multiple reactive centers with 
polycarboxylate peptides, a strategy utilizing orthogonally protected 
carboxylic amino acids was applied. Dirhodium metalation is generally 
robust, although it can be reversed through prolonged treatment with 
acetates at neutral pH. A metallopeptide, the sequence of which was derived 
from a !-hairpin motif of a “zinc finger” protein, was synthesized and 
structurally characterized by NMR, demonstrating the capability of bridging 
two carboxylic residues on the same peptide chain to form a well-defined 
metal macrocycle. 
Chapter 5 explores the capacity of dirhodium bridging metalation to 
enforce a peptide secondary structure.2 First, the heterodimerization of a 
coiled coil could be controlled through linking two distant residues on one of 
the peptides. Metalation results in the inability of this peptide to form a 
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coiled-coil assembly. The formation a coiled-coil structure can be initiated 
upon de-metalation by an acetate treatment. Second, dirhodium bridging of 
carboxylic residues positioned three and four residues apart constrains the 
peptide in an "-helical conformation. The geometry of dirhodium ligands is 
important; only cis-orientation of ligated amino-acid carboxylates produces 
improvement in peptide helicity, while trans-ligation is both unfavorable 
and helix-breaking. Furthermore, helical metallopeptides with two peptide 
chains ligated to the same dirhodium core can be produced. 
The development of helical dirhodium metallopeptides was most 
beneficial in the designing of enantioselective catalysts for diazo 
transformation. Chapter 6 focuses on the study of catalytic activity of 
dirhodium metallopeptides and the effect of axial coordination on their 
selectivity. For the first time, reactivity towards diazo compounds was 
recorded for dirhodium complexes with an axial ligand. The addition of 
triphenylphosphite ligands to the Si–H insertion reaction resulted in 
improved enantioselectivity for the reaction catalyzed by dirhodium 
complexes with a single peptide ligand. 
 In Chapter 7, dirhodium metallopeptides are evaluated as ligands for 
MDM2 protein.4  A study was performed with a series of metallopeptides 
based on the sequence of the wild type p53 protein and a peptide ligand with 
an enhanced affinity to MDM2. A multistep synthesis was executed, 
involving an orthogonal protection of carboxylate residues as allyl esters and 
an installation of fluorescein dye at the N-terminus. Affinities of the 
metallopeptides for MDM2 were measured with a fluorescence polarization 
assay and were found to be similar to the parent peptide sequences. 
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Chapter 2 
Design of functional metallopeptides 
2.1. Introduction 
Metals are an essential part of biological systems. They play a role in 
protein folding, oxygen transport and signal transduction. Metalloproteins 
can catalyze transformations unfeasible with purely biopolymer structures, 
placing them in a central role of metabolism. The unique functions of metals 
originate from their fundamental properties.1 Lewis acidity and high 
coordination number of metal ions define their role in protein folding. An 
electronic configuration of an open d-shell grants them multiple oxidation 
states and catalytic activity. The role of protein environments, however, 
cannot be underestimated. A protein scaffold organizes metals in multicenter 
enzymes, creates a unique environment around the catalytic metal center, 
provides high specificity and selectivity toward substrates, and activates 
metals by imposing a high-energy entatic state.2  
Not surprisingly, a number of research groups work on designing and 
mimicking the structure and function of natural systems, as well as 
attempting to produce unnatural ones.3 One approach to install a novel 
function is to combine a biomolecule with a non-native transition metal 
complex.4 The advancements of inorganic and organometallic chemistry in 
the last few decades offer a great variety of metal catalysts, electron-transfer 
(ET) systems and luminescent complexes, utilizing almost every metal of the 
periodic table. Incorporating unnatural metals and metal complexes within a 
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protein has the potential for improving their properties and creating 
metalloproteins with functions unprecedented in nature.  
A protein scaffold offers the ability to control first and second 
coordination spheres around the metal center.5,6 The environment around a 
metal can be tuned by altering a protein sequence via mutagenesis or by 
directly varying a peptide sequence in the solid-phase synthesis. Identifying 
functional systems can be accomplished by high-throughput screening of 
combinatorial libraries.3 In comparison to small–molecule ligands, changing 
the structure of protein ligands can be easier since it only requires the 
substitution of its building blocks—amino acids. Also, proteins possess 
intrinsic chirality that can be utilized to engineer catalysts for 
enantioselective reactions. Designing a chiral small molecule ligand is a 
costly and time-consuming endeavor. On the other hand, the modular 
structure and intrinsic chirality of polypeptides makes them potentially 
promising ligands for enantioselective synthesis. The size of proteins 
contributes to better regio- and stereo- specificity since more distal groups 
on the substrate can act as directing groups. Enhanced specificity would be a 
great advantage in the synthesis of complex molecules with multiple reactive 
functionalities that typically require intricate protecting schemes. Certainly, 
several issues are yet to be resolved for proteins to be utilized as widely as 
small molecule ligands. The solubility and activity in organic solvents, the 
ability to coordinate metals in a specific manner, or the necessity of 
unnatural ligands for catalytic function (phosphines or NHC for example) 
are just a few challenges that need to be addressed. 
Aside from catalysis, electron transfer (ET) and fluorescent properties 
can be incorporated into designed metalloproteins. Both the nano-scale size 
of proteins and their ability to form larger assemblies allow for the 
  7 
incorporation of ET complexes into functional arrays or for blending them 
with natural ET systems. Light-harvesting and photo-catalytic systems can 
be developed with this approach.5 A fusion of lanthanide binding peptide 
sequences to natural proteins has found applications for in-vivo imaging and 
protein structure determination.6  
Though there is no well-accepted distinction between proteins and 
peptides, the latter are typically defined as less than 40-50 residues in length. 
For the purpose of this introduction I will mainly focus on the design and 
development of functional metallopeptides. Various examples of 
metallopeptides with catalytic, electron-transfer and imaging properties are 
presented.  
2.2. Metallopeptide design 
When it comes to designing a novel metalloprotein, two general 
approaches have emerged: remodeling a natural protein or designing a 
metalloprotein from de novo principles.7 Starting with a native protein, one 
may consider several approaches to engineer a new metalloprotein: 
reconstitution of metal cofactor (covalent modification of heme for 
example), modification of a binding pocket to adopt alternative prosthetic 
groups or metals, covalent and potentially site-specific modification of 
protein to incorporate metal-binding ligands, or the use of small-molecule 
protein ligands as an anchor for non-covalent attachment of a metal 
complex.3,4 More recently, the incorporation of unnatural amino acids via an 
amber stop codon has become available, offering the capability to install 
metal ligands in the protein of interest at the defined position.8,9 All these 
methods take advantage of the unique structural composition of natural 
proteins and therefore require information about their structure. The de novo 
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approach first emerged as a tool to test our understanding of protein 
structure and ability first to reproduce metal-binding sites and later, to 
construct new functional systems.10 The design of metallopeptides (as 
smaller entities) thus served both as the testing ground and as the way to 
create small functional metalloproteins.   
In the de novo design approach metals are utilized for two common 
purposes. Similar to nature, metal-protein interactions can drive protein 
folding or inherent properties of the metal can define the function of 
metalloprotein. Designed peptides often require sequences that have a high 
propensity to form secondary structural elements, as their smaller size 
compared to proteins removes additional stabilization provided by the 
protein tertiary structure. Metallopeptide design is closely related to de novo 
design of proteins in general and DeGrado provides a nice outline of the 
principles as well as the various folds that can be utilized for this purpose.11 
Installation of metal binding sites can be used to stabilize the structure of 
designed peptide or to induce the formation of secondary superstructures and 
peptide assemblies.10 
 The most common secondary structural element in de novo design is 
an alpha helix due to its high stability provided by a rich hydrogen bond 
network spanning across the helix (Figure 2-1). After years of research, !-
helicity is well understood and extensively reviewed.12-14 Early examples of 
helical metallopeptides were produced in the Ghadiri group. In a helical 
structure, the side chains of amino acids four residues apart (i, i+4) are 
projected into close proximity to each other. Placing two electron-donor 
histidine residues in these positions was demonstrated to be suitable for 
bidentate binding of copper(II), zinc(II), nickel(II), and cadmium(II) metal 
ions (Figure 2-2),15 as well as ruthenium (III) complexes.16 Similar results 
  9 
 
Figure 2-1. Structure of an !-helix demonstrating rich hydrogen bond network (created 
in PyMol). 
 
Figure 2-2. Helical peptide with metal coordinated to histidine positioned four residues 
apart (i, i+4).15 
were achieved by Hopkins et al. utilizing unnatural amino-diacetic side 
chains in i, i+4 or i, i+3 arrangements.17,18 More recently, the same concept 
of bridging i, i+4 positions was used by Fairlie to induce helicity in very 
short peptides via metalation with ruthenium(III) and palladium(II) 
complexes.19-22 
Though !-sheets are widely found in native proteins, designing stable 
peptide systems with this structure is quite a challenging task.23,24 As a 
result, few examples of metallopeptides that employ this secondary structure 
element are found in the literature. !-hairpins capable of binding zinc(II) 
ions were developed initially by the Imperiali group.25 Searle later utilized a 
similar design for the stabilization of !-sheet conformation.26 In both cases, 
metal binding is mediated by two histidine residues placed on opposite 
strands of the hairpin. More stable folds can be achieved by recruiting amino 
NHN NHN
[MLn]
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Figure 2-3. Examples of !-hairpin metallopeptides with bipyridyl group on the side 
chain (image A) and the turn (image B) of the hairpin.27,28 
acids with unnatural side-chain ligands that have higher affinities for a metal 
ion. Strong nitrogen donor ligands—bipyridyl or phenanthrolyl groups—
were employed to induce folding of the !-hairpin in the presence of metal 
(Figure 2-3, A).28 Schneider and Kelly demonstrated that a bipyridyl 
structure could also be used as a mimic of the !-turn. A unique structure was 
designed with two strands of the hairpin connected via bipyridyl 
functionality (Figure 2-3, B) and was shown to exhibit copper(II)-dependent 
reversible folding.27 
A coiled coil structure is assembled from well-defined helical 
elements and allows construction of more complex systems, avoiding the 
need to synthesize long-chain peptides.29,30 It is considered to be a secondary 
superstructure rather than a quaternary structure, which is typically 
attributed to the assembly of two or more polypeptide chains. Because of the 
propensity to form higher order structures, it is a very common structural 
motif in proteins.31 Assembly of "-helices into a coiled coil is driven by 
hydrophobic interactions and is associated with the localization of 
hydrophobic residues on one side of a helix (Figure 2-4). 
Metals have been used to stabilize a coiled coil assembly by providing 
metal-ligand interactions in addition to the hydrophobic packing. 
N N
N
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Figure 2-4. (A) Packing of hydrophobic residues at coiled-coil interface (created in 
PyMol form PDB entry 1U0I) (B) Helical wheel diagram of a parallel coiled coil, 
hydrophobic residues in the positions a and d. 
For instance, coiled coil formation can be triggered with lanthanide ions, 
driven by ligation of the side-chain carboxylates positioned on the periphery 
of the helices.32 Cysteine residues are preferred ligands for metals and are 
often used for engineering metal binding pockets. Four cysteine residues, 
installed inside the hydrophobic interface of a coiled coil structure, favor 
folding via formation of a cadmium(II) thiolate complex (Figure 2-5, A).33 
Coiled-coil heterodimers composed of two distinct "-helices were utilized 
by Ogawa and colleagues to engineer an electron transfer system where two 
helices were decorated with different ruthenium complexes (Figure 2-5, B).5 
A secondary superstructure with two directly connected helices is defined as 
a helix-turn-helix motif. A remarkable example of a designed metallopeptide 
that simultaneously accommodates an iron cluster [Fe4S4] and a nickel(II) 
metallocenter was developed by Holm et al. (Figure 2-5, C).34,35 Helix-turn-
helix, however, is not limited to the formation of a coiled coil. A subclass—
!-! corners—have two helices overlapping at an angle and is a quite 
abundant motif.36 Lanthanide metallopeptides featuring this structural 
element were engineered in the Franklin group (see section 2.3.2).37,38 
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Figure 2-5. (A) Coiled coil assembly mediated by cadmium(II) – cysteine complex5 (B) 
Electron-transfer system based on coiled-coil assembly5 (C) Helix-turn-helix 
metallopeptide featuring metal centers: iron cluster [Fe4S4] and nickel(II).34 
 
Structures containing several helices in assembly—helix bundles—are 
directly related to coiled coils and rely on the same principle of hydrophobic 
packing.39 Installation of metal binding sites in the core of the bundles yields 
structures with a metal buried inside the assembly and isolated from the 
solvent. This attribute is valuable for the creation of metallopeptides with 
functions that would otherwise be compromised by exposure to the aqueous 
environment. 
The interaction between a metal and peptide side chains can be used 
as a driving force for the assembly of helix bundles. Significant 
contributions to the development of metallopeptides with three-helix bundle 
structures have been presented by Pecoraro and co-workers.10,40-44 Four-helix 
bundles are of particular interest as their size approaches that of small 
proteins. In the synthesis of diiron metallopeptides, DeGrado and colleagues 
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demonstrated a prime example of the retrostructural approach that 
encompasses identifying structural similarities in the natural systems and 
 
Figure 2-6. Four-helix bundle metallopeptides with (A) dizinc center and (B) iron-
porphyrin centers.7,49 
applying the knowledge in engineering a de novo protein.45 The metal-
binding sites of diiron proteins share a common structure; they were used to 
deduce and construct a four-helix bundle mimic that assembles into a well-
ordered miniprotein (Figure 2-6, A). A four-helix bundle model was also 
utilized to produce metallopeptides with porphyrin cofactors, therefore 
mimicking natural heme systems (Figure 2-6, B).46-50 
A beta-hairpin-loop-helix is one other motif that is accessible via 
solid-phase peptide synthesis and is a potential candidate for synthesis of 
metallopeptides. Though a "-hairpin is typically not very stable as a stand-
alone structure, association with a helix can somewhat favor its formation. 
This motif is typical in zinc finger proteins and can be isolated as a free 
metallopeptide. Other metals have been incorporated in place of zinc to 
produce metallopeptides retaining DNA-binding ability.51-53 
Though methods of designing new metallopeptide and metalloprotein 
structures have advanced significantly in recent years, the number of 
functionally useful structures remains limited. Simply combining 
polypeptide structures with a metal does not always lead to metallopeptides 
with desired properties. Progress in this area, however, provides a 
a b dc
the two-electron oxidation of 4-aminophenol, similar to the reaction 
catalysed by di-iron phenol oxidases18,19.
Motivated by the natural occurrence of Cys-rich coordination sites 
in proteins, the introduction of Cys ligands led to the development of 
α-helical coiled-coil metalloproteins capable of binding Co(ii), Fe(ii), 
Zn(ii), Cd(ii), Hg(ii) and As(iii)20–22. One interesting property of these 
de novo-designed proteins is that they can stabilize unusual metal-coor-
dination states, for example three-coordinate Hg(ii) stabilized by a tri-
helical bundle, in preference to more normal coordination states, such as 
the bis-coordination often preferred by Hg(ii)23,24. In other cases, metal 
binding can actually direct the folding and assembly of an α-helical bun-
dle from either a random coil or a less-folded or misfolded state, as has 
been shown for Cd(ii)25 and Hg(ii)26 binding to Cys-containing peptides 
predisposed to form helices. Interestingly, geometry-selective binding 
of two different Cd(ii) atoms in one designed protein has been achieved 
and confirmed by the correlation of 113Cd NMR and 111mCd perturbed-
angular-correlation spectroscopy27,28.
In stark contrast to the design of α-helical proteins, de novo design of 
β-structure proteins is still in its infancy, because there are few model 
systems with which to study β-sheets in isolation from other protein 
structures. The de novo design of a redox-active rubredoxin mimic, 
RM1, is a rare example of a structural and functional metallo-β-sheet 
protein29. RM1 was shown to bind iron and reversibly cycle between 
the Fe(ii) and Fe(iii) oxidation states, mimicking native rubredoxin. 
The RM1 β-hairpin structure was designed computationally by con-
straining the positions of the peptide that were strategic in mimicking 
and/or stabilizing the β-structure and by subsequently using another 
computer program, SCADS30, to select the most probable amino acids 
for the remaining positions.
Metalloprotein design in native protein scaffolds
Designing metalloproteins using de novo-designed scaffolds offers the 
prospect of complete control over a protein’s structure and metal-bind-
ing properties, but our current knowledge of protein folding limits the 
number of de novo-designed scaffolds to only a few types, such as the 
α-helical bundles discussed above. It has been observed that proteins 
containing β-sheets tend to support more rigid and more pre-organized 
metal-binding sites than α-helical proteins, which are inherently more 
flexible31. The Protein Data Bank contains many more natural protein 
scaffold types (~1,000) than it does de novo-designed scaffolds (http://
scop.mrc-lmb.cam.ac.uk/scop/count.html#scop-1.73), and most of the 
natural protein scaffolds maintain the same fold and are of a similar 
stability even after numerous mutations. Therefore, metalloprotein 
design using native protein scaffolds instead of those designed de novo 
provides many more scaffold choices that are more tolerant to muta-
tions, allowing less concern over decreased protein stability when 
incorporating metal-binding sites into proteins. When chosen care-
fully, native proteins are also easier to crystallize than de novo-designed 
scaffolds, making three-dimensional characterization possible, which 
is critical to success. Perhaps the strongest argument for designing 
metalloproteins by using native scaffolds is that nature uses a similar 
approach — the same scaffold is often seen in numerous proteins with 
diverse metal-binding motifs and functions, suggesting that these native 
scaffolds are robust and modifiable. For example, the β-barrel fold has 
been shown to be used by ~600 types of protein, with diverse functions 
such as oxidase, reductase, amylase and dismutase activities. Discover-
ing how nature is able to use the same scaffold to design a variety of 
metal-binding sites is an important goal of metalloprotein design1.
Biochemical techniques, such as site-directed mutagenesis, have 
been used extensively to study the function of metalloproteins. The 
loss of function accompanied by certain mutations (usually to highly 
conserved residues) allows the identification of residues essential for 
function. Although serving a different purpose, the same mutagenesis 
techniques can be use  in metalloprotein design to impart ew function 
into a protein scaffold by introducing residues that bind metal ions. This 
can be accomplished through the redesign of existing metal-binding 
sites to introduce novel functionality, the introduction of mononuclear 
metal-binding sites into proteins that do not bind metal ions natively, 
or the introduction of homonuclear or heteronuclear metal-binding 
sites into proteins. Design is often aided by empirical approaches based 
on prior knowledge and experience, the use of computer programs 
(rational design) or combinator al selections.
The redesign of an existing metal-binding site to introduce new 
function or metal specificity is the simplest form of metalloprotein 
design, as this approach relies on the structural differences between 
template and target proteins and is amenable to empirical approaches 
as mentioned above. Despite its simplicity, this approach is still power-
ful in elucidating structural features important for the change in, or 
gain of, function by redesign. Haem proteins have been extensively 
redesigned in this way. They are one of the most diverse classes of 
protein, having functions ranging from electron transfer to small-
molecule (for example oxygen and nitric oxide) transport, sensing 
and activation5,32,33. By systematically changing the characteristics 
of haem proteins, researchers have been able to convert one type of 
haem protein into another and to introduce new function or substrate 
specificity into a haem protein32–34.
The selectivity of designed metalloproteins for specific metals has 
also been used for the purpose of m tal-sensing applications. Ratiomet-
ric Zn(ii) sensors have been created by designing Zn(ii)-binding sites 
into green fluorescent proteins and by taking advantage of the resultant 
fluorescent signal variations due to Zn(ii)-dependent conformational 
changes35–37. The metal-binding site of NikR, a DNA-binding protein, 
Figure 1 | Designed metalloproteins using de novo-designed scaffolds. 
a, Computer model of a bis-histidine-ligated mono-haem α-helical bundle. 
The haem cofactor (central molecule) is in cyan, and the relevant haem-
binding His ligands are shown in stick format, with nitrogen in blue and 
carbon in cyan. (Panel modified from ref. 6 courtesy of W. DeGrado.) 
b, Computer model of a bis-histidine-ligated multi-haem four-α-helical 
bundle. Haem cofactors are shown in red. Relevant haem-binding His 
ligands are shown in cyan, and the disulphide bond is shown in yellow. 
(Panel modified from ref. 7 courtesy of P. L. Dutton.) c, X-ray crystal 
structure of As(iii)-bound three-stranded coiled-coil protein (Protein Data 
Bank (PDB) code 2JGO)16. As(iii) is represented as a green ball; relevant 
metal-ion-binding Cys ligands are indicated in stick format, with sulphur in 
yellow and carbon in cyan. d, X-ray crystal structure of di-Zn(ii) due ferro 
1 (PDB code 1EC5)17. Zn(ii) ions are represented by grey balls; relevant 
metal-ion-binding His and Glu ligands are also indicated in stick format, 
with nitrogen in blue, oxygen in red, and carbon in cyan.
856
NATURE|Vol 460|13 August 2009INSIGHT REVIEW
!""#!$%&'()*+,-&$&./&012*(33&&&!"$ $4!456&&&7"85589"
)''0DXZd`ccXeGlYc`j_\ijC`d`k\[%8cci`^_kji\j\im\[
A! B!
  14 
foundation for the next step of metallopeptide design focused on the 
engineering of practically valuable systems. 
2.3. Functional metallopeptides 
2.3.1. Electron transfer 
Electron transfer (ET) is a focus of many research groups because of 
its importance in energy transmission inside biological systems.54 ET is 
central to photosynthesis, respiration, regulatory mechanisms and 
biochemical synthesis.54-56 Due to the challenges associated with natural ET 
systems that are typically integrated into cell membranes,57,58 alternative 
ways to study them have emerged.5,59 Modeling natural systems with de-
novo designed metallopeptides has been a productive approach.5 Initial 
models focused on a simple attachment of two chromophores to polypeptide 
chains.60 Natural ETs, however, more often proceed intermolecularly, 
occurring between separate species. In pursuit of a design that better 
represents a real system, more interesting examples have appeared such as 
metallopeptides that have a well-defined secondary structure and are capable 
of supramolecular organization.59,61  
Redesigned ET systems often feature the same metals and cofactors as 
encountered in native proteins: most commonly hemes, copper(I), and iron-
sulfur clusters.58 Their activity however is highly dependent on the 
coordination environment, making the design of functional ET 
metallopeptides quite challenging. Among unnatural metals, ruthenium 
complexes are particularly favored due to their range of electropotential, the 
minimal structural changes during oxidation or reduction, and a strong 
affinity for histidine residues.54 
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A significant effort to study ET processes with de novo 
metallopeptides was made by Ogawa and colleagues. Various systems with
ruthenium complexes were produced to evaluate ET along the polypeptide 
chain as well as across supramolecular assemblies.5,60 Especially interesting 
results were obtained in the systems that had been constructed based on the 
coiled coil structure. In an early example, they demonstrated that electron 
transfer can occur across a non-covalent assembly of two homologous 
helices that are ligated with [Ru(trpy)(bpy)](His) and [Ru(NH3)5](His) 
complexes at the histidine residues (Figure 2-5, B).59,61 In the following ET 
experiments, coiled coil assemblies were used to assess the effects of the 
helix dipole moment that results from alignment of backbone carbonyls,62 
and of the dipoles produced by the charged residues in the electrostatic 
protein complexes (Figure 2-7).63 Ogawa’s group had also designed a unique 
four-helix metallopeptide with a multinuclear copper(I) thiolate cluster that 
is active in photoinduced ET with various ruthenium complexes via 
intermolecular collisional mechanism.64  
Electrostatic forces were also put in use to study ET within the 
electrostatic assembly of cytochrome c protein with a simple ruthenium 
metallopeptide that features a polyglutamate sequence.65,66 Two parallel 
electron transfer pathways were observed from emission lifetime 
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Figure 2-7. Electron transfer across electrostatic dimer composed of coiled-coil 
ruthenium metallopeptides.59,63 (KK and EE are lysine- and glutamate- rich peptides that 
assemble into a heterodimeric coiled coil) 
 
Figure 2-8. Four-helix bundle heme-metallopeptide mimicking cytochrome c protein.50 
measurements. Double exponential decay kinetics was attributed to 
simultaneous ET in a transient complex of photoexcited metallopeptide with 
the protein and in an equilibrium complex between a metallopeptide with the 
protein. The concept of using non-covalent interactions to construct ET 
systems with natural proteins had also been rewarding with non-peptide 
systems.67,68 
A metallopeptide that mimics natural systems provides a model that 
can be used to understand natural processes. One such metallopeptide with a 
four-helix bundle architecture was designed by Dutton and co-workers 
(Figure 2-8) to study redox chemistry of c-type cytochromes.50 Specifically, 
this model has allowed them to look into the coupling of heme redox 
The pulse radiolysis of a 15 µM solution of the electrostatic
heterodimer in 50 mM phosphate buffer yields an initial
bleach at 490 nm corresponding to the formation of the
[Ru3+(trpy)(bpy)KK(37-mer)] species which recovers via
first-order kinetics (not shown). The rate constant for this
process was s en to vary with the conce trati n of ET
heterodimer within the range of 5 to 15 µM to yield a value
of kinter ) 3.2(2) × 107 M-1 s-1 for the i termolecular ET
reaction occurring between discrete heterodimers. Interest-
ingly, unlike for the related H21(30-mer) system, no evidence
could be observed for an intracomplex electron-transfer
reaction occurring within the electrostatic heterodimer. This
may be due in part to the faster intrinsic decay of the [RuIII-
(trpy)(bpy)KK(37-mer)] species which occurs on the same
time scale as the previously observed intracomplex electro -
transfer reaction. In addition, we note that a principal
modification of the EE(37-mer)/KK(37-mer) heterodimer is
the different arrangement of interhelix salt-bridges that were
used by the H21(30-mer) to ensure the formation of a parallel
coiled-coil. These differences will likely affect the confor-
mational properties of the peptide, and it is possible that the
electrostatic heterodimer may exist in conformation(s) that
would have longer donor-acceptor distances to result in a
slower rate of intracomplex electron-transfer.
Ionic Strength Dependence of kinter. An important feature
of the ET hetereodimer is that its metal-based electron-donor
and acceptor sites were placed within oppositely charged
surfaces of the protein (Figure 4). Thus, the ruthenium
pentammine electron-donor was attached to the positively
charged surface of the EE(37-mer) and the ruthenium
polypyridyl electron-acceptor was attached to the negatively
charged surface of the KK(37-mer). Upon formation of the
electrostatic heterodimer, this situation afforded the pos-
sibility that each metalloprotein possessed a set of comple-
mentary electrostatic recognition domains that may affect
the rates of intermolecular ET occurring between separate
dimers. To investigate this hypothesis, ET measurements
were performed in phosphate buffers having ionic strengths
in the range of 0.01-0.2 M. As shown in Table 1, the
resulting bimolecular rate constants increased with increasing
ionic strength to indicate that the electrostatic ET effects were
dominated by the mutual repulsion of the two positively
charged ruthenium centers. These results are consistent with
earlier observations that electrostatic interactions involving
metalloproteins frequently involve localized charges and not
the overall charge of the protein (27, 28).
As a first approach toward understanding how the protein
environment of the ET heterodimer can influence the rates
of bimolecular electron-transfer, the data in Table 1 were
analyzed according eq 3 which results from considering the
ionic strength dependence of the activity coefficients of the
reactants and transition state in terms of the
Debye-Huckel theory. In eq 3, k is the bimolecular electron-
transfer rate constant at ionic strength µ, k0 is the rate constant
at µ ) 0, R ) 1.17 in water, Z1 and Z2 are the reactant
charges, κ ) 0.329 "µ Å-1, and Rav is the reactant radius
which must be identical for each of the two reactants if eq
3 is to obtain (29, 30). In this study, the electron-transfer
reaction involves the two solvent-exposed ruthenium centers,
and it is assumed that Rav ) 5.25 Å, which is the arithmetic
mean of the radii of Ru(NH3)62+ (R1) 3.5 Å) and Ru(bpy)33+
(R2 ) 7 Å) (31). Figure 5a shows that the data presented in
Table 1 can be accurately described by eq 3, as the plot of
ln k vs "µ/(1 + 1.7 "µ) is linear. However, a fit of these
data to the equation yields values of k0 ) 1.4 × 107 M-1 s-1
and Z1Z2 ) 1.7 ( 0.3, of which the latter is significantly
smaller than the charge product expected for a cationic
electron-donor/acceptor pair having charges of +2 and +3,
respectively. It is further noted that this value of Z1Z2 is
FIGURE 4: Schematic representation of the EE/KK electrostatic
heterodimer emphasizing the charges on the solvent-exposed and
interfacial regions of the heterodimer.
Table 1: Ionic Strength Dependence of Intermolecular
Electron-Transfer Rate Constants
ionic strength (M) kinter (107 M-1 s-1)
0.01 1.9(4)
0.10 3.2(2)
0.20 3.7(5)
FIGURE 5: Ionic strength dependence of the bimolecular ET rate
constants: (a) Fit of the data to the Debye-Huckel expression in
eq 3. (b) Fit of the data to eq 4. The observed data are from Table
1.
ln k ) ln k0 +
2RZ1Z2"µ
1 + κRav
(3)
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A Beckman Optima XL-A analytic l ultrac ntrifuge was
used to perform equilibrium ultracentrifugation on the
prototype maquette and its variants in the single heme bound
form at both pH 8.5 and pH 4. The data were collected at
three different peptide concentrations and two different
centrifuge speeds (20 000 and 30 000 rpm). Partial specific
volumes (νj) of the prototype and variants were calculated
from the sequence as described in (41) and were used to fit
the data to obtain the apparent molecular weight of the
peptides.
UV-Visible Spectroscopy. The spectra were recorded on
a Perkin-El er Lambda 2 spectrophotometer. The peptide
concentration was determined optically by the absorbance
of the Trp (position 7 on each R-helix), using !280 ) 5600
M-1 cm-1. Heme binding was monitored by loss of the
absorption at 385 nm due to free hemin, and the concomitant
appearance of a sharp Soret band at 412 nm, corresponding
to heme bound to the protein via bis-histidine axial coordina-
tion.
Circular Dichroism. CD spectra were recorded on an
Aviv Associates Model 60DS spectropolarimeter using a 2
mm quartz cuvette at 25 °C. The buffers used in the presence
of 100 mM NaCl were 50 mM citric acid (pH 1-6), 50 mM
Tris/HCl (pH 7-9), 50 mM boric acid (pH 9-10), and 50
mM 3-(cyclohexylamino)-1-propanesulfonic acid (CAPS)
(pH 10-12). The helicity of the peptide was calculated from
the absorbance at 222 nm (Θ222) which was normalized to
-32 000 deg cm2 dmol. For the chemical denaturation
experiments, dilutions of 8 M guanidine hydrochloride (Gdn‚
HCl; Pierce, Rockford, IL) and concentrated protein solution
were performed to obtain a 10-20 µM protein, x M Gdn‚
HCl sample, where x varied from 0 to 7.8. The denaturation
curves were fit to a dimer-folded to monomer-unfolded
equilibrium model (42) to obtain ∆G° according to
where ∆Gunf ) ∆G° - m[Gdn‚HCl], m is a parameter
reflecting the cooperativity of the unfolding transition, and
P is the molar concentration of total monomeric protein.
Heme Protein Preparation. The concentrated hemoprotein
solution was prepared in advance by addition of 5 µL aliquots
of a 10 mM solution of iron protoporphyrin IX (hemin;
Porphyrin Products Inc., Logan, UT) in dimethyl sulfoxide
(DMSO) to the stirred peptide in 10 mM Tris/HCl, 100 mM
NaCl buffer, pH 8.5. Samples of the single-heme-bound
protein, heme-(RssR)2, were prepared by titration of only 0.8
heme equiv per four-helix bundle in order to keep the
population of two-heme-bound species negligibly low. For
FTIR spectroscopic measurements, all solutions were pre-
pared in D2O. The heme-bound peptide was concentrated
in a low-speed Beckman J-21C centrifuge to reach a
concentration of about 300 µM for redox experiments or 2-3
mM f r FTIR experiments and stored at 4 °C. The dimethyl
ester of iron protoporphyrin IX (DME-heme; Porphyrin
Products Inc.) showed only partial binding to the peptide at
a concentration of 10 µM. To avoid interferen e from t
presence of free porphyrin in solution, only 0.2 equiv of
DME-heme per (RssR)2 of about 50-100 µM concentration
was added.
Redox Titrations. Redox titrations were performed in
combination with optical analysis, using the UV-visible
spectrophotometer described above. The concentrated sample
of hemoprotein prepared in advance was diluted to 5-10
µM into a buffer at a selected pH for each individual titration.
The buffer solutions used were the same as those described
above for the CD measurements. The redox titrations were
performed using an in-house-designed glass redox cuvette
with platinum measuring and calomel reference electrodes
(Radiometer Analytical, Lyon, France) (8); the reported redox
potentials are referenced to a standard hydrogen electrode.
All redox titrations were performed anaerobically using <1
µL additions of freshly prepared sodium dithionite to adjust
the solution potential to more negative values and potassium
ferricyanide to more po itive values. T e following redox
mediators were used to stabilize solution redox potential:
20 µM duroquinone, 10 µM pyocyanine, 10 µM 2-hydroxy-
1,4-naphthoquinone, 10 µM anthraquinone-2-sulfonate, 2 µM
FIGURE 1: (A) A working model of the heme-(RssR)2 maquette
illustrating a single heme cofactor li ated to the bundle via two
histidines and also showing two nonligating histidines in the
adjacent RssR subunit. (B) A helical wheel representation of the
bundle (residues 5-31 are shown, residues 1-4 of the loop region
are excluded) displaying the heptad positions indicated by letters
a through g.
% folded ) 1 -
exp(-∆Gunf/RT)
4P [(1 + 8Pexp(-∆Gunf/RT))
1/2
- 1] (1)
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processes with heme protonation/deprotonation that is often observed in 
natural cytochromes. An unexpected role of carboxylic residues and 
consequent dependence on pH was determined, motivating a search for 
similar structures in natural metalloproteins. 
Dutton further probed proton-coupled redox chemistry with the mimic 
metallopeptide immobilized on gold surface.69 The observed dependence of 
redox potential on pH in this system was consistent with the previous study. 
An inquiry into the binding of carbon monoxide (CO) in this model revealed 
that CO absorption could be modulated by the electro-potential of the 
surface. Electroreduction of the heme iron(III) to iron(II) gives the 
preference for CO ligation proceeding with the histidine displacement from 
the heme axial site. Re-oxidation of the system results in the release of the 
CO and reconstruction of the bis-histidine metal site. The authors suggest 
that designed metallopeptide films could be used for engineering sensors. 
Natural ET metalloproteins, however, are usually integrated inside lipid 
membranes. To examine ET occurring across a hydrophobic–hydrophilic 
interface, Dutton designed amphiphilic metallopeptides that can be 
successfully incorporated into the micelle bilayer.70-72 Aside from the 
examples described here, many other metallopeptides with ET capabilities 
have been designed, demonstrating the importance of this topic and its 
potential applications.73-83 
2.3.2.  Luminescent metallopeptides  
The photophysical properties of some metal complexes make them 
attractive for incorporation into a protein scaffold for imaging applications. 
Lanthanide ions terbium(III) and europium(III) are of particular interest, 
because of their long-lived fluorescence lifetimes, narrow emission profile, 
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and large Stokes shifts (difference between the wavelengths of absorption 
and emission maxima).6,84,85 The similarity between lanthanides and calcium 
ions allows their integration into calcium-binding proteins.86,87 A short 
peptide modeled after a Ca2+-binding loop was successfully used to produce 
a terbium metallopeptide exhibiting luminescence upon energy transfer from 
the attached salicylic acid donor.88 Various other examples of lanthanide-
binding peptides were published as well.89-95 
 
Figure 2-9. (A) A model of the chimera metallopeptide generated from the 
homeodomain engrailed (green, PDB: 2HDD) and the EF-hand of calmodulin (orange, 
PDB: 1OSA). (B) Increase in the Tb(III) fluorescence intensity upon titration of the 
designed peptide with TbCl3.96  
Franklin and co-workers remodeled the helix-turn-helix motif of the 
DNA-binding protein homeodomain engrailed (PDB: 2HDD) to incorporate 
the metal-binding site of calmodulin (Figure 2-9).37,38 Subsequent metalation 
with europium(III) or terbium(III) produces luminescent metallopeptides 
that retain DNA-binding capability.97,98 Intense terbium fluorescence was 
observed at 545 nm upon FRET from the proximal tryptophan excited at 290 
nm (Figure 2-9, B). The same peptide was utilized to bind a gadolinium(III) 
ion for the potential application as an MRI contrast agent.99 
et al. 2003; Wong-Deyrup et al. 2006), though folding is
modest.
To test the versatility of modular loop substitution in the
context of a full domain and to optimize folding and DNA
interactions, we employed a similar design strategy to the
full engrailed homeodomain. An important consideration
for loop mutation in the context of a protein rather than
isolated peptides is that poorly matched loops can propa-
gate longer range structural errors and, thus, misfolding.
Successful incorporation of calcium (Toma et al. 1991; Ye
et al. 2003, 2005a,b) or copper loops (Robinson et al. 1999;
Lu et al. 2001) into alternate scaffolds have been reported.
However, for the less geometrically rigid Ca(II)/Ln(III)
sites, these mutants have required flexible linker segments
or highly homologous host proteins for structural integrity.
Here we sought to predictably generate a folded protein by
grafting a Ca(II) loop into a small, unrelated domain
directly without additional linkers.
Results and Discussion
Metallohomeodomain design and modeling
Four chimeric metalloproteins were designed to test small
translations in the loop register (C1–C4) (Fig. 1). Com-
putational models of the four chimeras were then com-
pared to the isolated proteins, to validate our predictions.
In each case, a 12-residue EF-hand loop (Babu et al. 1988)
with the consensus Asp/Glu-rich coordination set (Fig.
1B, red) was grafted into the engrailed homeodomain
based on the colinear helical axes of the two turn motifs.
The N-terminal arm, which participates in DNA recogni-
tion by contacting the minor groove of DNA (Kissinger et
al. 1990), is also retained. Sequence variations flanking
the loop were incorporated by retention or deletion of two
residues of the homeodomain (QQ or LR) to either side of
the insertion site. Note that in analogy to our earlier
peptide design (P3W), the residues AQ of en (Fig. 1B,
blue) are replaced by the corresponding residues of the
homeodomain antennapedia (LR) (Kim et al. 2001). The
greater basicity of Arg near the loop was included to
enhance potential DNA interactions near the loop. Several
hydrophobic contacts important for EF-hand structural
stability were also retained before and after the loop, al-
though they were derived from the HTH motif (Drake et al.
1997). These variations were incorporated to determine the
insertion length and position that would adopt the least
strained conformation within the homeodomain scaffold.
Computational models of C1–C4 with Ca(II) were gener-
ated using molecular dynamics simulations (Fig. 2), as
Figure 1. (A) SwissPDBviewer model of the metallohomeodomain chimeras generated by structural overlays of homeodomain
engrailed (green; 2HDD) and one EF-hand of calmodulin (orange; 1OSA). (B) Sequences of chimeras C1–C4, which differ in residues
flanking the metal binding loop (blue QQ and LR). The metal binding loop is underlined, with ligand residues in red. The residues
omitted from engrailed (en) are shaded, and the three helices (designated a1, a2, and a3 in the ribbon diagram) are underlined. As with
earlier peptide designs (Kim et al. 2001), residues AQ (blue) of en are replaced by LR to enhance potential DNA interactions near the
loop.
Lim and Franklin
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single Trp band at 290 nm (W24) and following the emission
of Tb(III) at 545 nm. A 495-nm band-pass filter was included
to edit the direct emission of Trp. Because the observed Tb-
based emission is generated by energy transfer from the
excited Trp, this method is a sensitive reporter of Tb(III)
ions interacting with Trp residues within approximately 10
Å.25
Figure 3 shows the Tb emission spectra and the resultant
intensity as a function of added TbCl3 for representative
peptide P3W(D). The data for each peptide were nicely fit
to a 1:1 association model as described in ref 25, although
the inclusion of additional nonspecific sites in the model did
not improve the fit. The peptides bind 1 equiv of Tb(III),
with low micromolar affi ities (Table 1). It should be noted
that similar values were determined by direct observation
of the Trp emission (data not shown), the intensity of which
decreases as a function of added metal. This decrease in Trp
emission is seen in wild-type engrailed homeodomains
because it folds as well.41
It is clear from the data in Table 1 that the putative second-
shell interaction between loop position 9 and the metal (either
indirectly through bound solvent or directly) does impact
the affinity of the site of the mid-sized lanthanide ion Tb-
(III). The most notable difference is between P3W(D) and
P3N, which differ in only a functional group, taking the
carboxylate of Asp to the amide of Asn. The resultant change
in charge (negative to neutral) and potential role (charged
hydrogen-bond acceptor to either neutral acceptor or donor)
apparently results in a less favorable metal-binding site, with
the Tb(III) affinity destabilized by approximately 3.6 kJ/mol,
equivalent to a very weak hydrogen bond.42 This is a small
effect in terms of the metal affinity were it a direct contact
but is not insubstantial for a second-shell interaction, wherein
the hydrogen bond stabilizes a metal ligand (water).39,43
In comparison, P3A removes the hydrogen-bond acceptor
entirely and also removes some steric bulk around the metal
center. Thus, solvent exchange and hydrogen bonding with
a bulk solvent (rather than specific second-shell interactions
with a peptide side chain) is more readily available. The loss
of the favorable Asp f H2O interaction in P3W(D) costs
∼2.5 kJ/mol of Tb(III)-binding affinity, but the “hole” in
the coordination shell and accessible solvent hydrogen
bonding are apparently slightly more favorable than the
neutral Asnf H2O interaction. P3E has essentially the same
affinity for Tb(III) as P3A does, suggesting that the longer
Glu side chain may neither be directly ligating the Tb(III)
nor be aligned efficiently to help stabilize the first-shell water
molecule. Determination of the hydration number for the
various (Eu) metallopeptides will help to address whether
P3E has the same open site for solvent as P3A or whether
the similarity in the binding affinities arises from other
coincidences.
An investigation of the structure of these four peptides as
a function of metal-binding further illustrated the importance
of the subtle stabilizing influence of the gateway position
on the loop structure and thus the overall peptide fold (Figure
(41) Stollar, E. J.; Mayor, U.; Lovell, S. C.; Federici, L.; Freund, S. M.
V.; Fersht, A. R.; Luisi, B. F. J. Biol. Chem. 2003, 278, 43699.
(42) Desiraju, G. R. Acc. Chem. Res. 2002, 35, 565.
(43) It should be noted that here we are defining “second-shell interactions”
as the electronic, steric, and structural component to metal binding
that is dependent on the gateway residue. This includes long-range
coordination effects through water, although it is likely that these may
be transient in some cases.
Figure 3. Titration of representative peptide P3W(D) with TbCl3, followed by Tb(III) fluorescence spectroscopy (FRET). Samples containing 30 µM
peptide in a 10 mM HEPES buffer at pH 6.9 were titrated with up to 10 equiv of Tb. The TbCl3 stock solution contained 30 µM peptide to maintain a
constant peptide concentration throughout the titration. Samples were excited at 290 nm (Trp band), and emission at 545 nm was observed following energy
transfer from Trp to Tb(III). (A) Tb(III) excitation spectra (peak growing in). (B) Emission intensity at 545 nm vs equivalents of Tb(III) and a fit to 1:1
association (as in ref 29).
Table 1. Tb-Binding Affinities of Chimeric Peptides and
Metallohomeodomain C2 (10 mM HEPES Buffer, pH 6.9)a
chimera Tb(III) Kd (µM) chimera Tb(III) Kd (µM)
P3W(D) 4.2 ( 0.5 P3E 10.6 ( 0.5
P3N 17.0 ( 3.3 C2 8.7 ( 2.1
P3A 11.4 ( 2.6
a Conditional affinities were determined by Trp-Tb FRET, and reported
errors are standard deviations of three measurements.
Harris et al.
10008 Inorganic Chemistry, Vol. 45, No. 25, 2006
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Imperiali has further developed small lanthanide binding sequences 
with improved affinity to the lanthanide metals as well as enhanced 
fluorescence intensity. Initial optimizations yielded a peptide with Kd = 220 
nM, a 10-fold improvement over previous examples.100 Further 
combinatorial screening resulted in a peptide with Kd = 57 nM, which is 
lowered to 2 nM affinity upon constraining the peptide with a disulfide 
bond.101,102 Structural characterization of the optimized peptide demonstrates  
 
Figure 2-10. (A) Structure of high affinity lanthanide-binding tag peptide and 
terbium(III) ion (LBT-Tb3=) (B) Electrostatic surface potential of  LBT metallopeptide 
(C) Dependence of binding free energy with the LBT on the effective ionic radii of rare-
earth metals.103 
that terbium(III) ion is isolated from the aqueous environment and results in 
enhanced fluorescence (Figure 2-10, A and B).103 It is also quite selective for 
terbium(III) ion when compared with other rare-earth metals. The 
lanthanide-binding tag was utilized to study protein-protein interactions,104 
modified to display other sensitizing groups,85 and incorporated into proteins 
to act as a handle for NMR and X-ray structure determination.6,105-107 
A! B! C!
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2.3.3. Catalysis 
Metallopeptides with catalytic function are attractive targets and are 
gaining interest in scientific circles.108,109 The benefits of peptides arise from 
their modular structure allowing construction of a ligand from easily 
accessible building blocks. Though polypeptide ligands can potentially alter 
catalyst reactivity, the capability of controlling the spatial environment 
around the catalytic center is more valuable. Specifically, enantioselectivity 
of the catalyst can be coupled to the chirality of a peptide and amino acids, 
or regioselectivity can be attained via control of the secondary coordination 
sphere and non-covalent interactions between a peptide ligand and a 
substrate.110,111 In comparison to small molecule ligands, the size of a peptide 
offers the prospect of designing ligands that can direct selectivity with 
respect to the distal functionalities on a substrate.  
Amino acids by themselves were recognized as a convenient source of 
chirality and have been widely explored as ligands to transition metal 
complexes and auxiliaries in organic synthesis.112-115 Combining amino acids 
into peptides can also provide stereocontrol around the catalytic center116 as 
a defined secondary structure of peptides brings additional structural 
information and symmetry elements. Enantio- and regio- selectivity of 
catalysts with peptide ligands is a function of its primary structure that can 
be tuned via optimization of peptide sequence.117-119 Screening libraries of 
peptide ligands allows discovery of promising catalysts whereas intelligent 
design can be complex. The intrinsic chirality of amino acids determines 
chirality of the secondary structures. Thus inversion of reaction selectivity 
can be achieved utilizing enantiomers of amino acids, i.e. using D or L 
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isomers.120 D-amino acids, however, are expensive, again making sequence 
optimization a more reasonable approach.  
Transition metal catalysts often have functional groups that are 
distinct from natural amino-acid side chains, such as phosphine, carbene, 
oxazoline, pyridyl, dienyl, cyclopentadienyl or alkenyl functionalities.121 At 
the same time, certain ligands resemble the functional groups found in 
peptides. Examples include a phenolic hydroxyl group present in both the 
tyrosine side chain and series of BINOL ligands or nitrogen heterocycles 
represented in the histidine side chain and pyridyl-type ligands (Figure 
2-11). 
 
Figure 2-11. Functional group similarity between amino-acid side chains and common 
chiral ligands. 
Surprisingly though, most of the efforts were focused on the 
incorporation of amino acids that display unnatural functional groups. This 
is partially due to stronger affinities of non-native ligands as well as wider 
ranges of their electronic properties. Also, peptide ligands are not always 
optimal for metal catalysis because of potential issues that come with 
peptide structures. The acidity of an amide backbone may be unsuitable for 
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catalysis of a reaction requiring strongly basic conditions where a proton 
source can quench the reaction. Due to the insolubility of peptides in most 
organic solvents, catalysis is often limited to polar and protic solvents 
(water, alcohols, DMSO or DMF), therefore methods that can address this 
problem are highly beneficial.  
Gilbertson and co-workers developed procedures for the synthesis of 
peptides with amino acids containing a phosphine side chain and utilized 
them to produce catalytic metallopeptides with transition metal centers.122 
 
Figure 2-12. Gilbertson’s synthesis of Ru(I) metallopeptide with unnatural phosphine 
side chains. 
The phosphine functionality is not suitable for solid support peptide 
synthesis as it is readily oxidized under these conditions. To circumvent this 
problem, the synthesis was carried out with a phosphosulfide derivative. The 
sulfide analogue of phosphoalanine (also referred as phosphoserine) was 
successfully used to synthesize unnatural peptides using standard Fmoc 
procedures. A free phosphine can be produced by reduction with Raney 
nickel and metallated with rhodium(I) (Figure 2-12).123-125 Alternatively, a 
phosphine group can be installed in postsynthetic modification of tyrosine.126 
Two phosphine amino acids spaced four residues apart in the 12 
amino-acid helical peptide ligate to rhodium(I) forming a catalytically active 
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metallopeptide with a well-defined secondary structure (Figure 2-12).124,125  
These rhodium metallopeptides do not lose their catalytic activity if 
immobilized on a solid support.127 To demonstrate the utility of peptide 
sequence optimization in search for an enantioselective catalyst, libraries of 
metallopeptides were created and screened for enantioselective reduction of 
methyl 2-acetamidoacrylate.118,119 Though only low enantioselectivity values 
were obtained, the validity of libarary screening was demonstrated.  
 
Figure 2-13. (top) Gilbertson’s !-turn phosphine peptide and model structure of its 
palladium(II) complex and (bottom) asymmetric allylic substitution reaction catalyzed by 
the metallopeptide complex.128,129 
To improve selectivity of phosphine-peptide ligands, the second 
generation of ligands was developed based on the "-turn motif. Phosphine 
amino acids were placed in i, i+3 positions on both sides of the Pro–X turn, 
where X is a variable D-amino acid.128 This time, a palladium(II) 
metallopeptide was produced and tested as an asymmetric catalyst for 
asymmetric allylic substitution. Even the initial hits gave 60% ee in the 
model reaction between dimethyl malonate and cyclopentenyl acetate 
(Figure 2-13) and selectivity was improved up to 75% ee with a ligand 
identified from a 96-member library.128 Further optimization of peptide 
position d away from the carboxyl and amino ends of the
turn and toward the residues critical for turn formation,
proline and the D-amino acid (Figure 1). In an attempt to
exert direct control over the environment at the face of the
transition metal, different turn-forming amino acids were
pl ced in the critical i + 1 and i + 2 positions (4). A variety
of hydroxyproline derivatives were examined along with
different D-serine derivatives (3). In general, these changes
resulted in a decrease in reactivi y and selectivity. Another
approach to influence the catalytic selectivity would be to
make changes to the aromatic groups on the phosphine.
While possible using the original synthesis of phosphine
amino acids, the synthesis of a variety of amino acids would
require a considerable amount of work.1 To overcome this
limitation, a new route to phosphine-containing amino acids
had to be developed.13
The new route utilizes chemistry developed by Knochel
(Scheme 2).14,15 Commercially available iodo amino ester
(5) was metalated with zinc and, following transmetalation
with copper, was reacted with a chloro dialkyl or diaryl-
phosphine. The phosphine was then protected as the phos-
phine sulfide. Ester hydrolysis and exchange of Boc for Fmoc
protection provided the desired amino acid in high yield.
This method makes a wide variety of phosphine amino acids
available. For the purposes of this study, a series of
diaromatic phosphine amino acids were synthesized (Table
1) and examined.
With these phosphine amino acids in hand, a library was
synthesized using the aromatic groups on the phosphine as
the source of diversity. Table 2 contains the results from
the study of a small library of !-turn-type peptides with
various aromatic groups attached to the phosphine moiety.
The starting point for the library was Ac-D-Phg-Pps-Pro-D-
Ala-Pps-D-Leu-support, a sequence that provided moderate
success in an earlier study. In general, it appears that when
the phosphine next to proline was larger, the catalyst provided
higher selectivity. There also appears to be a preference for
symmetrical groups on the phosphine, with 3,5-dimethyl-
substituted phenyl providing the highest selectivity (entries
5 and 6). The library also contains examples where the
phosphine amino acid was chiral at phosphorus, as well as
at the R-carbon. These examples provided some of the lowest
selectivities in the study (entries 16-19).
After determining the “best” phosphine-containing amino
acids for the ligand, the other amino acids in the sequence
were examined (Table 3). The turn-forming motif was
retained by maintaining Pro or Oic and a D-amino acid at
the critical i + 1 and i + 2 positions. Substitution of amino
(13) Greenfield, S. J.; Gilbertson, S. R. Synthesis 2001, 2337-2340.
(14) Langer, F.; Puntener, K.; Sturmer, R.; Knochel, P. Tetrahedron:
Asymmetry 1997, 8, 715-738.
(15) Knochel, P.; Yeh, M. C. P.; Berk, S. C.; Talbert, J. J. Org. Chem.
1988, 53, 2390-2392.
Scheme 1
Figure 1.
Scheme 2
Table 1.
entry Ar
yielda,b
of 7
yielda,b
of 8
1 phenyl 75% (7a) 80% (8a)
2 1-naphthyl 43% (7b) 43% (8b)
3 2-naphthyl 55% (7c) 61% (8c)
4 3,5-xylene 73% (7d) 73% (8d)
5 mesityl 40% (7e) 63% (8e)
6 phenyl, 1-naphthylc 73% (7f) 65% (8f)
7 3,5-di-tert-butyl-4-methoxy phenyl 70% (7g) 95% (8g)
8 2,5-xylene 66% (7h) 40% (8h)
a Isolated yields. b Products were enantiomerically pure as determined
by chiral HPLC. c Two diastereomers were separated by column chroma-
tography.
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sequence and reaction conditions yielded catalyst with 95% ee.129,130 The 
study also shows that selectivity is uniquely linked to the chirality of "-turn 
secondary structure and not chirality of individual residues. The substitution 
of turn-stabilizing residues or an increase in the spacing between the 
phosphines results in significantly lower ee values.122,131 Meldal and 
colleagues also utilized peptide-phosphine ligands to synthesize palladium 
metallopeptides for the same asymmetric allylic substitution reaction.132,133  
Aside from phosphine-containing peptides, some work was published 
on the inclusion of amino acids with N-heterocyclic carbene (NHC) 
functionality134 as well as the synthesis of NHC metallopeptides.135-137 
However, only preliminary catalytic results are available.135 
Along with oligopeptides, various groups assessed shorter di- and tri-
peptides in enantioselective catalysis. Hoveyda’s group has been developing 
a series of ligands that have a short peptide backbone and are drastically 
modified at the side chains and termini. Phosphine, pyridyl or phenolic 
groups at the N-terminus provide the metal binding and the unnatural side 
chains of the peptide establish stereoselectivity (Table 2-1). Using the 
combinatorial library approach, they were able to achieve highly 
Table 2-1. General structure of Hoveyda’s peptide ligands149 and examples of the 
enantioselective reactions catalyzed by their metal complexes. 
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enantioselective ligands for a number of metals and a large variety of 
transformations.117,138-154 Similar examples include alkene epoxidation by 
Francis et al.,155 conjugate addition by Breit et al.,156 and Heck reaction by 
Jayasinghe et al.157 In comparison to Gilbertson’s work, these systems 
directly rely on the chirality of the amino acids and not the secondary 
structure of the peptide ligand. 
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Chapter 3 
3.1. Structure and synthesis of dirhodium complexes 
The first records of dirhodium complexes date back to the early 
1960’s when a dirhodium tetraacetate complex was first isolated from the 
reaction of a rhodium(III) salt and acetic acid in ethanol.1,2 An elemental 
analysis provided the composition of the product to be Rh(O2CCH3)2 and its 
crystal structure was determined, establishing a distinctive paddle-wheel 
structure with two rhodium(II) atoms bridged by four carboxylate ligands 
(Figure 3-1).2,3 The distance of only 2.4 Å between the rhodium atoms 
corresponds to a direct bond between the two and explains the unique 
properties of the these binuclear complexes.4 Since this discovery, various 
other complexes were produced featuring a number of bridging ligands 
largely dominated by carboxylates and carboxyamidates.5 The coordination 
of equatorial ligands is typically strong and irreversible, requiring high 
temperatures for ligand exchange to occur.6,7 On the contrary, ligation to the 
axial dirhodium sites is labile, showing preference for soft Lewis bases such 
as phosphines and N-heterocyclic carbenes.7 The properties of the dirhodium 
complexes vary considerably depending on the ligand environment; this 
inspired a number of research groups to undertake ligand optimization to 
produce dirhodium complexes with diverse applications as described below. 
A thorough review of various dirhodium complexes can be found in 
the “Multiple Bonds Between Atoms” book,5 which covers the diversity of 
the available complexes. It is necessary to emphasize the importance of
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Figure 3-1.  Structure of dirhodium tetraacetate complex.4  
equatorial ligands that are typically anionic in character and provide #2 
coordination via a delocalized negative charge. The assortment of the 
bridging ligands can be classified by the atoms bound to the dirhodium: #2-
O,O’ dioxygen ligands such as carboxylates, thiocarboxylates, carbonates 
and sulfates; #2-O,X oxygen-heteroatom(X) ligands such as amidates and 
phosphates; #2-N,N’ dinitrogen ligands such as amidinates and triazenaides; 
and other complexes with rhodium ligated to phosphorus and carbon atoms. 
Though bridging does stabilize the dirhodium core, the complexes with non-
bridging equatorial ligands were also prepared, such as simple complexes 
with monochelating aqua and nitrile ligands or unique diimine and porphyrin 
complexes.5,8-11 
Axial sites of dirhodium complexes are usually occupied by solvent 
molecules unless stronger ligands are present. The scope of axial ligands is 
enormous with examples representing most of the electron-donor 
functionalities.5 Dirhodium complexes have been reported with electron-rich 
nitrogen ligands such as nitriles and nitrogen heterocycles, oxygen-donors 
like water, alcohols and DMSO, and various adducts with phosphines and 
carbenes. The unique structural geometry of the complexes was utilized to 
Rh
Rh
O
O
O
O
O
O
CH3
CH3
CH3
O
O
H3C
L
L
1668 D I C t t R O M I U M  A N D  D I R H O D I U M  T E T R A - A C E T A T E  D I H Y D R A T E  
Table 8. Interatomic distances (A)for 
Cr2(O2CCH3)4(H20)2 
(a) Intramolecular bond distances (b) Short intramolecular 
nonbonded distances 
Cr- -Cr '  2"362 (1) Cr---O(2) 
Cr--O(5) 2.272 (3) Cr---O(3) 
Cr--O(1) 2.030 (2) Cr- -C(1)  
Cr'--O(2) 2.031 (2) Cr---C(3) 
Cr'--O(3) 2.009 (2) O(1)-0(4) 
Cr--O(4) 2.001 (2) O(1)-0(3) 
Average Cr-O 2"018 (8) O(2')-O(4) 
0(2) -0 (3 )  
C(1)-O(1) 1-263 (4) O(1)-0(2) 
c(1)-0(2) 1.268 (4) 0(3)-0(4) 
c(3)-0(3) 1.266 (3) 0(1)-c(2) 
c(3)-0(4) 1.262 (4) 0(2)-c(2) 
Average C-O 1.265 (5) 0(3)-C(4) 
0(4) -C(4) 
C(1)-C(2) 1.488 (4) C(1)-I-I(4) 
C(3)-C(4) 1.492 (5) C(1)-H(22) 
Average C-CH3 1.490 (5) C(1)-H(23) 
C(3) -H(41) 
C(2)-H(21) 0-89 (6) C(3)-H(42) 
C(2)-H(22) 0.80 (4) C(3)-H(43) 
C(2)-H(23) 0.97 (5) Cr---H(51) 
C(4)-H(41) 0.89 (5) Cr---H(52) 
C(4)-H(42) 0.87 (5) 
C(4)-H(43) 0.84 (5) 
Average C-H 0.88 (8) 
O(5)-H(51) 0.79 (4) 
O(5)-H(52) 0"70 (4) 
Average O(5)-H 0-74 (5) 
3.041 (2) 
3.029 (2) 
2.876 (3) 
2.845 (3) 
2.789 (3) 
2.902 (3) 
2.873 (3) 
2.843 (3) 
2.222 (3) 
2.226 (3) 
2.378 (4) 
2.363 (4) 
2.372 (4) 
2.366 (5) 
1.97 (4) 
1"96 (3) 
2.08 (4) 
1.98 (5) 
2"00 (5) 
1"88 (5) 
2'69 
2"78 
(c) 
o(5)-o(i) 
0(5)-0(2) 
Intermolecular distances 
Vector between molecules 
2.962 !, !, 0 
2.820 0 0 -!  
Results 
The molecular structure of the chromium compound is 
shown in Fig. 1 ; the two molecules are isostructural in 
the true sense of the word so that, aside from slight 
quantitative discrepancies, this may be considered to 
co) (- o(1) 
• 0(2) 
4") 
~J~'o(4") v ,,j 
0(1°) ~ 0(2') 
Fig. 1. A convenient projection of the molecular structure of 
Cr2(OECCH3)4.2HaO and RhE(O2CCH3)4.2H20. The 
numbering scheme used in all tables is shown. 
Table 9. Bond angles (o)for Crz(O2CCH3)4(H20)2 
Cr--Cr'--O(3) 87.32 (4)" 
Cr'--Cr--O(4) 88.80 (5) 
Cr '--Cr--O(1) 88-76 (5) 
CruCr ' - -O(2)  87.27 (5) 
Average Cr-Cr-O 88.04 (30) 
Cr'--O(2)-C(1 ) 121.21 (17) 
Cr" --O(3)-C(3) 120.71 (15) 
Cr--O(4)-C(3) 119.67 (12) 
Cr--O(1)--C(1) 119.85 (9) 
Average Cr-O-C 120.36 (45) 
O(1)-C(1)-O(2) 122.7 (1) 
O(3)-C(3)-O(4) 123"4 (2) 
Average O-C-O 123.1 (3) 
O(1)-C(1)-C(2) 119.4 (2) 
O(2)-C(1)-C(2) 117.8 (2) 
O(3)-C(3)-C(4) 118.4 (2) 
O(4)-C(3)-C(4) 118-2 (2) 
Average O-C-CH3 118-5 (5) 
C(1)-C(2)-H(21) 109 (2) 
C(1)-C(2)-H(22) 114 (2) 
C(1)-C(2)-H(23) 114 (2) 
C(3)-C(4)-H(41) 110 (2) 
C(3)-C(4)-H(42) 112 (2) 
c(3)-c(4)-n(43) 104 (3) 
Average C-C-H 111 (5) 
H(21)-C(2)-H(22) 
H(21)'C(2)-H(23) 
H(22)-C(2)-H(23) 
H(41)-C(4)-H(42) 
H(41)-C(4)-H(43) 
H(42)-C(4)-H(43) 
Average H-C-H 
O(1)--Cr--O(5) 
0(2)' -Cr--0(5)  
0(3') -Cr--O(5) 
O(4)--Cr--O(5) 
Average O-Cr-O(5) 
0(1)--Cr--0(4) 
O(1)--Cr--O(3") 
0(4)--Cr--0(2') 
O(2') -Cr O(3') 
Average O-Cr-O 
Cr' Cr--O(5) 
O(1)--Cr--O(2') 
O(4)--Cr--O(3') 
116 (5) 
95 (3) 
108 (4) 
117 (5) 
97 (5) 
115 (5) 
108 (8) 
93.97 (9) 
90.08 (9) 
89.15 (8) 
94-75 (8) 
92"0 (10) 
87"57 (6) 
91"84 (8) 
90"88 (8) 
89.44 (6) 
89-9 (8) 
175-61 (11) 
175"76 (10) 
176.08 (10) 
equatorial ligands!
axial ligand! Rh–O " 2.04 Å!
Rh–L " 2.31 Å  !
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prepare oligomeric and polymeric constructs using multidentate ligands 
coordinated to the opposite axial sites.13,14 The axial dirhodium sites are 
central in catalysis and as the result, strong axial ligands are usually avoided 
as they can interfere with reactivity both via competitive inhibition and via 
the trans-effect between the axial sites.12 The trans-effect is an effect of a 
coordinated ligand on the affinity of the ligand in the trans-position. In this 
case, the decrease in Lewis acidity of the axial dirhodium site affects both 
binding of a substrate and reactivity of the dirhodium center.  
Dirhodium complexes are synthesized via three general methods: the 
reduction of rhodium(III), the oxidation of rhodium(I) compounds in the 
presence of equatorial ligands, or ligand substitution on a dirhodium 
precursor (Figure 3-2). The reduction method is usually employed to 
produce simple tetracarboxylates complexes,1,2,15-18 while the oxidation 
method is only utilized for the synthesis of amidinate complexes.19 Most of 
the dirhodium complexes are prepared from the generic dirhodium 
tetraacetate. Carboxylate exchange can be performed either by heating the 
precursor with neat ligand or by using excess ligand at reflux in a high-
boiling solvent like chlorobenzene.5 This method is efficient for the 
synthesis of a large number of complexes, yet is not suitable under 
circumstances in which the amount of ligand is limited or the ligand is 
unstable at high temperatures. A reduced amount of ligand in the second 
procedure is achieved using Soxlet extraction allowing the ligand exchange 
reaction to be driven to completion by absorbing evolved acetic acid (Figure 
3-2).20 Typically, ligand substitution is pushed until all four ligands are 
replaced, although it can be stopped at the partial exchange, yielding mixed-
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Figure 3-2. General methods for synthesis of dirhodium complexes (left) and Sohlet 
extraction set-up for driving ligand exchange by absorbing volatile acetic acid 
(right).15,17,19,20    
ligand complexes. Kinetic analysis of the exchange of acetates to 
trifluoroacetate ligands demonstrates the preference for formation of the cis-
disubstituted product due to the trans-equatorial effect.7 Cis-geometry 
complexes are also favored with ligands other than carboxylates, indicating 
generality of this trend,19,21-24 with a few exceptions in case of amidates.25,26 
3.2. Catalysis 
Dirhodium complexes are efficient at catalytic decomposition of diazo 
compounds to form highly reactive intermediates that can further undergo a 
variety of transformations, such as insertion into the bonds with hydrogen 
atoms, cycloaddition to unsaturated bonds and ylide formation with electron 
rich atoms. These reactions can be performed enantioselectively, employing 
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one of many chiral equatorial ligands that were developed over the last 
couple decades, therefore making dirhodium a commercially valuable 
catalytic system. Aside from the diazo chemistry, dirhodium had also been 
applied as a catalyst in allylic oxidation, Diels-Alder, silylformylation, 
hydrosilylation, silane alcoholysis and hydroboration.27-36 
Catalytic activity of the dirhodium complexes is attributed to the 
Lewis acidity of the axial coordination sites. In the case of diazo chemistry, 
an electrophilic attack on the diazo-carbon proceeds to the formation of a  
diazonium intermediate (Scheme 3-1, B) that, after expulsion of dinitrogen, 
yields a dirhodium metallocarbene intermediate (Scheme 3-1, C).37,38 The 
slow step of the reaction has been suggested to be the formation of the 
metallocarbene with the preceding step existing as an equilibrium between 
the free diazo substrate and the substrate bound in the diazonium 
intermediate.38 No direct observation of a dirhodium metallocarbene 
intermediate, however, has been reported as the result of its high reactivity. 
The metallocarbene undergoes an immediate attack on an electron-rich 
center of the substrate (Scheme 3-1), or proceeds to the formation of a 
dimer.39  
 
Scheme 3-1. Catalytic cycle of the dirhodium in diazo-chemistry.   
[Rh2] [Rh2]
X
Y
N
X Y
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A diversity of transformations available with this chemistry can be 
categorized in 3 groups: the insertion of carbene across C–H or X–H bond 
(X = N, O, S, Si, etc), the carbene addition to unsaturated bonds with the 
formation of various size rings (cyclopropanation, cyclopropenation, 
aromatic cycloaddition, etc.), and the attack on an electron lone pair of 
heteroatom proceeding with an ylide formation (O, N, P, S ylides).40,41 
Figure 3-3 provides just some of the typical examples while in-depth 
literature is available for a more broad overview.40,42-46 Dirhodium catalysis 
of cyclopropanation and C–H insertion reactions are by far the most 
developed and have found widest application in organic synthesis. These 
reactions can be accomplished in a highly enantioselective manner using 
chiral carboxylate and amidate ligands (Figure 3-3, a-d).5,20,40,45 
Models of reaction transition states help to rationalize 
enantioselectivity and to design new chiral catalysts. In the case of 
cyclopropanation, the $-orbital of the double bond attacks an electrophilic 
carbon at the rhodium center and proceeds to form the product via a three-
centered transition state and simultaneous dissociation of the metal (Figure 
3-1).47-49 A four-centered transition state, on the other hand, was suggested in 
case of the cyclopropenation reaction with an alkyne taking over the 
coordination site at the equatorial position (Figure 3-4).50 Both three-center 
and four-center transition states were proposed to occur in the C–H insertion 
reaction, though the non-dissociative three-centered path is generally more 
accepted.43,44,48,51,52 Enantioselectivity of these transformations is the result of 
steric congestion around the dirhodium active site created by chiral ligands. 
The two major classes of the characteristic dirhodium chiral complexes 
differ in symmetry: D2 in the case of carboxylate complexes with steric bulk 
positioned on the opposing quadrants of the model (Figure 3-4) and C2 in 
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Figure 3-3. Examples of dirhodium catalyzed diazo-reaction: (a) intermolecular 
cyclopropanation,53 (b) intramolecular cyclopropanation,54 (c) intermolecular C-H 
insertion,55 (d) intramolecular C-H insertion,56 (e) Si-H insertion,57 (f) N-H insertion,58(g) 
aromatic cyloaddition,59 (h) carbonyl ylide formation followed by 1,3-dipolar 
cycloaddition.60 (for ligand structure see Figure 3-5) 
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Figure 3-4. Symmetry and transition state of chiral carboxylates and amidate catalysts in 
cyclopropanation and C-H insertion reactions. Black blocks represent steric hindrance 
imposed by chiral ligands.44,47 (Note: amidate catalyst are typically used in intramolecular 
reactions and are depicted as such)44 
the case of amidate complexes that project steric hindrance at the adjacent 
quadrants (Figure 3-4). Both the orientation of the carbene and the approach 
of the substrate are controlled by the chiral environment, providing a 
preference for the formation of one enantiomer. 
The most successful chiral carboxylate ligands are derived from 
amino acids that have chirality at the alpha-carbon (Figure 3-8). Bulky 
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sulphonyl or phthaloyl groups are attached to the amine and oriented toward 
the space around the reaction center. Because these structures tend to be 
rather flexible, the second generation of ligands was designed to allow 
simultaneous coordination of two equatorial positions in the cis-arrangement 
(Figure 3-8). The series of amidate ligands feature four- and five- member 
rings with a chiral center in the position ! to the amide nitrogen (Figure 
3-8). Amidate ligands are subcategorized into pyrollidinates, 
imidazolidinates, oxazolidinates and azetidinates based on the nature of the 
amidate ring. 
The choice of a catalyst depends on the reactivity of the diazo 
substrate and the type of reaction.43 Dirhodium carboxylates are more 
reactive and are preferred catalysts for reactions with acceptor/acceptor and 
donor/acceptor diazo compounds (Figure 3-6).44 The acceptor/acceptor 
substrates tend to be unreactive and require electron-poor dirhodium 
complexes for catalysis, making them challenging substrates for 
enantioselective transformations. The donor/acceptor diazo substrates work 
the best with most carboxylate complexes, fitting well into their reactivity 
profile. High reactivity tends to negatively affect selectivity and thus, 
carboxylate catalysts are often limited to substrates with low reactivity and 
require reactions to be executed at low temperatures.42,44 On the other hand, 
dirhodium amidates are used with the acceptor substrates and perform best 
in intramolecular reactions. Due to the limited symmetry of the complexes, 
they often work poorly in asymmetric intermolecular reactions, where 
carboxylate complexes are most effective.61 In addition, the chemoselectivity 
of these catalysts differs as a function of the electron withdrawing properties  
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Figure 3-5. Examples of chiral dirhodium carboxylate and amidate catalysts.43 
of the equatorial ligands. It was well demonstrated in a competition 
experiment between intramolecular C-H insertion vs. cyclopropanation 
reactions. The catalyst with perfluorinated carboxylate ligands are highly 
selective toward the C-H insertion, the carboxylate complex yields a mixture 
of both products, and the amidate complex favors a cyclopropanation 
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pathway.62 Thus, multiple factors need to be taken into the consideration 
when performing dirhodium-catalyzed diazo transformations. Also, the 
limitations of the catalysts and the diazo substrates leave this area open for 
further development of chiral complexes with a broader scope of reactivity 
and selectivity.  
 
Figure 3-6. Three different classes of diazo substrate depending on the donor/acceptor 
properties of the adjacent groups.44 (Note: !-carbonyl diazo compounds are the most 
common substrates) 
 
Figure 3-7. Chemoselectivity of dirhodium catalysts.62 
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Figure 3-8. Examples of dirhodium catalysis in total synthesis. (a) C-H insertion in the 
synthesis of (S)-(+)-imperanene56 (b) [4+3] dipolar cycloaddition in the synthesis of (-)-
barekol63 (c) N-H insertion in the synthesis of thienmycin64 (d) cyclopropanation and 
rearrangement in the synthesis of (±)-tremulenolide A65 (e) C-H insertion in the synthesis 
of  (-)-colombiasin A.66 
Dirhodium catalysis have found utility in the synthesis of natural 
products and pharmaceuticals with medicinally valuable properties (Figure 
3-8). The asymmetric transformations described above are especially useful, 
allowing for the installation of stereocenters in a complex molecule with a 
high degree of control. Achiral dirhodium catalysts were also widely 
applied, as in the commercialized synthesis of thienamycin antibiotic 
involving dirhodium-catalyzed N-H insertion step (Figure 3-8, c).  
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In summary, dirhodium catalysis in the area of diazo chemistry has 
made great progress in the last few decades and has become an important 
asset for synthetic organic chemistry. Development of chiral ligands 
significantly advanced asymmetric cyclopropanation and C–H insertion 
reactions, while the ability to catalyze oxidation and reduction reactions 
spurs further interest in utilizing dirhodium complexes toward these 
transformations. Also, activity toward diazo compounds has recently been 
recognized as a promising biorthogonal reaction with the capability of 
covalent modification of peptide and protein substrates (section 3.3). 
3.3. Bioorthogonal reactivity 
One of the inspirations for my project stems from the work of Antos 
and Francis, who first evaluated the utility of dirhodium catalysis for site-
selective modification of tryptophan residues with diazo reagents.67,68 In 
their search for bioorthogonal methods of protein modification, they 
explored various transition-metal catalyzed transformations that could 
selectively modify amino-acid side chains.69 The abundance of residues such 
as cysteine, tyrosine and tryptophan are relatively low in natural proteins, 
which makes them attractive targets for selective protein labeling. Some 
methods were available for targeting cysteine or tyrosine residues, yet 
tryptophan had not been previously investigated.  
The tryptophan contains an indole ring that was previously 
demonstrated to be able undergo dirhodium-mediated insertion reactions 
with diazo reagents.70,71 Because the electron-rich character of indoles makes 
them reactive substrates for metallocarbenes they could potentially provide 
the selectivity of modification.72 The challenge with carbene chemistry, 
however, is its intolerance toward water, resulting in the formation of 
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Figure 3-9. Initial reactivity study of dirhodium catalyzed insertion reaction with 3-
methyl indole and styryl-diazo reagent in aqueous solution.67 
an O–H insertion byproduct.73 After screening various diazo compounds, 
Francis identified styryl-diazoacetate as the best substrate.74 The 
donor/acceptor nature of this reagent provides stabilization of the dirhodium 
metallocarbene and sets the preference for reaction with the more reactive 
indole group, rather than water. To improve solubility of the reagent in an 
aqueous environment, a PEG chain was attached to the ester group. In the 
initial test of reactivity with 3-methyl indole, two products were observed, 
corresponding to the C–H and N–H insertions (1.4:1.0 ratio) with an overall 
51% yield along with the by-products of O–H insertion and 
electrocyclization (Figure 3-9). 
The optimized reaction conditions were successfully applied to the 
modification of protein substrates. Based on the MS analysis, the exposed 
tryptophan residues of myoglobin (Figure 3-10) and subtilisin Carlsberg 
were labeled in around 50% yield. Selectivity of modification was further 
confirmed by MS/MS fragmentation, validating the insertion exclusively at 
the expected residues.67 Further studies aimed at improving the methodology 
by expanding the pH range necessary for efficient modification. A 
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significant improvement was observed by employing a tert-butyl 
hydroxylamine buffer (TBHA), allowing the reaction to proceed at a pH up 
to 9, compared to the prior optimal best results with a hydroxylamine buffer 
working only at pH < 6.68 The melitin peptide could be labeled at 60% 
conversion in TBHA buffer at pH 6. The protein lysozyme, which does not 
have any tryptophan residues on the surface, is only labeled under 
denaturing conditions at the temperatures above 75 °C.68 
  
Figure 3-10. Selective labeling of myoglobin at the exposed tryptophan residues with 
styryl-diazo substrate and dirhodium catalyst. 67 
 
Figure 3-11. pH range improvement of the dirhodium-catalyzed protein labeling by using 
tert-butyl hydroxylamine buffer (Reprinted with permission from Antos, J. M. et al. J. 
Am. Chem. Soc. 2009, 131, 6301. Copyright 2009 American Chemical Society).68 
  
Conditions:!
100 µM protein!
10 mM diazo substrate!
100 µM Rh2(OAc)4!
75 mM H2NOH·HCl!
80:20 H2O/ ethylene glycol!
Myoglobin! Labeled tryptophan residues!
tBuNHOH was found to promote efficient melittin modification,
while H2NOH was completely ineffective.
With regard to the site selectivity of the reaction at pH 6.0,
the observation of a doubly modified melittin species suggested
the possibility that additional residues besides tryptophan were
modified as melittin contains only a single tryptophan residue
(W19). In small molecule studies with 3-methylindole, it was
observed that multiple additions could be achieved under
analogous reaction conditions. LC-ESI-MS analysis revealed
that adducts containing as many as three covalent modifications
could be obtained (albeit in minute amounts) using a large excess
of diazo compound (see Figure S4), although this species has
not been observed on peptide and protein substrates. In the case
of melittin, ESI-MS/MS analysis of the doubly modified product
ultimately indicated that both modifications were indeed con-
fined to W19 (Figure 6). Both modifications were restricted to
daughter ions containing W19 and were clearly absent from
fragments lacking this residue. For example, a doubly modified
y′′-ion containing residues 19-26 (m/z) 1754.0) was observed,
while the y′′-ion corresponding to residues 20-26 (lacking W19)
possessed zero modifications (m/z ) 955.6). No fragments were
observed that suggested the modification of any other residue.
While the modification itself was found to be relatively labile
under collisional activation conditions, the use of collision
energies of 15 V or less was sufficient to fragment the peptide
with minimal loss of the modification.
Th detailed structure of the double addition product remains
unknown, largely due to the fact that it is a minor reaction
product that is difficult to isolate. Based on our previous small
molecule studies, we speculate that N-H insertion and alky-
lation at the 2-position of the tryptophan indole ring remain
the major r action pathways.5 Acquisition of both types of
modifications on a single tryptophan residue could account for
the observed doubly modified melittin product. We are also
exploring other reaction possibilities, including the addition of
carbenoids to the double bond in the reaction product itself, or
oligomerization of the diazo compound prior to tryptophan
modification. MS/MS analysis of singly modified melittin was
also performed using MALDI-TOF/TOF (Figure S7) and was
consistent with modification at W19.
Given the structural similarity between H2NOH and tBuN-
HOH, it is tempting to hypothesize that a specific and analogous
interaction between these compounds and the rhodium catalyst
is responsible for the beneficial effects that are observed. Though
rare, the use of solution additives and secondary ligands in
reactions catalyzed by dirhodium tetracarboxylate dimers have
been documented in the literature.24-26 However, in the case
of H2NOH at pH ∼3.5, a specific interaction between hydroxy-
lamine and Rh2(OAc)4 does not appear to be necessary for the
modification of myoglobin with rhodium carbenoids (Figure
7a,b). Rather, the generation of low pH by this HCl salt appears
to be the major role for this additive. This is supported by the
observation that phosphate buffer at pH 3.5 produced compa-
rable levels of myoglobin modification despite the absence of
H2NOH (Figure 7b).
In contrast, the ability of tBuNHOH to promote the modifica-
tion of melittin at pH 6.0 appears to be unique to this additive
(Figure 7c). Phosphate buffer (Figure 7d) or other additives (see
Table 1) all yielded significantly lower levels of melittin
modification. An important role for tBuNHOH appears to be
ts ability to promote efficient carbenoid formation over a much
wider pH range than was attainable using H2NOH. As depicted
in Figure S5, pH profiles measuring the catalytic degradation
of 1 in the presence of H2NOH and tBuNHOH showed that
while H2NOH fails above pH 5.0, tBuNHOH was able to
promote carbenoid formation beyond pH 7.0. Notably, these
results suggest that the nitrogen of tBuNHOH does not inactivate
the rhodium catalyst at higher pH. While the precise mode of
action for tBuNHOH remains unclear, we speculate that a
specific interaction between this additive and Rh2(OAc)4 is
responsible for the substantial increase in catalytic activity.
Currently, we propose that the oxygen of tBuNHOH binds to
Rh2(OAc)4 rather than the nitrogen, the latter being disfavored
by the bulky tert-butyl substituent (Figure 8). We have also
determined that the pKa values for tBuNHOH and H2NOH are
comparable (Figure S6), ruling out the possibility that significant
differences in basicity are responsible for the dramatic differ-
ences in reactivity observed for these additives above pH 5.
Modification of Lysozyme under Thermally Denaturing Condi-
tions at pH 6.0. Having demonstrated successful tryptophan
(24) Nelson, T. D.; Song, Z. J.; Thompson, A. S.; Zhao, M. Z.; DeMarco,
A.; Reamer, R. A.; Huntington, M. F.; Grabowski, E. J. J.; Reider,
P. J. Tetrahedron Lett. 2000, 41, 1877–1881.
(25) Wynne, D. C.; Olmstead, M. M.; Jessop, P. G. J. Am. Chem. Soc.
2000, 122, 7638–7647.
(26) Davies, H. M. L.; Venkataramani, C. Org. Lett. 2003, 5, 1403–1406.
Table 1. Modification of Melittin in the Presence of Various
Solution Additivesa
a Conditions: 100 µM melittin, 100 µM Rh2(OAc)4, 20 mM 1, 2%
tBuOH (v/v), RT, 24 h. Product ratios estimated by MALDI-TOF-MS.
Values represent the average of three independent MALDI-TOF-MS
analyses of the same sample.
Figure 5. Use of tBuNHOH substantially improved the pH range over
which successful modification of melittin could be achieved. Note: Percent
conversion was estimated by MALDI-TOF-MS (sinapinic acid matrix), and
values represent the average of three independent analyses of the sa e
sample (standard deviation indicated by error bars). Conversion values
represent the sum total of all modified species.
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Conditions:!
100 µM melitin!
20 mM diazo substrate!
100 µM Rh2(OAc)4!
75 mM additive!
2% tBuOH in water!
24 h, rt!
tBuNHOH!
H2NOH!
              !
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This chemistry allows labeling of exposed tryptophan residues under 
mild aqueous conditions. It displays good chemoselectivity, especially 
considering the potential reactivity of other electron-rich and often exposed 
residues, such as histidine and tyrosine. While developing my own project, 
one goal was to explore the potential of using peptide-dirhodium conjugates 
to further improve selectivity of this technique. Peptide-protein interactions 
were envisioned to provide selectivity for the targeting and modification of 
the protein of interest with the catalytic dirhodium. The foreseen benefits 
would be an ability to label a specific protein in a mixture, such as a lysate, 
and an improvement in the efficiency of labeling through an enhanced 
effective concentration of the substrate, i.e. amino acid side-chain.  
3.4. Antitumor properties 
Soon after the discovery of dirhodium complexes, they were found to 
possess anticancer properties.75,76 Their activity was suggested to be similar 
to cisplatin, proceeding via interaction of the metal with nucleotides of 
DNA. The potency of typical carboxylate complexes, however, was not a 
match to the cisplatin standard.77 Nevertheless, further discoveries 
demonstrated potential for certain complexes with alternative ligands such as 
amidates or formamidinates and ligands based on 
methoxyphenylphosphine.78-80  
The Aoki and Dunbar groups made a considerable effort to elucidate 
the mechanism of the dirhodium anticancer activity and characterize 
coordination complexes of dirhodium with DNA. It was demonstrated that 
dirhodium was able to form not only axial-coordination adducts with 
nucleotides,26,81,82 but also bridging equatorial complexes.77,83,84 Furthermore, 
chelate complexes with dinuclotides were prepared and structurally 
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characterized by NMR and X-Ray.77,85,86 The pair of nucleotide bases 
coordinates in cis-geometry to the dirhodium, forming a macrocyclic loop 
structurally similar to the cisplatin adduct (Figure 3-12). In more recent 
examples, adducts with oligonucleotides were characterized where 
dirhodium forms an equatorial type complex with adjacent adenine and 
cytosine bases.87 
Heteroleptic (i.e. ligands are not identical) dirhodium complexes with 
diimine ligands are being investigated by Turro and colleagues as candidates 
for photochemotherapy. Dirhodium carboxylate complexes can undergo 
photoexcitation by visible light (300-600 nm) to produce a long-lived 
excited state.88 In the presence of a variety of acceptors, an electron transfer 
leads to formation of the oxidized RhII-RhIII species that are capable of DNA 
cleavage.89 Diimine complexes developed by Turro incorporate an acceptor 
into the dirhodium complex. Bipyridine- and phenanthroline- based ligands  
 
 
Figure 3-12. (left) Overlay of diguanidine (pGpG) adducts of dirhodium (gray, green and 
red) and cisplatin (blue).83 (right) Chemdraw structure of the dirhodium adduct. 
(Reprinted with permission from Chifotides, H. T et al. J. Am. Chem. Soc. 2003, 125, 
10714. Copyright 2003 American Chemical Society).  
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Figure 3-13. Examples of diimine dirhodium complexes developed by Turro for DNA 
photocleavage and cancer treatment.94 
(Figure 3-12) serve a dual purpose, providing intercalation into DNA via $-
stacking and serving as electron acceptors in the direct DNA 
photocleavage.90-93 Significantly, the toxicity of the these dirhodium 
complexes is relatively low in the dark and increases upon illumination.94 
HeLa and COLO-316 cancer cells were successfully killed with the series of 
dppn complexes with LD50 values in the range 70-200 µM.94 Inducing cell 
apoptosis with light has the potential to be developed into a technology for 
cancer treatment. 
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Chapter 4 
Synthesis of dirhodium metallopeptides 
4.1. Introduction 
The development of the procedures for the synthesis of dirhodium 
metallopeptides was one of the initial challenges faced in the beginning 
stages of this project. The difficulties arise from the harsh conditions that are 
used in typical methods of dirhodium complex synthesis as described in 
detail in Chapter 3. Specifically, procedures requiring high temperatures and 
organic solvents are not well-suited for peptide chemistry. Although high 
stability and exchange-inertness of tetracarboxylate complexes were the 
reasons that drew our interest, the same attributes had complicated the 
synthesis of metallopeptides with dirhodium center. In search of a new 
approach, a few other precursors were found in the literature, aside from the 
common dirhodium tetraacetate. The benefits of alternative precursors arise 
either from the point of aqueous synthesis as with dirhodium tetracarbonate 
or lower temperatures as with dirhodium complexes bearing nitrile or 
trifluoroacetate equatorial ligands. 
Dirhodium carbonate is prepared as a sodium salt and is completely 
soluble in water.1-3 Carbonate ligands undergo exchange with carboxylates in 
aqueous solution at reflux (100 °C). The exchange is irreversible due to 
formation of carbon dioxide and does not require excess of the carboxylate 
ligands. The method is attractive because the reaction proceeds in aqueous
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Figure 4-1. Synthesis of dirhodium complexes with dirhodium tetracarbonate 
precursor.1,2 
solution and ligand substitution can potentially be optimized to proceed at 
lower temperatures (Figure 4-1).  
Cotton et al. employed cationic dirhodium complexes with four 
acetonitrile ligands to synthesize organometallic macrocycles where three 
dirhodium centers are bridged via dicarboxylate ligands.4,5 This precursor 
undergoes fast ligand exchange at rt in acetonitrile as the solvent (Figure 
4-2). High reactivity of the complex could provide a necessary improvement 
for development of milder conditions of metallopeptide synthesis. 
 
Figure 4-2. Synthesis of dirhodium complexes from dirhodium precursor with 
acetonitrile ligands and crystal structure of organometallic macrocyclic product.4 
In the most recent example, dirhodium complexes with 
trifluoroacetate ligands were used to produce mixed-ligand complexes 
containing amidate and carboxylate ligands.6 As in the previous case, the 
advantage of this method comes from the mild exchange conditions (Figure 
4-3). However, the use of organic solvents like acetonitrile or THF remains 
an obstacle for application of these methods to peptide substrates. 
Rh2(OAc)4
Na2CO3
Rh2(CO3)4
H2O, 100 °C H2O, 100 °C
RCO2H
Rh2(O2CR)4
MeCN, rt
(Et4N)2(C2O4)
Rh2(Ph2PC6H4)2(MeCN)6*(BF4)2
[ Rh2(Ph2PC6H4)2(C2O4) ]3
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Figure 4-3. Synthesis of dirhodium complexes from dirhodium precursor with 
trifluoroacetate ligands (DPTI is the amidate with its structure displayed in the product).6 
In the development of a protocol of dirhodium metallopeptide 
synthesis, I have tested dirhodium tetraacetate as well as the new precursors 
similar to the ones described above. Small-molecule carboxylate ligands, a 
short dipeptide and longer chain peptides were tried as substrates for 
carboxylate exchange. As a result of these studies, I was able to achive an 
efficient method that allows synthesis of dirhodium metallopeptides under 
mild aqueous conditions. 
4.2. Development of metalation conditions 
The four dirhodium complexes shown in Figure 4-4 were examined as 
precursors for the synthesis of dirhodium metallopeptides. An initial 
screening of the reaction conditions for carboxylate exchange was primarily 
performed with the small dipeptide aspartame that is used as a sweetener. 
  
Figure 4-4. Dirhodium precursors used in developing peptide metalation conditions. 
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Figure 4-5. Synthesis of acetylated aspartame (Amac). 
The structure of aspartame is surprisingly convenient for these studies. It 
features aspartate as the carboxylate source and phenylalanine as the handle 
for UV detection. The methylated C-terminus eliminates the problem of 
multiple   carboxylates that can complicate results via formation of 
oligomeric structures. The only modification that was performed to 
aspartame was acetylation of N-terminal amine (“Amac” substrate, Figure 4-
5) to increase solubility and exclude a potentially reactive group.  
In spite of the complications with dirhodium tetraacetate precursor 
Rh2(OAc)4 described above, this precursor was also evaluated. Heating a 
mixture of this precursor and Amac in a sealed vial at 100 °C overnight gave 
a range of products as a result of mono-, di-, tri- and tetra- substitution 
(Figure 4-6). The reaction can be shifted towards mostly the tetra-substituted 
product by using an excess of the dipeptide or/and using a Soxhlet extractor 
(Figure 4-7). Attempts to use the described conditions for oligopeptide 
metalation have failed. 
Simultaneously I pursued ligand exchange with the other precursor—
dirhodium acetonitrile complex [Rh2(OAc)2(MeCN)6](BF4)2. All attempts to 
achieve ligand exchange with Amac were unsuccessful. Though some 
results were obtained with phenylacetic acid and its sodium salt as 
substrates, a mixture of products was typically observed resulting from the 
O
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Figure 4-6. HPLC of crude ligand exchange reaction between Amac and Rh2(OAc)4 via 
the sealed vial procedure. 
 
Figure 4-7. HPLC of crude ligand exchange reaction between Amac and Rh2(OAc)4 via 
Soxhlet extraction procedure. 
 
Figure 4-8. HPLC of crude ligand exchange reaction between phenylacetic acid (L) and 
[Rh2(OAc)2(MeCN)6](BF4)2 precursor.  
replacement of conditions worked for Amac or aspartame systems and 
resulted in either no reaction or an unidentified mixture of products. 
After positive results were attained with the dirhodium-
trifluoroacetate complexes, studies with the other precursors were 
discontinued. Screening was mostly focused on the cis-Rh2(OAc)2(tfa)2 
complex which is similar to the acetonitrile complex in that the labile 
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ligands are in a cis conformation. Such arrangement of the ligands was 
viewed to be important for potentially bridging two carboxylates chains on 
the same secondary structure elements like a "-hairpin or an !-helix. Clean 
exchange was observed with Amac substrate in various aprotic organic 
solvents in the presence of DIEA as base (Figure 4-9). More importantly, the 
ligand exchange can proceed in aqueous solution buffered with MES (Figure 
4-10). The success of this reaction was found to be strongly dependent on 
pH. Displacement of trifluoroacetates was observed even in unbuffered 
conditions as long as the pH remains in the range of 4.5-6. Lower pH causes 
carboxylates on the side chains of aspartate to be protonated and higher pH 
affects efficiency of the exchange. The effect of free amine was tested via 
addition of butyl amine to mimic side chain of lysine residues.  
 
Figure 4-9. HPLC of crude ligand exchange reaction between Amac and cis-
Rh2(tfa)2(OAc)2 in THF.
 
Figure 4-10. HPLC trace of metalation reaction between acetylated aspartame (Amac, 3 
equiv) and Rh2(OAc)2(tfa)2 (1 equiv) in MES buffer (pH 5.1), 50 °C, 3h. 
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Figure 4-11. HPLC trace of metalation reaction between acetylated aspartame (Amac, 3 
equiv) and Rh2(OAc)3(tfa)1 (1 equiv) in MES buffer (pH 5.1), 50 °C, 3h. 
 
Figure 4-12. HPLC of crude ligand exchange reaction between Amac and 1:1 mixture of 
Rh2(tfa)3(OAc)1 and Rh2(tfa)4 under aqueous reaction conditions. 
No negative effect was observed if the pH was adjusted to the proper value. 
Other precursors with trifluoroacetate ligands Rh2(OAc)n(tfa)4-n also react 
successfully under the described conditions (Figure 4-11 and Figure 4-12). 
4.3. Synthesis of the “zinc finger” (ZF) dirhodium metallopeptide  
The oligopeptide employed for initial studies was derived from bis-
cysteine hairpin domain from a typical zinc finger protein, ZIF268.7 I chose 
to examine the generality of the zinc-binding domain to determine if it could 
serve as the basis for new dirhodium-binding domains through amino-acid 
substitutions to position two Asp residues in place of the zinc-binding Cys. 
The peptide sequence ZF, derived from the ZIF268 fragment P62–A73, 
contains a number of functional groups. Although I considered selective 
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Figure 4-13. Synthesis of a dirhodium metallopeptide ZF-Rh2(OAc)2. 
 
Figure 4-14. HPLC of crude metalation reaction demonstrating complete conversion of 
peptide ZF into metallopeptide ZF-Rh2(OAc)2 (starting from a 1:1 ratio of peptide and 
precursor). 
protection strategies to mask potentially reactive groups, I have discovered 
that developed method provides selective reactivity toward carboxylate side 
chains and enables access to a single dirhodium metallopeptide complex ZF-
Rh2(OAc)2 (Figure 4-13).  
HPLC analysis indicates an efficient transformation with complete 
conversion of the peptide (Figure 4-14). The metallopeptide can be purified 
to homogeneity by RP-HPLC and isolated in 70% yield. Trifluoroacetic acid 
used in the HPLC purification does not affect the structure or function of the 
adduct. The method affords a remarkably efficient synthesis in the presence 
of numerous functional groups, including free amines and potential bridging 
ligands for dirhodium such as terminal carboxamide and guanidine groups. 
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Although at that point I had not yet attempted the metalation of peptides 
containing every natural amino acid side chain, I had tested the inclusion of 
models for His- and Met-containing peptides, two amino acids that show a 
high affinity for other transition metals. The metalation succeeds in the 
presence of 2 equiv of Ac-His-NHMe, allowing isolation of the same 
metallopeptide ZF-Rh2(OAc)2 in >50% yield. The desired metalation is 
observed in the presence of 2 equiv of Ac-Met-OMe as well, but in lower 
yield (ca. 40%), together with unidentified adducts.  
Noteworthy is the ease of macrocyclic ring formation. Bridging the 
dirhodium tetracarboxylate core with traditional ligands has proven 
challenging. Preparative yields of bridged structures have been largely 
limited to m-phenylene structures,3,8-11 and it has been reported that aliphatic 
!,'-diacids give product mixtures and low yields of chelate products.12 Here 
I demonstrate a dirhodium-bridged, 17-membered ring product that can be 
formed in very high yields. 
4.4. Synthesis of metallopeptides with free carboxylates 
Dirhodium metalation at carboxylate side chains is a kinetic, 
irreversible, and largely non-selective process; multicarboxylate peptides 
yield isomeric mixtures of metalated products. As in a generalized example 
shown in Scheme 4-1, metalation with bis-trifluoroacetate precursor of a 
peptide containing three carboxylate side chains would yield a mixture of 
three major products. In some cases it is more expedient to separate the 
statistical mixture of metalated peptides. For example, treatment of the 
peptide Ac-VQDTRL-OH with 1 equiv Rh2(OAc)3(tfa) under developed 
metalation conditions (aq. buffer, pH 4.5, 50 °C) afforded a mixture of 49% 
side-chain metalation, 30% C-terminal metalation, and 21% bis-metalation. 
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These species could be separated by preparative HPLC, but more complex 
peptides with three or more carboxylates make the statistical approach 
unproductive, so a more general synthetic approach was needed. 
The capability to preserve free carboxylates became important in 
designing dirhodium metallopeptides as ligands for proteins. Carboxylate 
residues are often found to be highly conserved and crucial for binding in 
protein–protein interactions, as for example in the interaction between 
proteins with BH3 domain and Bcl-2 protein.13 The overall charge of the 
peptide also has an impact on its solubility, cellular uptake, and electrostatic 
interactions at the protein interface.14,15 I wanted to assess the importance of 
carboxylate-containing residues in the peptide derived from the helical 
domain of the p53 protein (Chapter 7).  
 
Scheme 4-1. (A) Dirhodium metalation is non-selective process that results in formation 
of multiple products in case of polycarboxylate peptide (B) Orthogonal protection 
scheme via allyl ester and palladium-catalyzed deprotection. 
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Scheme 4-2. (right) Synthesis of fluorescein-labeled metallopeptide F-P4-Rh2(OAc)2 and 
(left) HPLC traces of reaction products. Conditions: (a) cis-Rh2(tfa)2(OAc)2, MES buffer 
(pH 4.5), 50 °C, 70% isolated yield. (b) 0.5 equiv Pd(PPh3)4, morpholine, THF/water, 
53% isolated yield for in-situ deprotection (i.e. over two steps). (c) 1.5 equiv FITC, 
DIEA, DMSO. FITC = fluorescein isothiocyanate (yields nor determined). 
To accomplish that I turned to orthogonal carboxylate protection as an 
allyl ester.16 This approach provides a rare example of a transition-metal-
catalyzed transformation on a transition-metal complex as substrate and 
avoids potential complications from dirhodium carboxylate instability under 
acidic, basic, or redox conditions. As shown in Scheme 4-2, metalation of 
peptide P4PG was followed by palladium-catalyzed deprotection of the allyl 
esters. No interference from dirhodium and complete de-allylation were 
observed. In the last step, a fluorescein dye was attached to the N-terminal 
"-alanine to afford the final product F-P4-Rh2(OAc)2. Because fluorescein 
P4PG!
P4PG-Rh2(OAc)2 !
P4-Rh2(OAc)2 !
F-P4-Rh2(OAc)2!
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contains a carboxylate group, it was necessary to delay fluorescent labeling 
to the end of the synthesis. This example also demonstrates ability of 
dirhodium metallopeptide to undergo multiple transformations without 
deterioration of metal complex.  
4.5. Solution structure and stability of zinc-finger metallopeptide 
To understand the effects of a bridging ZF-Rh2(OAc)2 center on 
peptide structure, the solution structure of the metallopeptide in water was 
examined, first by circular dichroism (Figure 4-15). The CD spectrum for 
peptide ZF displays a strong negative peak, diagnostic of a random coil 
conformation, at 200 nm. Upon binding to dirhodium, this feature disappears 
and a new negative feature was observed at 235 nm. These changes are 
consistent with the appearance of a turn element; similar spectra have been 
reported for short turn structures enforced with disulfide bond formation at 
similar (i, i+3) spacing.17,18 
 
Figure 4-15. CD spectra (residual molar ellipticity in deg cm2 dmol-res-1 ( 103) of the 
free peptide ZF (broken line) and metallopeptide ZF-Rh2(OAc)2 (solid line) at pH = 7 in 
water.  
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 The structure in aqueous solution was further probed by NMR, 
employing COSY, NOESY, ROESY, HSQC-13C and HSQC-15N 
experiments. Distance, dihedral, and coupling restraints from 2D NMR 
experiments were used in simulated-annealing molecular dynamics 
calculations with CNS software (Figure 4-16).19 An overlay of 16 
representative structures (Figure 4-16) indicates that the Phe2 to Gly8 region 
of ZF-Rh2(OAc)2 is well ordered in solution, while the C-terminal domain is 
best described as a random coil.20 Comparison of the structure of ZF-
Rh2(OAc)2 with that of the parent zinc-finger protein indicates that the turn 
domain, D4–D7, exhibits a similar backbone structure. However, the ligating 
Asp residues project into the opposite face of the turn structure compared to 
the zinc-finger structure, a change that alters the direction of both chains and 
greatly alters their orientation. 
Table 4-1. Statistics for 16 representative solution structures of the ZF-Rh2(OAc)2 from 
molecular dynamics simulations. 
  
 
restraining constraints   constraint violations   
total:  103 distance violations, >0.5 Å 0 
distance, i= j 51 rms deviations 0.03 
distance, | i - j | = 1 32 dihedral violations, >5° 1 
distance, | i - j | > 1 10 rms deviations 3.35 
dihedral 3 J coupling violations, >1 Hz 3.13 
J coupling  7 rms deviations 0.98 
constraints/ residue 9.4   
  rmsd for selection  (Ala3-Gly8 and dirhodium center): 
  backbone and  rhodium atoms 0.27 
  all heavy atoms 0.40 !
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Figure 4-16. (top) Overlay of 16 representative conformations of ZF-Rh2(OAc)2 
metallopeptide from simulated annealing molecular dynamics calculations based on 
NMR structural constraints and (bottom) overlay of one calculated conformation (blue) 
with that of the analogous zinc-finger sequence (orange). 
The dirhodium metallopeptide was found to be stable to a variety of 
buffers and pH. Nevertheless I have observed slow decomposition of ZF-
Rh2(OAc)2 in acetate buffer (pH 7) with clean formation of free peptide ZF. 
Further exploration has revealed that the dirhodium center can be cleaved 
from the peptide under relatively mild conditions (Figure 4-17): treatment of 
a solution of ZF-Rh2(OAc)2 with acetate buffer (0.1 M) at pH = 6 results in 
ligand substitution that produces the original peptide ZF and dirhodium 
tetraacetate complex Rh2(OAc)4. The release of dirhodium from the peptide 
is slow at room temperature, requiring days to reach completion. Mild 
heating (50 °C) allows this process to be complete within a few hours, and 
increased potassium acetate concentrations also accelerate the reaction. The 
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mild metalation and cleavage conditions allow cycling between bound and 
unbound states in a single pot. Thus, treatment of the peptide ZF with 
developed metalation conditions affords quantitative conversion of the 
peptide to the bridging dirhodium structure ZF-Rh2(OAc)2. Direct treatment 
of the reaction mixture with an acetate solution reverses this transformation, 
reforming the free peptide without significant by-products being observed. 
 
Figure 4-17. HPLC analysis of reversible dirhodium metalation of peptide ZF. (a) 
Peptide ZF. (b) Crude reaction of the complex Rh2(tfa)2(OAc)2 with peptide ZF to form 
ZF-Rh2(OAc)2. (c) Direct treatment of the crude metalation reaction with KOAc, 
demonstrating reversibility of the complexation process through release of Rh2(OAc)4 in 
a single reaction pot. (d) Metallopeptide ZF-Rh2(OAc)2 after purification by RP-HPLC. 
4.6. Conclusion 
I present an efficient and reversible method of bridging distal 
carboxylate side chains with a dirhodium metal center. The method is 
compatible with aqueous, non-denaturing conditions and features chemistry 
that is orthogonal to other peptide cross-linking strategies. I demonstrate that 
dirhodium binding can be used to control the conformation of the bound 
peptide via formation of a macrocycle. Further investigations that utilize this 
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concept are described in the other chapters of this thesis and demonstrate 
control of peptide secondary structure and coiled coil heterodimerization.  
Peptide-dirhodium conjugates offer unique and modular control over the 
ligand environment around a dirhodium center. Thus dirhodium reactivity 
and selectivity might be controlled by appropriate polypeptide ligands. This 
essential development of dirhodium metallopeptide synthesis and initial tests 
of their catalytic activity have further led to application of peptides as 
ligands in dirhodium catalysis. 
4.7. Experimental section 
4.7.1. General information 
Peptide synthesis. All peptides were synthesized with an Advanced 
ChemTech APEX 396 Automated Multipeptide Synthesizer using standard 
solid-phase Fmoc protocols. The purification was accomplished by reverse-
phase HPLC with gradients of water-acetonitrile containing 0.1% 
trifluoroacetic acid, and peptides were isolated by lyophilization. Analysis 
and purity assessment was attained by mass spectrometry and analytical 
HPLC. Peptides were prepared using Rink amide MBHA resin (AAPPTEC) 
to afford the C-terminal amide and were acetylated at the N-terminus prior 
to cleavage from the resin. 
Circular Dichroism Spectroscopy.  CD spectra were obtained on 
Jasco-J810 spectropolarimeter using a 0.01 cm cell. The spectra were 
acquired with a 1 nm interval in the range of 180–250 nm. The temperature 
was maintained at 20 °C by Jacso PTC423S water bath. Peptide 
concentrations were 0.5 mM in buffer (50 mM PO4, 100 mM KCl). The 
results were converted to mean residual ellipticity by the equation below: 
[)] = )obs / (10(l(C(N) 
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where )obs is the ellipticity in millidegrees of rotation, l is the optical path 
length of the cell in cm, C is the concentration of the peptide in mol/L, and 
N is the number of residues in the peptide. 
HPLC analysis and purification. HPLC was performed on a 
Shimadzu CBM-20A instrument with Phenomenex Jupiter 4* Proteo 90A 
(250 ( 15 mm preparative) and Phenomenex Jupiter 4* Proteo 90A (250 ( 
4.6 mm analytical) columns. Flow rates of 8 mL/min and 1 mL/min were 
used for preparative and analytical columns, respectively. Analytical and 
preparative HPLC were performed with gradient of acetonitrile in water. 
Both solvents contained 0.1% trifluoroacetic acid (TFA) unless otherwise 
noted. Two wavelengths — 220 nm and 300 nm — were used to allow for 
independent analysis of peptides and dirhodium complexes.  
Mass Spectrometry. MALDI-MS and MS/MS analyses were 
performed on a Bruker Daltonics Autoflex MALDI- TOF/TOF mass 
spectrometer with CHCA matrix (10 mg/mL, Thermo Scientific Pierce). 
ESI-MS was performed on Bruker Daltonics micrOTOF instrument. 
NMR Spectroscopy. 1D Spectra were measured with Bruker 500 
UltraSield™ (500 MHz) spectrometer or Oxford (400 MHz) spectrometer. 
1H NMR are reported in units of part per million (ppm). Standard 
abbreviations are used to indicate signal multiplicity: s, singlet; d, doublet; t, 
triplet; q, quartet; m, multiplet. Coupling constants are reported as J value in 
Hertz (Hz). nH describes the number of protons (n) from integration.  All 2D 
NMR spectra were acquired on 500 MHz Varian Inova NMR Spectrometer 
at 25°C. Samples were prepared in 90:10 H2O/D2O at 6 mM concentration 
and were buffered to pH 5.5 with sodium acetate-d3. Mixing time used for 
NOESY was 400 ms and for ROESY, 200 ms. Acquisition times of 500 ms 
(ROESY) and 1000 ms (NOESY) were used in the direct dimension and 100 
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ms in the indirect dimension. 2D NMR data were processed with 
NMRPipe19 and analyzed using the Sparky program(21) (Table 4-2). 
4.7.2. Synthetic procedures 
Synthesis of known compounds. The dirhodium complexes cis-
Rh2(tfa)2(OAc)2, Rh2(OAc)2(MeCN)6•(BF4)2 and Rh2(CO3)4 were prepared 
according the published procedures.2,5,6 Rh2(tfa)1(OAc)3, Rh2(tfa)3(OAc)1 and 
Rh2(tfa)4was isolated as the byproducts of cis-Rh2(tfa)2(OAc)2 synthesis. 
Synthesis of N-acetyl-L-aspartyl-L-phenylalanine methyl ester 
(Amac). Aspartame (100 mg, 0.34 mmol, 1 equiv) was suspended in 
acetonitrile (1.15 mL) and pyridine (275 *L, 3.4 mmol, 10 equiv) was 
added. Acetic anhydride (64 *L, 0.68 mmol, 2 equiv) in acetonitrile (0.85 
mL) was then added to a stirring mixture. After 5 minutes the solvent was 
removed by nitrogen stream and solid was dissolved in 5 mL of 0.5 M 
KHSO4. The solution was extracted with 3 portions of EtOAc. The organic 
phase was dried with anhydrous Na2SO4 and solvent removed in vacuo. No 
purification was needed and product was isolated as white solid (87.8 mg, 
77%). 1H NMR (MeOD, 400MHz): 1.93 (s, 3H, CH3-C(O)), 2.59 (dd, 1H, 
J=7.6 Hz, J=16.8 Hz, CH(H)-COOH), 2.77 (dd, 1H, J=6 Hz, J=16.8 Hz, 
CH(H)-COOH), 3.03 (dd, 1H, J=3.6 Hz, J=14 Hz, CH(H)-Ph), 3.13 (dd, 1H, 
J=5.6 Hz, J=14 Hz, CH(H)-Ph), 3.69 (s, 3H, COOCH3), 4.65 (dd, 1H, J=3.6 
Hz, J=5.6 Hz, CH(Phe)), 4.72 (dd, 1H, J=7.6 Hz, J=6 Hz, CH(Asp)), 7.17-
7.29 (m, 5H, PhH). 
Procedure for ligand exchange on Rh2(OAc)4 precursor in sealed 
vial. The dipeptide Amac (2.3 mg, 6 equiv) and Rh2(OAc)4 (0.5 mg, 1 equiv) 
were placed in a 4mL vial. The vial was tightly closed with a screw cap with 
PTFI/SIL septum. Atmosphere inside the vial was replaced with nitrogen 
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and a solvent (0.5 ml per 1 mg of rhodium acetate) was added. The cap 
wrapped by Teflon tape and reaction was heated at 100 °C for overnight. 
After mixture was cooled to rt, 1 mL of 50:50 water/MeCN solvent was 
added and filtered through 13 mm/ 0.2 *m syringe filter. Analysis and 
separation were done by HPLC (Figure 4-6) and products were analyzed by 
MALDI-MS. 
Procedure for ligand exchange on Rh2(OAc)4 precursor with 
Soxhlet extraction. The dipeptide Amac (40 mg, 12 eq), Rh2(OAc)4 (5 mg, 
1 equiv) and a stir bar were placed in two-necked round bottom flask. The 
Soxhlet extractor was filled with potassium carbonate-sand mixture and 
installed on the top of the flask. The second neck was tightly closed with a 
screw cap with PTFI/SIL septum. A condenser was mounted on the top of 
the extractor and all joint were tightly secured. Atmosphere inside the 
system was replaced with nitrogen and 5 mL of solvent (THF, dioxane or 
PhCl) was added. The assembly was connected to nitrogen line through the 
top of the condenser and was heated at 120-180 °C for 12-72 hours. Mixture 
was cooled to rt; the solvent was removed by a nitrogen jet; 1 mL of 50:50 
water/MeCN solvent was added and solution was filtered through 13 mm/ 
0.2 *m syringe filter. Analysis and separation were done by HPLC (Figure 
4-7) and products were analyzed by MALDI-MS. Tetra-substituted product 
Rh2(Amac)4 was isolated by lyophilization (12.2 mg, 70 %). 
Procedure for ligand exchange reaction between phenylacetic acid 
and Rh2(OAc)2(MeCN)6*(BF4)2 precursor. Sodium salt of phenylacetic 
acid (6.2 mg, 5 eqiuv), Rh2(OAc)2(MeCN)6•(BF4)2 precursor (5.77 mg, 1 
equiv) and a stir bar were placed in a 4 mL vial. Vial is sealed with a screw 
cap with PTFI/SIL septum and atmosphere inside the system was replaced 
with nitrogen. Methanol (0.5 mL) was added via syringe and reaction is 
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heated at 50 °C overnight. Analysis and separation were done by HPLC 
(Figure 4-8).  
General procedure for ligand exchange with cis-Rh2(tfa)2(OAc)2 
precursor in organic solvents. Aspartame or Amac (3 equiv), cis-
Rh2(tfa)2(OAc)2 (1 equiv) and a stir bar were placed in the 4 mL vial. A 
solvent (1 mL per 3 mg of the precursor) was added. DIEA (10 equiv) was 
added and reaction stirred at rt overnight. Analysis and separation were done 
by HPLC and products were analyzed by MALDI-MS. Using this procedure 
Rh precursor (3 mg) was converted into Rh2(Amac)2(OAc)2 product (4.1 mg, 
75% yield) in THF as the solvent (Figure 4-9). 
Procedure for ligand exchange with cis-Rh2(tfa)2(OAc)2 precursor 
in aqueous solution. Amac (1.8 mg, 3 equiv), cis-Rh2(tfa)2(OAc)2 (1 mg, 1 
equiv) and a stir bar were placed in a 4 mL vial. The mixture was dissolved 
in water (0.33 mL) and pH adjusted to 5.1 with 0.1 M NaOH. The reaction 
was heated at 50 °C for 3 h and monitored by HPLC (Figure 4-10). (Note: 
initial screening conditions; for optimized conditions, refer to general 
procedure for synthesis of metallopeptides) 
Procedure for ligand exchange with Rh2(tfa)1(OAc)3 precursor in 
aqueous solution. Amac (2.0 mg, 3 equiv), Rh2(tfa)1(OAc)3 (1 mg, 1 equiv) 
and a stir bar were placed in a 4 mL vial.  MES buffer (0.33 mL) was added 
and pH adjusted to 4.4 with 0.1 M NaOH.  The reaction was heated at 50 °C 
overnight and analyzed by HPLC (Figure 4-11). 
Procedure for ligand exchange with a 1:1 mixture of 
Rh2(tfa)3(OAc)1 and Rh2(tfa)4 precursors in aqueous solution. Amac 
(2.27 mg, ~5 equiv), precursors mixture (1 mg) and a stir bar were placed in 
a 4 mL vial. MES buffer (0.4 mL) was added and pH adjusted to 4.5 with 
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0.1 M NaOH.  The reaction was heated at 50 °C overnight and analyzed by 
HPLC (Figure 4-12). 
Synthesis of dirhodium-peptide complex ZF-Rh2(OAc)2. Peptide 
ZF (18.6 mg, 0.014 mmol, 1 eq), cis-Rh2(tfa)2(OAc)2 (7.7 mg, 0.014 mmol, 
1 eq), MES (108 mg, 0.56 mmol, 40 eq) and a stir bar were placed in a 4 mL 
vial. Water (2.6 mL) was added and pH adjusted to 4.5 with 0.1 M NaOH. 
The reaction was heated to 50 °C for 3 h and monitored by HPLC (Figure 
4-19). The complex was purified by HPLC and was isolated in pure form 
upon lyophilization. Isolated product is a green solid (16.1 mg, 70 %).  
In situ formation and cleavage of the dirhodium-peptide complex 
ZF-Rh2(OAc)2 (Figure 4-17). Peptide ZF (1.0 mg, 0.76 *mol), cis-
Rh2(tfa)2(OAc)2 (7.7 mg, 0.76 *mol), MES (5.9 mg, 0.15 mmol) and a stir 
bar were placed in ta 4-mL vial. Water (0.3 mL) was added and the pH 
adjusted to 4.1 with NaOH (0.1M aq. solution). The reaction was heated to 
50 °C for 2.5 h and monitored by HPLC. After complex formation was 
complete KOAc (59.0 mg, 0.60 mmol) was added as a solid. The reaction 
proceeded at 50 °C and was monitored by HPLC.  
Synthesis of dirhodium metallopeptide P4PG-Rh2(OAc)2. Peptide 
P4PG (18.6 mg, 0.014 mmol, 1 eq), cis-Rh2(tfa)2(OAc)2 (7.7 mg, 0.014 
mmol, 1 eq), and a stir bar were placed in a 4 mL vial. MES buffer (0.1 M, 
pH 4.9) was added and the reaction was heated to 50 °C for 3 h. The 
complex was purified by HPLC and was isolated in pure form upon 
lyophilization. Isolated product is a green solid (16.1 mg, 70 %) (Figure 
4-23). 
General procedure for palladium deprotection.  Allyl deprotection 
was performed directly on the crude metalation reaction (1 mM in MES 
buffer, pH 4.5). A solution of Pd(PPh3)4 (0.5 equiv) and morpholine (10 
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equiv) in THF (volume is equivalent to the volume of buffer solution in the 
preceding reaction, i.e. 50:50 THF/water final solution) were added to the 
crude metalation reaction and the pH was adjusted to 7.0 with KOH (0.1 M 
aq solution).22 The reaction was monitored by HPLC, reaching completion 
after 0.5–1.5 h. Metallopeptides were purified by RP-HPLC, isolated by 
lyophilization, and characterized by ESI–MS. Using this general procedure 
P4 peptide (1.80 mg) was converted to the unlabeled P4-Rh2(OAc)2 
metallopeptide (1.06 mg, 53%) (Figure 4-21). (Note: deprotection can be 
performed on isolated metallopeptide as well) 
4.7.3. NMR study and structure calculation.  
Structure calculations were performed with the software program 
CNS using three-stage simulated annealing in cartesian molecular 
dynamics.19 We used 103 distance restraints, 3 dihedral restraints and 7 
coupling restraints for the 12 residue peptide, for an average of 9.4 restraints 
per residue (Figure 4-16). Topology and parameter files for the dirhodium 
core were created based on the Cambridge Structural Database entry 
KABWOZ (dirhodium tetraacetate). To ensure that the topological 
constraints of ligation to the dirhodium core did not bias the computational 
sampling of structures consistent with our experimental NMR data, we 
treated the dirhodium diacetate, ligand and the peptide as initially distinct 
molecules, with a starting structure for our conformational search consisting 
of the fully extended peptide chain and the newly described DRA 
(dirhodium acetate) residue. The metal core was represented as dirhodium 
tetraacetate but with non-bonded interactions eliminated for the atoms of 
two cis acetates, and distance restraints were used to superimpose the CG, 
OD1, and OD2 atoms of Asp4 and Asp7 on the carboxylate carbons and 
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oxygens of the replaced acetate ligands. Simulated annealing was used to 
search for conformations that simultaneously satisfy the experimental NOE 
and dihedral restraints as well as the distance restraints that position the Asp 
carboxylates so that they ligate the dirhodium. The results of these searches 
did not change significantly when the force constants for distance restraints 
connecting the Asp side chains to the dirhodium core were varied. From 30 
simulated annealing structures, 16 structures were accepted that had low 
overall energy, good bonded geometry, and no NOE violations larger than 
0.5 Å. Atoms for the replaced acetates were deleted from the PDB files but 
can be regenerated by superimposing the coordinates of KABWOZ on the 
rhodium and acetate atoms. 
 
4.7.4. Experimental data 
 
Figure 4-18. HPLC and MALDI-TOF MS of the peptide ZF. Calculated mass [M+H]+: 
1322.7; found: 1322.4. 
Minutes
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Figure 4-19. HPLC of the crude coupling reaction (left) and of the isolated complex ZF-
Rh2(OAc)2  (right) and ESI-MS of the isolated complex ZF-Rh2(OAc)2. Calculated mass 
[M+H]+: 1644.6; found: 1644.6. 
 
Figure 4-20. HPLC trace and MS data for isolated P4PG peptide. Calculated mass 
[M+H]+: 2143.0; found: 2143.0. 
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Figure 4-21. HPLC trace and MS data of purified metallopeptide P4-Rh2(OAc)2. 
Calculated mass [M+H]+: 2384.8; found: 2385.9. 
 
Figure 4-22. HPLC trace and MS data of purified fluorescein-labeled metallopeptide F-
P4-Rh2(OAc)2. Calculated mass [M+Na]+: 2796.2; found: 2796.8.  
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Figure 4-23. HPLC trace of crudes of metalation reaction (top), in-situ palladium 
deprotection (center) and fluorescein labeling with FITC (bottom) for P4 metallopeptide 
synthesis. 
 
 
 
Figure 4-24. 1H-NMR in 90:10 H2O/D2O of peptides and their dirhodium complexes (A) 
peptide ZF, and (B) metallopeptide ZF-Rh2(OAc)2 . 
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Figure 4-25. Representative region of the ROESY spectrum for ZF-Rh2(OAc)2 
metallopeptide.  
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Table 4-2. Chemical shifts of ZF-Rh2(OAc)2 metallopeptide. 
 
Continued on the next page 
  
Residue Atom name Atom type 
Shift 
(ppm)  Residue Atom name 
Atom 
type 
Shift 
(ppm) 
Pro1 HA H 4.31  Ser5 HN H 8.05 
 HB2 H 2.42   HA H 4.1 
 HB3 H 2   HB2 H 3.91 
 HG H 2.01   HB3 H 3.84 
 HD H 3.37   CA C 62.15 
 CA C 62.42   CB C 63.03 
 CB C 32.57  Ile6 HN H 7.87 
 CE C 49.48   HA H 4.1 
 CG C 26.54   HB H 2.03 Phe2 HN H 8.73   HG1 H 1.03 
 HA H 4.67   HG21 H 1.34 
 HB2 or HB3 H 3.04   HG22 H 1.52 
 HB2 or HB3 H 3.12   HD H 1 
 HD H 7.26   CA C 60.58 
 HE H 7.31   CB C 38.15 
 HH H 7.3   CD C 13.93 
 HZ H 7.3   CG1 C 18.12 
 CA C 62.42   CG2 C 28.09 
 CB C 32.57  Asp7 HN H 7.35 Ala3 HN H 8.49   HA H 4.32 
 HA H 4.27   HB2 or HB3 H 2.73 
 HB H 1.33   HB2 or HB3 H 2.69 
 CA C 52.73   CA C 54.57 
 CB C 18.91   CB C 39.48 Asp4 HN H 8.27  Gly8 HN H 7.97 
 HA H 4.74   HA1 H 3.86 Asp4 HB2 H 2.43   HA2 H 3.95 
 HB3 H 2.69   CA C 45.55   CB   40.02  !! !! !! !!!
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Continued 
 
 
Residue Atom name Atom type 
Shift 
(ppm) 
!
Residue Atom name Atom type 
Shift 
(ppm) 
Arg9 HN H 7.88 
!
Phe11 HN H 8.24 
 HA H 4.28 
!
 HA H 4.61 
 HB2 or HB3 H 1.75 
!
 HB2 or HB3 H 3.02 
 HB2 or HB3 H 1.79 
!
 HB2 or HB3 H 3.15 
 HG H 1.57 
!
 HD H 7.26 
 HD H 3.16 
!
 HE H 7.31 
 HE H 7.13 
!
 HH H 7.3 
 HH1 H 7.02 
!
 HZ H 7.3 
 HH2 H 6.98 
!
 CA C 57.65 
 CA C 56.26 
!
 CB C 43.51 
 CB C 30.8 
!
Ala12 HN H 8.21 
 CG C 27.05 
!
 HA H 4.24 Lys10 HN H 8.21 
!
 HB H 1.34 
 HA H 4.24 
!
 CA C 52.34 
 HB H 1.66 
!
 CB C 19.57 
 HG1 H 1.26 
!
OAc1 H H 1.88 
 HG2 H 1.32 
!
 C C 25.57 
 HD H 1.61 
!
OAc2 H H 1.89 
 HE H 2.94 
!
 C C 25.57 
 HZ H 7.5 
! ! ! ! ! CA C 56.46 
! ! ! ! ! CB C 33.1 
! ! ! ! ! CD C 29.09 
! ! ! ! ! CE C 42.22 
! ! ! ! !  CG C 24.72 
!
! ! ! !!
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Chapter 5 
Dirhodium based control of peptide folding and 
assembly 
 
5.1. Introduction 
Peptide secondary structure drives molecular functions such as 
binding to target proteins and aggregation into defined supramolecular 
materials. As such, there is a long-standing interest in chemistries that 
control secondary structure in a well-defined manner. One powerful way to 
affect polypeptide structure is through methods that link, or bridge, two 
amino-acid side chains to form a cyclic product. Metal ions serve structural 
roles in metalloproteins, where side chains act as ligands, which are bridged 
by a metal ion. Taking a cue from these biological examples, the effects of 
metal binding on peptide structures is an active area of study.1-9 Peptide-
metal interactions have been used to understand metalloprotein folding and 
energetics and to shed light on potential toxicity pathways.10,11 Many 
transition metals can bind to peptides in aqueous solution, most commonly 
through cysteine or histidine residues.12-18 
In this chapter, I describe the utility of dirhodium to control peptide 
structure by bridging two carboxylate residues. In the first part, reversible 
dirhodium metalation is evaluated as an approach to control assembly of a 
coiled-coil structure and in the second part, bridging metalation is utilized as 
a technique to stabilize or induce peptide helical conformation. 
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I sought to establish if reversible dirhodium binding could be used to 
control the supramolecular association and ordering of multiple peptides. 
Coiled coils are peptide assemblies that play key roles in biological 
processes, such as signal transduction. Altering these interactions allows 
elucidation of important pathways and also forms the basis for new 
therapeutic strategies.  These studies were focused on the model E3/K3 
heterodimeric coiled-coil system (Figure 5-1), initially reported by Hodges19 
and widely utilized by others.20-23 Based on naturally occurring coiled-coil 
protein domains, coiled-coil systems feature a heptad repeat (denoted 
abcdefg) in which hydrophobic residues at positions a and d are situated 
along one side of an !-helix structure, providing a driving force for peptide 
dimerization through the hydrophobic effect.24 A heterodimeric coiled coil 
can be achieved through additional interactions.25 In the E3/K3 system, 
charged residues flanking the hydrophobic interface (positions g and e) 
create salt bridges stabilizing the heterodimer assembly. Thus, the 
 
Figure 5-1. E3/K3 heterodimeric coiled coil (ISAL series) developed by Hodges.19 
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polycationic K3 dimerizes in the presence of the polyanionic E3, while 
charge-charge repulsion prevents homodimerization. Finally, the peptides E3 
and K3 adopt !-helical conformations only when present as dimeric coiled-
coils. Otherwise, they exist as random coils. 
At the same time, I became interested in using dirhodium centers as 
ligands for carboxylate side chains to stabilize helical structure. Helix 
stabilization is an established method to improve or re-establish the binding 
affinity of peptides and hence, to improve the biological function.26 To 
achieve structure stabilization, a variety of methods have been explored by 
others.27-30 Non-natural amino acids have been employed in covalently-
bridging distal amino acids to favor helix formation.31 Covalent 
modifications by ring-closing metathesis32-34 and 1,3-dipolar cycloaddition35 
have enabled the creation of helical structures in short peptide sequences. 
Wholly non-natural peptide mimics, such as " peptides and aryl-based 
oligomers, have also been shown to achieve improved helicity.36-44 Although 
progress has been made in this area, the requirement for non-natural amino 
acids represents a considerable drawback. Control of peptide secondary 
structure with organic reagents through selective bioconjugation 
methodologies also remains limited.45-55 Alternatively, metal–polypeptide 
interactions are a long-standing area of study that enables the control of 
structure and function in metallopeptide complexes.2-6,9,56-60 
A new strategy employing a dirhodium linker could address a number 
of limitations of current methods.61,62 First, carboxylate side chains are 
largely unexplored as sites for selective reactivity or metal binding.62-67 
Well-defined metal binding to natural polypeptides in water typically has 
been confined to histidine, cysteine, and methionine residues that contain 
“soft” ligands for monomeric metal centers (see Scheme 5-1).56,57,68-74 
  95 
Whereas selective binding of carboxylate residues in a fully deprotected 
peptide remains a challenge, dirhodium is well suited for carboxylate 
metalation, in part because carboxylates coordinate through a #2 orientation 
that bridges the Rh–Rh bond and engenders increased stability against ligand 
substitution.  
Second, previous studies of metal-mediated helix induction typically 
examine peptides under controlled conditions. Metallopeptides with non-
biological metal centers ligated by natural amino acid side chains that are 
stable in the presence of diverse biomolecules are rare,75,76 and the toxicity of 
metallopeptides is largely unexplored. Third, the extent of helical 
stabilization in metallopeptides is limited or difficult to predict, and the 
structural requirements for efficient helix induction are not fully understood. 
For example, simple hydrocarbon tethers have been successfully used to 
induce helicity,34 but tethered peptides do not necessarily show significant 
increases in helicity—the impact of tether length, tether structure, and 
peptide sequence on the extent of increased helicity is not clear. 
Computational progress toward a predictive model for helical induction for 
hydrocarbon tethers has recently been reported.77 
 
Scheme 5-1. Strategies to stabilize or induce a-helical secondary structure in peptides. 
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5.2. Control of coiled coil heterodimerization 
Based on the previous reports, I synthesized E3 and K3 peptides 
identical to those of Hodges except for an isostructural C-terminal 
modification of K3 (E21Q) to remove the third glutamate residue to simplify 
product analysis. According to the theory of coiled-coil peptides, this 
modification should not affect interstrand interactions. Metalation of K3 
peptide affords K3-Rh2(OAc)2, which can be analyzed by mass spectrometry 
and purified to homogeneity by HPLC. The dirhodium efficiently bridges 
carboxylates to afford a cyclic product with 30 atoms in the ring. 
As anticipated, E3, K3, and K3-Rh2(OAc)2 all exist as random coils 
when examined separately in aqueous solution, as evidenced by their CD 
spectra (Figure 5-2). Consistent with previous work, a 1:1 mixture of the 
peptides E3 and K3 dimerize to give a coiled-coil structure (Scheme 5-2 and 
Figure 5-3).19 The K3 peptide has two Glu residues with i, i+7 spacing. In an 
!-helix, Glu side chains are not long enough to span the i, i+7 spacing 
(Scheme 5-2), so that dirhodium adduct K3-Rh2(OAc)2 should not be 
capable of achieving an !-helical structure. In line with my hypothesis, 
mixtures of E3 and K3-Rh2(OAc)2 display no evidence of coiled-coil 
structure (Figure 5-2), remaining as random coils even in the presence of the 
complementary peptide. Thus, dirhodium bridging allows us to prevent the 
folding and binding of the complementary peptide E3 as well. Dirhodium 
binding is readily reversible in this case as well; treatment of the mixture of 
E3 and K3-Rh2(OAc)2 with potassium acetate at pH 6 allows facile removal 
of the dirhodium center. CD analysis indicates that the coiled-coil secondary 
structure is reestablished upon dirhodium cleavage (Figure 5-3). The full 
magnitude of the ellipticity at 222 nm for the coiled-coil structure is restored 
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 upon dirhodium cleavage, indicating the high yield and lack of side 
reactions in the cleavage step. 
 
Scheme 5-2. Reversible control of coiled-coil heterodimerization.
 
Figure 5-2. CD spectra of peptide coiled coil systems. Residual molar ellipticity in deg 
cm2 dmol-res-1 ( 103. All spectra taken in water at 20 °C and pH 6.  
Ac-EISALEKEISALEKEISALEK-NH2 RhRh
O
O
O
O O
OO
Me
O
Me
coiled coil
K3 peptide K3-Rh2(OAc)2
Rh2(OAc)2
KOAc, pH 6
random
addition of complimentary E3 peptide
Ac-KISALKEKISALKEKISALKQ-NH2 Ac-KISALKEKISALKEKISALKQ-NH2
cis-Rh2(OAc)2(tfa)2
- Rh2(OAc)4
-20!
-10!
0!
10!
20!
30!
40!
190! 200! 210! 220! 230! 240! 250!
M
ola
r R
esi
du
e E
llip
tic
ity
!
Wavelength, nm!
 E3!
 K3!
                               !
 E3 + K3!
 !
K3-Rh2(OAc)2!
E3 + K3-Rh2(OAc)2!
  98 
 
Figure 5-3. Cleavage of the dirhodium-peptide adduct re-establishes coiled-coil 
structure. Spectra given for a mixture of E3 and K3-Rh2(OAc)2 at pH 6 before and after 
treatment with 0.2 M KOAc for 90 h at 40 °C. (Residual molar ellipticity in deg cm2 
dmol-res-1 ( 103. All spectra taken in water at 20 °C and pH 6.) 
5.3.  Stabilization of helical conformation with dirhodium linker 
To probe ability of dirhodium to form metallopeptides that retain 
helical conformation, a series of peptides were designed. They are 18 amino 
acids in length and have helical propensity due to an alanine-rich sequence 
(Table 5-1).78 A complete turn of an ! helix requires between three and four 
amino acids, so carboxylate side chains (Asp, Glu) were placed in i, i+3 or i, 
i+4 relationships. Bridging amino acids in an i, i+4 arrangement has been 
studied extensively for helix stabilization as well as a some examples of 
helix stabilization by means of an i, i+3 arrangement.79 As expected, all free 
peptides exhibit some degree of helicity in water (Figure 5-4). Owing to the 
helix-disrupting properties of Asp residues, peptides containing this amino 
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acid exhibit substantially less helicity than comparable Glu-containing 
sequences (see, Figure 5-4, A).80 
The peptides react with cis-Rh2(OAc)2(tfa)2 to produce adducts with 
bridging dirhodium centers for both i, i+3 and i, i+4 carboxylate spacing 
(Scheme 5-3). Circular dichroism (CD) spectroscopy was employed to 
assess the effect of dirhodium binding on helicity. In the i, i+4 series, both 
Asp (DD4) and Glu (EE4) peptides exhibit increased helicity on dirhodium 
binding (Figure 5-4 (A) and Figure 5-5). The effect of binding is most 
pronounced in the Asp case; the helix-destabilizing influence of hydrogen 
bonding from the carboxylate side chain to the amide back- bone is removed 
upon binding dirhodium.80 Next, I considered peptides with i, i+3 
carboxylate spacing. The free peptide EE3 is helical in solution, and binding 
to a dirhodium center results in increased helical content, in line with i, i+4 
examples discussed above (Figure 5-4, D). However, the structural 
requirements for helix stabilization in i, i+3 peptides are clearly stricter than 
those for the i, i+4 case: all sequences with at least one Asp residue binding 
to dirhodium (peptides DD3, ED3, and DE3) display complete disruption of 
helicity upon binding to dirhodium (Figure 5-4, B). The data suggest that the 
extra methylene unit in the Glu side chain is necessary to allow proper 
positioning at a dirhodium center. Although residues at i, i+3 spacing are 
proximal in space in a helical structure, the side chains project in different 
directions and there is no previous examples of helix induction or 
stabilization through metal binding in an i, i+3 fashion. 
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Table 5-1. Helicity of free peptides and dirhodium metallopeptide complexes. 
Peptides Sequence [!]220a fH b fH(TFE) c Rel. 
Held., % 
Yield, 
% 
EE3 Ac-YGKAAAAEAAEAKAAAAK-NH2 -11.49 39 44 70  
EE3-Rh2(OAc)2    -13.8 45 51 82 70 
EE3-Rh2(pyrr)2 -A   -12.55 42 47 76 50 
EE3-Rh2(pyrr)2 -B  -10.42 36 40 65 29 
(EE3)2Rh2 -A  -7.71 26 31 51 25 
(EE3)2Rh2 -B  -7.55 25 31 50 25 
DD3 Ac-YGKAAAADAADAKAAAAK-NH2 -5.3 21 24 39  
DD3-Rh2(OAc)2    -1.47 10 12 19 80 
DE3 Ac-YGKAAAADAAEAKAAAAK-NH2 -7.97 29 32 52  
DE3-Rh2(OAc)2    -0.89 11 10 16 67 
ED3 Ac-YGKAAAAEAADAKAAAAK-NH2 -11.4 38 43 70  
ED3-Rh2(OAc)2    -1.69 11 12 20 59 
EE3G Ac-YGKAAAAEAGEAKAAAAK-NH2 -2.46 13 15 24  
EE3G- Rh2(OAc)2    -9.62 33 38 61 80 
EE4 Ac-YGKAAAAEAAAEKAAAAK-NH2 -12.34 41 46 75  
EE4-Rh2(OAc)2    -17.26 55 62 100 65 
trans-EE4-
Rh2(OAc)2   
 0.3 5 6 10 19 
(EE4)2Rh2 -A  -9.81 31 38 62 30 
(EE4)2Rh2 -B  -10.97 34 42 68 24 
sEE4 Ac-KAEAAAEAK-NH2 -0.38 9 8 13  
sEE4-Rh2(OAc)2    -11.64 48 44 71 58 
DD4 Ac-YGKAAAADAAADKAAAAK-NH2 -5.72 22 25 41  
DD4-Rh2(OAc)2    -16.01 51 58 94 73 
EE4G Ac-YGKAAAAEAGAEKAAAAK-NH2 -1.88 12 13 21  
EE4G-Rh2(OAc)2    -8.34 30 34 54 73 
trans-EE4G-
Rh2(OAc)2   
 0.47 5 6 9 65 
ED4G Ac-YGKAAAAEAGADKAAAAK-NH2 -1.08 9 10 17  
ED4G-Rh2(OAc)2    -12.14 40 46 74 57 
DD4G Ac-YGKAAAADAGADKAAAAK-NH2 -1.12 9 11 17  
DD4G-Rh2(OAc)2    -10.8 37 41 67 70 
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Figure 5-4. Circular dichroism spectra demonstrating the effect of dirhodium binding on 
the secondary structure of bis-carboxylate peptides. For sequences, see Table 5-1. 
 
Figure 5-5. A model structure of the EE4-Rh2(OAc)2 metallopeptide (structure is 
generated in PyMOL). 
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Scheme 5-3. Dihrodium metallopeptides with i, i+4 (EE4) and i, i+3 (EE3 and DD3) 
residue spacing. 
5.4. Induction of helical conformation with dirhodium linker 
Producing secondary structure upon metal binding in otherwise 
unstructured peptides potentially allows metal-based switching of molecular 
function. The polyalanine sequences discussed above contain at least some 
helical bias in the unbound state, and upon dirhodium binding appear more 
strongly helical. Inducing helicity in unstructured peptides is a more 
stringent test, and to probe helix induction in otherwise random-coil 
peptides, I introduced glycine—a powerful helix disrupting residue—into 
my peptide sequences at the i+2 position.81 All of the glycine-containing 
peptides exhibit a random-coil structure in aqueous solution. CD analysis of 
the metallopeptide adducts, however, indicates a helical structure (Figure 
5-4, C). For peptides with i, i+4 spacing, as before, good helix induction was 
observed regardless of whether the binding residues are Asp or Glu. A 
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glycine-containing peptide with i, i+3 carboxylate spacing (EE3G) was also 
prepared. The peptide EE3G is a random coil in the unbound state but 
becomes helical following metalation by dirhodium, as evidenced by the 
appearance of a negative feature at + = 220 nm (Figure 5-4, D). This result 
extends the possibilities for metal-induced helicity beyond the i, i+4 systems 
reported with other metals to Glu-Xaa-Xaa-Glu sequences. The assignment 
of helical structure to the adduct EE3G-Rh2(OAc)2 is further supported by 
NMR spectroscopy experiments. Due to the repetitive nature of these 
sequences, unambiguous assignment of peaks was not possible at the 
periphery of the EE3G sequence (Y1–A5 and K13–K18). Nonetheless, 
peaks in the key dirhodium-binding region were readily identified through 
COSY experiments. Within the dirhodium-binding region (A6–A12), the 
3JHN–Ha coupling constants are all less than 6 Hz, consistent with a helical 
structure. In addition, unambiguous long-range !N i, i+3 NOEs were 
observed, together with short-range i, i+1 interactions (!N and NN) to 
residues in proximity to dirhodium-bound glutamates (Figure 5-6).82 
 
Figure 5-6. 3JHN–HA coupling constants and NOE connectivity for the metal- binding 
region of the EE3G-Rh2(OAc)2 complex. The NOE intensity is represented by the 
thickness of the bars. 
The ability of dirhodium complexes to induce peptide helicity has 
proven to be quite general. For example, a significantly shorter peptide, 
KAEAAAEAK (sEE4), which is too short to exist with defined secondary 
structure in the free state, adopts a helical structure upon dirhodium binding 
!
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(see Table 5-1, entry 21 and 22 and Figure 5-4). In addition, variation of the 
dirhodium-reagent structure is tolerated both in the synthesis and in the 
secondary structure of metallopeptides. For example, the bis-amidate 
complex cis-Rh2(tfa)2(pyrr)2 (pyrr = pyrrolidonate) reacts cleanly with the 
peptide EE3 to afford the bis-carboxylate, bis-amidate product as two 
stereoisomers, which are separable by preparative HPLC (Scheme 5-4). Both 
isomers display helicity similar to the corresponding bis-acetate complex 
(Figure 5-4, D). 
Scheme 5-4. Synthesis of a peptide–dirhodium complex with amidate ligands. The 
identity of the product stereoisomers has not been assigned. 
5.5. Bis-peptide and trans-complexes with dirhodium 
 In addition to 1:1 dirhodium:helix adducts, I was able to produce 
adducts with 1:2 dirhodium:peptide stoichiometry with the reagent Rh2(tfa)4 
83. Treatment of peptide EE4 with Rh2(tfa)4 results in the formation of a 
Rh2(EE4)2 adduct. The CD spectrum indicates helical structure for the di-
peptide adduct as well, which identifies the adduct stereochemistry as that in 
which each peptide chelates to the dirhodium center in a cis geometry 
(Figure 5-7). The observation of cis binding is opposite that which might be 
predicted on the basis of the trans ligand effect: dirhodium complexes of the 
type Rh2(RCO2)(tfa)3 are known to react in ligand exchange processes to 
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give the trans bis-tfa product.84 Labilization of the trans-trifluoroacetate 
ligand should form the trans product, rather than the observed cis. Potential 
explanations for this observation include fast intermolecular ligations 
relative to intramolecular trans chelate formation, cis-trans isomerization of 
an intermediate trans-complex, associative displacement of a cis-
trifluoracetate ligand by the second chelating-carboxylate ligand, and 
trifluoroacetate displacement due to a competing cis-ligand effect via a 
dissociative interchange (Id) mechanism.85 Further mechanistic 
investigations will be necessary to identify the origin of this result. 
 
Figure 5-7. Circular dichroism spectra of bis-peptide–dirhodium complexes and a model 
structure of the antiparallel (EE4)2Rh2 metallopeptide (structure was generated in 
PyMOL). Isomers A and B correspond to parallel or antiparallel orientation of the two 
peptide chains, but exact correlation was not identified. 
Because dirhodium bis-acetate complexes described here can exist in 
cis or trans isomeric forms, I was interested in examining the effects of 
coordination stereochemistry on helix induction. Modeling indicates that 
only cis coordination should be compatible with a helical structure, and this 
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is born out by experiment. Treatment of peptide EE4 with the isomeric 
trans-Rh2(OAc)2(tfa)2 complex84 results in the formation of the bridged 
dirhodium complex, trans-EE4-Rh2(OAc)2 (Scheme 5-5). The structure of 
this complex can be inferred from mass spectrometry and the fact that trans-
EE4-Rh2(OAc)2 exhibits different HPLC run times and markedly a different 
CD spectrum from that of the cis isomer. Consistent with expectations from 
modeling, the CD spectrum of trans-EE4-Rh2(OAc)2  exhibits none of the 
features above 200 nm that would imply helical structure (Figure 5-8). The 
trans-dirhodium linkage appears to destroy any helical propensity, despite 
the significant helical bias of the free peptide. 
 
Figure 5-8. Circular dichroism spectra of trans-dirhodium-peptide complexes. 
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Scheme 5-5. Synthesis of metallopeptides from dirhodium precursors that have trans 
geometry. 
5.6. Conclusions 
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chains with a dirhodium metal center are presented. The method is 
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peptides. These properties make dirhodium ligation an attractive platform 
for examining the alteration of peptide function through control of secondary 
structure. 
Coiled coil E3/K3 heterodimer provides a simplistic model of protein-
protein interaction. Various cellular pathways are mediated via network of 
interacting proteins and peptide mimics of their binding domains are 
becoming promising candidates for therapeutic applications. Reversible 
dirhodium metalation provides a unique release mechanism that is based on 
the regulation of the peptide folding state. Aside from controllable release of 
an active peptide; dirhodium metallopeptides might be used to control the 
growth of supramolecular materials. 
Dirhodium–carboxylate ligation was demonstrated to have powerful 
helix-inducing properties. Helix induction upon dirhodium binding is 
extremely general for bis-carboxylates with i, i+4 spacing, and this work 
also expands the scope of known metal-binding topologies to include helix 
induction in peptides with i, i+3 spacing. The tolerance of this method for 
other metal-binding side chains is particularly significant as it may make it 
possible to switch the structure of a peptide among multiple states through 
the use of complementary metal-ligation strategies. 
Finally, peptide-dirhodium conjugates offer unique and modular 
control over the ligand environment around a dirhodium center. Well-folded 
helical peptide ligands can be used to introduce chirality at the catalytic 
center and the unique architecture of bis-peptide complexes provides the 
symmetry of the two dirhodium sites. On the other hand, the catalytic 
activity of dirhodium can be modulated with hybrid amidate/peptide 
complexes. Dirhodium metallopeptide catalysis with diazo compounds in the 
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contexts of small molecule enantioselective synthesis and peptide/protein 
modification became the consequence of studies.86-90 
5.7. Experimental section 
5.7.1.  General information 
Peptide synthesis. All peptides were synthesized with an Advanced 
ChemTech APEX 396 Automated Multipeptide Synthesizer using standard 
solid-phase Fmoc protocols. The purification was accomplished by reverse-
phase HPLC with gradients of water-acetonitrile containing 0.1% 
trifluoroacetic acid, and peptides were isolated by lyophilization. Analysis 
and purity assessment was attained by mass spectrometry and analytical 
HPLC. Peptides were prepared using Rink amide MBHA resin (AAPPTEC) 
to afford the C-terminal amide and were acetylated at the N-terminus prior 
to cleavage from the resin. 
Circular Dichroism Spectroscopy.  CD spectra were obtained on 
Jasco-J810 spectropolarimeter using a 0.01 cm cell. The spectra were 
acquired with a 1 nm interval in the range of 180–250 nm. Millidegrees of 
rotation were converted to mean residual ellipticity. 
HPLC analysis and purification. HPLC was performed on a 
Shimadzu CBM-20A instrument with Phenomenex Jupiter 4* Proteo 90A 
(250 ( 15 mm preparative) and Phenomenex Jupiter 4* Proteo 90A (250 ( 
4.6 mm analytical) columns. Flow rates of 8 mL/min and 1 mL/min were 
used for preparative and analytical columns, respectively. Analytical and 
preparative HPLC were performed with gradient of acetonitrile in water. 
Both solvents contained 0.1% trifluoroacetic acid (TFA) unless otherwise 
noted. Two wavelengths — 220 nm and 300 nm — were used to allow for 
independent analysis of peptides and dirhodium complexes.  
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Mass Spectrometry. MALDI-MS and MS/MS analyses were 
performed on a Bruker Daltonics Autoflex MALDI- TOF/TOF mass 
spectrometer with CHCA matrix (10 mg/mL, Thermo Scientific Pierce). 
ESI-MS was performed on Bruker Daltonics micrOTOF instrument. 
NMR Spectroscopy. 1D Spectra were measured with Bruker 500 
UltraSield™ (500 MHz) spectrometer or Oxford (400 MHz) spectrometer. 
1H NMR are reported in units of part per million (ppm). Standard 
abbreviations are used to indicate signal multiplicity: s, singlet; d, doublet; t, 
triplet; q, quartet; m, multiplet. Coupling constant are reported as J value in 
Hertz (Hz). nH describes the number of protons (n) from integration.  All 2D 
NMR spectra were acquired on 500 MHz Varian Inova NMR Spectrometer 
at 25°C. Samples were prepared in 90:10 H2O/D2O at 6 mM concentration 
and were buffered to pH 5.5 with sodium acetate-d3. Mixing time used for 
NOESY was 400 ms and for ROESY, 200 ms. Acquisition times of 500 ms 
(ROESY) and 1000 ms (NOESY) were used in the direct dimension and 100 
ms in the indirect dimension. 2D NMR data were processed with 
NMRPipe91 and analyzed using the Sparky program.92 
5.7.2. Synthetic procedures 
Synthesis of known compounds. The dirhodium precursors cis-
Rh2(tfa)2(OAc)2 and trans-Rh2(tfa)2(OAc)2 were prepared according to the 
published procedures. 93 
General procedure for the synthesis of dirhodium metallopeptides 
from cis-Rh2(tfa)2(OAc)2. Peptide (1 equiv), cis-Rh2(tfa)2(OAc)2 (1 equiv), 
MES (40 equiv), and a stir bar were placed in the 4 mL vial. Water 
(calculated for 2.5 mM peptide concentration) was added and the pH was 
adjusted to 4.5 with NaOH (0.1 M). The reaction was heated to 50 °C for 2-4 
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h and monitored by HPLC. Purification of the metallopeptides was 
performed by direct injection of the reaction mixture on a preparative RP-
HPLC column. All complexes were isolated as a green solid upon 
lyophilization (Table 5-2). 
Synthesis of K3-Rh2(OAc)2 metallopeptide. Peptide K3 (5.93 mg, 
2.5 *mol), cis-Rh2(TFA)2(OAc)2 (1.38 mg, 2.5 *mol), MES (19.5 mg, 0.1 
mmol) and a stir bar were placed in the 4-mL vial. Water (1 mL) was added 
and the pH adjusted to 4.5 with NaOH (0.1 M aq soln). The reaction was 
heated to 50 °C for 3 h and monitored by HPLC (Figure 5-13). Two 
wavelengths were used (220 nm and 300 nm) to allow for independent 
analysis of peptides and dirhodium complexes. Purification of the 
metallopeptides was performed by direct injection of the reaction mixture on 
a preparative RP-HPLC column. The product was isolated as a green solid 
(4.11 mg, 61 %) upon lyophilization. 
Cleavage of the metallopeptide K3-Rh2(OAc)2 in presence of the 
peptide E3. KOAc (4.91 mg) was added to the mixture of the complex K3-
Rh2(OAc)2 and peptide E3 in the buffered solution (0.5 mL, 50 mM 
phosphate, 0.1 M KCl) to achieve a 0.1 M KOAc soln (pH 6.8). The 
cleavage of the complex K3-Rh2(OAc)2 (at rt and 50 °C) was monitored by 
HPLC and CD (Figure 5-10).  
Synthesis of dirhodium-peptide complex trans-EE4-Rh2(OAc)2. 
Peptide EE4 (4.51 mg, 2.64 *mol), trans-Rh2(tfa)2(OAc)2 (1.45 mg, 2.64 
*mol), MES (20.7 mg, 0.11 mmol) and a stir bar were placed in the 4-mL 
vial. Water (1.06 mL) was added and the pH adjusted to 4.5 with NaOH 
(0.1M). The reaction was heated to 50 °C for 24 h and monitored by HPLC. 
Purification of the metallopeptides was performed by direct injection of the 
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reaction mixture on a preparative RP-HPLC column and lyophilization 
affords the product as a green solid (1.0 mg, 19%). 
Synthesis of dirhodium-peptide complex trans-EE4G-Rh2(OAc)2. 
Peptide EE4G (0.92 mg, 0.54 *mol), trans-Rh2(tfa)2(OAc)2 (0.27 mg, 0.49 
*mol), MES (3.8 mg, 0.02 mmol) and a stir bar were placed in the 4-mL 
vial. Water (0.19 mL) was added and the pH adjusted to 4.5 with NaOH 
(0.1M). The reaction was heated to 50 °C for 8 h and monitored by HPLC. 
Purification of the metallopeptides was performed by direct injection of the 
reaction mixture on a preparative RP-HPLC column and lyophilization 
affords the product as a green solid (0.64 mg, 65%). 
Synthesis of the cis-Rh2(pyrr)2(tfa)2 precursor.  Rh2(OAc)4  (30 mg, 
68 mmol) and 2-pyrrolidinone (2.7g, 32 mmol) were heated at 125 °C for 20 
h under nitrogen atmosphere. The excess of 2-pyrrolidinone was removed by 
Kugelrohr distillation at 125 °C and 0.4 torr. The solid was dissolved in 
trifluoroacetic acid (2mL) and stirred for 3 h at rt. The product was isolated 
by HPLC as a violet solid (10.1mg, 21%). 1H NMR (CD3CN, 500 MHz): 
1.82-1.95 (m, 4H), 2.20-2.35 (m, 4H), 3.38-3.50 (m, 4H). 13C NMR 
(CD3CN, 500 MHz): 21.32, 33.00, 54.86, 118.41, 191.02.   
Synthesis of dirhodium-peptide complex EE3-Rh2(pyrr)2 iso-A and 
EE3-Rh2(pyrr)2 iso-B. Peptide EE3 (3.60 mg, 2.11 *mol), cis-
Rh2(pyrr)2(tfa)2 (1.44 mg, 2.11 *mol), MES (16.5 mg, 0.084 mmol) and a 
stir bar were placed in the 4-mL vial. Water (0.84 mL) was added and the 
pH adjusted to 4.5 with NaOH (0.1M). The reaction was heated to 50 °C for 
2 h and monitored by HPLC. Purification of the metallopeptides was 
performed by direct injection of the reaction mixture on a preparative RP-
HPLC column. The products were isolated as a violet solid upon 
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lyophilization. EE3-Rh(pyrr)2 iso-A: 2.27 mg, 50%. EE3-Rh(pyrr)2 iso-B: 
1.30 mg, 29%. 
Synthesis of dirhodium-peptide complex (EE3)2Rh2 iso-A and 
(EE3)2Rh2 iso-B. Peptide EE3 (4.70 mg, 2.76 *mol), Rh2(tfa)4 (0.89 mg, 
1.57 *mol), MES (21.6 mg, 0.11 mmol) and a stir bar were placed in the 4-
mL vial. Water (1.1 mL) was added and the pH adjusted to 4.5 with NaOH 
(0.1M). The reaction was heated to 50 °C for 22 h and monitored by HPLC. 
Purification of the metallopeptides was performed by direct injection of the 
reaction mixture on a preparative RP-HPLC column. The products were 
isolated as a violet solid upon lyophilization. (EE3)2Rh2 iso-A: 1.41 mg, 
25%. (EE3)2Rh2 iso-B: 1.43 mg, 25%. 
Synthesis of dirhodium-peptide complex (EE4)2Rh2 iso-A and 
(EE4)2Rh2 iso-B. Peptide EE4 (12.0 mg, 7.05 *mol), Rh2(tfa)4 (2.0 mg, 3.52 
*mol), MES  (27 mg, 0.14 mmol) and a stir bar were placed in the 4-mL 
vial. Water (2.8 mL) was added and the pH adjusted to 4.5 with NaOH 
(0.1M). The reaction was heated to 50 °C for 3 h and monitored by HPLC. 
Purification of the metallopeptides was performed by direct injection of the 
reaction mixture on a preparative RP-HPLC column. The products were 
isolated as violet solids upon lyophilization. (EE4)2Rh2 iso-A: 3.78 mg, 
30%. (EE4)2Rh2 iso-B: 3.00 mg, 24%.  
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Table 5-2. Yields of the metallopeptides obtained from cis-Rh2(tfa)2(OAc)2 precursor 
using general procedure for synthesis of dirhodium metallopeptides described above. 
Metallopeptide Isolated mass, mg Yield 
EE3-Rh2(OAc)2   2.58 70% 
DD3-Rh2(OAc)2   1.68 80% 
DE3-Rh2(OAc)2   1.60 67% 
ED3-Rh2(OAc)2   1.40 59% 
EE4-Rh2(OAc)2   2.41 65% 
DD4-Rh2(OAc)2   1.76 73% 
DD4G-Rh2(OAc)2   2.51 70% 
EE4G-Rh2(OAc)2   1.44 73% 
ED4G-Rh2(OAc)2   1.96 57% 
sEE4-Rh2(OAc)2   1.31 58% 
EE3G-Rh2(OAc)2   2.93 80% 
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5.7.3. Analytical data 
 
Figure 5-9. NH-H" region of the ROESY spectrum of the EE4G-Rh2(OAc)2 complex. 
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Figure 5-10. HPLC (left) and CD spectroscopy (right) of a mixture of E3 and K3-
Rh2(OAc)2 demonstrating the time course of dirhodium cleavage in KOAc solution (0.1 
M). For HPLC: (a) time = 0 (b) 22 h at rt (c) 2 d at rt (d) 3 d at rt (e) 5 d at rt (f) 7 d at rt 
(g) 10 h at 50 °C. 
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Figure 5-11. HPLC and MALDI-TOF MS of the peptide K3. Calculated mass [M+H]+: 
2367.5; found: 2367.1 
  
Figure 5-12. HPLC and MALDI-TOF MS of the peptide E3. Calculated mass [M+H]+: 
2371.3; found: 2370.9. 
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Figure 5-13. HPLC of the crude coupling reaction (left) and of the isolated complex K3-
Rh2(OAc)2  (right), and ESI-MS of the isolated complex K3-Rh2(OAc)2 (bottom). 
Calculated mass [M+H]+: 2689.4; found: 2689.2. 
 
  
Figure 5-14. HPLC and MALDI-TOF MS of the peptide EE3. Calculated mass [M+H]+: 
1703.9; found: 1703.9. 
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Figure 5-15. HPLC and MALDI-TOF MS of the peptide DD3. Calculated mass [M+H]+: 
1675.9; found: 1675.9. 
  
Figure 5-16. HPLC and MALDI-TOF MS of the peptide DE3. Calculated mass [M+H]+: 
1689.9; found: 1689.9. 
  
Figure 5-17. HPLC and MALDI-TOF MS of the peptide ED3. Calculated mass [M+H]+: 
1689.9; found: 1689.9. 
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Figure 5-18. HPLC and MALDI-TOF MS of the peptide EE4. Calculated mass [M+H]+: 
1703.9; found: 1322.4. 
  
Figure 5-19. HPLC and MALDI-TOF MS of the peptide DD4. Calculated mass [M+H]+: 
1675.9; found: 1675.9. 
  
Figure 5-20. HPLC and MALDI-TOF MS of the peptide DD4G. Calculated mass 
[M+H]+: 1661.9; found: 1661.9. 
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Figure 5-21. HPLC and MALDI-TOF MS of the peptide EE4G. Calculated mass 
[M+H]+: 1689.9; found: 1689.9. 
  
Figure 5-22. HPLC and MALDI-TOF MS of the peptide ED4G. Calculated mass 
[M+H]+: 1675.9; found: 1675.9. 
  
Figure 5-23. HPLC and MALDI-TOF MS of the peptide sED4. Calculated mass 
[M+Na]+: 937.5; found: 937.5. 
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Figure 5-24. HPLC and MALDI-TOF MS of the peptide EE3G. Calculated mass 
[M+H]+: 1689.9; found: 1690.0. 
  
 
 
Figure 5-25. HPLC of the crude coupling reaction (left) and of the isolated complex 
EE3-Rh2(OAc)2  (right) and ESI-MS of the isolated complex EE3-Rh2(OAc)2. Calculated 
mass [M+Na]+: 2047.8; found: 2047.8. 
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Figure 5-26. HPLC of the crude coupling reaction (top) and of the isolated complex 
EE3-Rh2(pyrr)2 iso-A  (bottom left),  EE3-Rh2(pyrr)2 iso-B (bottom right).  
      
 
Figure 5-27. ESI-MS of the isolated complex EE3-Rh2(pyrr)2 iso-A  (top),  EE3-
Rh2(pyrr)2 iso-B (bottom). Calculated mass for EE3-Rh2(pyrr)2 iso-A [M+Na]+: 2097.9; 
found: 2097.8. Calculated mass for EE3-Rh2(pyrr)2 iso-B [M+Na]+: 2097.9; found: 
2097.7.
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Figure 5-28. HPLC of the crude coupling reaction (top) and of the isolated complex 
(EE3)2Rh2  iso-A (bottom left), (EE3)2Rh2 iso-B (bottom right).  
      
  
Figure 5-29. ESI-MS of the isolated complex (EE3)2Rh2 iso-A  (top), (EE3)2Rh2 iso-B 
(bottom). Calculated mass for (EE3)2Rh2 iso-A: [M+2H]2+ 1804.8, [M+H+Na]2+ 1815.8, 
[M+2Na]2+ 1826.8; found: 1804.8, 1815.8, 1826.8. Calculated mass for (EE3)2Rh2 iso-B: 
[M+H]+ 3608.6, [M+2H]2+ 1804.8, [M+H+Na]2+ 1815.8, [M+2Na]2+ 1826.8; found: 
3608.6, 1804.8, 1815.8, 1826.8. 
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Figure 5-30. HPLC of the crude coupling reaction (left) and of the isolated complex 
DD3-Rh2(OAc)2  (right) and ESI-MS of the isolated complex DD3-Rh2(OAc)2. 
Calculated mass [M+Na]+: 2019.8; found: 2019.7.  
  
 
Figure 5-31. HPLC of the crude coupling reaction (left) and of the isolated complex 
DE3-Rh2(OAc)2  (right) and ESI-MS of the isolated complex DE3-Rh2(OAc)2. Calculated 
mass [M+Na]+: 2033.8; found: 2033.8. 
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Figure 5-32. HPLC of the crude coupling reaction (left) and of the isolated complex 
ED3-Rh2(OAc)2  (right) and ESI-MS of the isolated complex ED3-Rh2(OAc)2. Calculated 
mass [M+Na]+: 2033.8; found: 2033.8. 
 
 
Figure 5-33. HPLC of the crude coupling reaction (left) and of the isolated complex 
EE4-Rh2(OAc)2  (right) and ESI-MS of the isolated complex EE4-Rh2(OAc)2. Calculated 
mass [M+Na]+: 2047.8; found: 2047.8. 
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Figure 5-34. HPLC of the crude coupling reaction (left) and of the isolated complex 
trans-EE4-Rh2(OAc)2  (right) and ESI-MS of the isolated complex trans-EE4-
Rh2(OAc)2. Calculated mass [M+Na]+: 2047.8; found: 2047.8. 
 
  
Figure 5-35. HPLC of the crude coupling reaction (top) and of the isolated complex 
(EE4)2Rh2 iso-A  (bottom left), (EE4)2Rh2 iso-B (bottom right).  
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Figure 5-36. ESI-MS of the isolated complex complex (EE4)2Rh2  iso-A  (top), 
(EE4)2Rh2 iso-B (bottom). Calculated mass for (EE4)2Rh2 -Rh2 iso-A: [M+H]+ 3608.6, 
[M+2H]2+ 1804.8, [M+H+Na]2+ 1815.8, [M+2Na]2+ 1826.8; found: 3608.4, 1804.7, 
1815.7, 1826.7. Calculated mass for (EE4)2Rh2 iso-B: [M+H]+ 3608.6, [M+2H]2+ 1804.8, 
[M+H+Na]2+ 1815.8, [M+2Na]2+ 1826.8; found: 3608.5, 1804.7, 1815.7, 1826.7 
  
 
 
Figure 5-37. HPLC of the crude coupling reaction (left) and of the isolated complex 
DD4-Rh2(OAc)2  (right) and ESI-MS of the isolated complex DD4-Rh2(OAc)2. 
Calculated mass [M+H]+: 1921.8; found: 1921.8. 
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Figure 5-38. HPLC of the crude coupling reaction (left) and of the isolated complex 
DD4G-Rh2(OAc)2  (right) and ESI-MS of the isolated complex DD4G-Rh2(OAc)2. 
Calculated mass [M+Na]+: 1983.8; found: 1644.6. 
 
 
Figure 5-39. HPLC of the crude coupling reaction (left) and of the isolated complex 
EE4G-Rh2(OAc)2  (right) and ESI-MS of the isolated complex EE4G-Rh2(OAc)2. 
Calculated mass [M+Na]+: 2033.8; found: 2033.7. 
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Figure 5-40. HPLC of the crude coupling reaction (left) and of the isolated complex 
trans-EE4G-Rh2(OAc)2  (right) and ESI-MS of the isolated complex trans-EE4G-
Rh2(OAc)2. Calculated mass [M+H]+: 2011.8; found: 1644.6. 
 
 
Figure 5-41. HPLC of the crude coupling reaction (left) and of the isolated complex 
ED4G-Rh2(OAc)2  (right) and ESI-MS of the isolated complex ED4G-Rh2(OAc)2. 
Calculated mass [M+Na]+: 2019.8; found: 2019.7. 
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Figure 5-42. HPLC of the crude coupling reaction (left) and of the isolated complex 
sED4-Rh2(OAc)2  (right) and ESI-MS of the isolated complex sED4-Rh2(OAc)2. 
Calculated mass [M+Na]+: 1259.4; found: 1259.3. 
 
Figure 5-43. HPLC of the crude coupling reaction (left) and of the isolated complex 
EE3G-Rh2(OAc)2  (right) and ESI-MS of the isolated complex EE3G-Rh2(OAc)2. 
Calculated mass [M+Na]+: 2033.8; found: 2033.8. 
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Chapter 6 
Kinetic and stereoselectivity effects of phosphite ligands 
in dirhodium catalysis 
6.1. Introduction 
Dirhodium complexes are one of the most synthetically useful 
examples of homogenous catalysts containing multiple metal atoms.1-3 A 
large number of enantioselective reactions have been developed through the 
design of chiral carboxylate and carboxamidate ligands for the bridging 
equatorial sites of the dirhodium core, and these reactions play important 
roles in the synthesis of diverse classes of chiral targets. The development of 
selective dirhodium catalysts for diazo decomposition has typically treated a 
dirhodium complex as though it were a mono-metallic site. Reaction with 
diazo compounds is assumed to result in the formation of a metallocarbene 
intermediate with loss of dinitrogen. The reactive metallocarbene 
intermediate then undergoes reaction with substrate through X–H insertion, 
cyclopropanation, ylide formation, or other processes.3,4 Because the two 
labile, axial coordination sites point in opposite directions, they are typically 
assumed to catalyze reactions independently. Homoleptic (i.e. all ligands are 
identical) tetracarboxylate and tetraamidate complexes have an axis of 
symmetry perpendicular to the metal-metal bond, and so the two metal sites 
are chemically equivalent as well. However, polymetallic complexes offer 
attractive targets for the development of selective catalysts precisely because 
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metals can interact in diverse ways, allowing dual binding of substrate(s) or 
influencing the catalytic cycle through steric or electronic effects.  
In the context of examining peptide ligands for enantioselective 
catalysis, I decided to examine the potential for improving the 
enantioselectivity through the addition of labile axial ligands. In pursuing 
this line of inquiry, I was aware that added ligands almost certainly inhibit 
diazo decomposition (Figure 6-1). Indeed, a previous kinetic study with 
other ligand classes concluded that ligated dirhodium complexes are not 
competent catalysts for diazo decomposition, even if one of the two rhodium 
atoms remains free of ligand.5,6 Despite efforts to understand the mechanism 
of dirhodium-catalyzed diazo reactions,5-12 mechanistic understanding of 
product-determining steps, which occur after the turnover-limiting diazo-
decomposition step, is limited. The effects of the coordination environment 
of the distal rhodium atom on catalytic reactivity may be an important 
variable in determining catalytic selectivity and efficiency, yet is little 
studied. Sporadic evidence indicates that catalysis can be altered with 
solution additives,13-15 including an observation that phosphate and 
phosphine-oxide additives can rescue enantioselectivity from the detrimental 
effects of trace water in asymmetric cyclopropanation reactions.14 Recently 
the catalytic activity of dirhodium complexes with exchange-inert NHC 
ligands bound to an axial site has been described.16-19 In this chapter, I 
present the discovery that phosphite complexes improve the 
enantioselectivity observed in silane insertion reactions20-27 catalyzed by 
peptide-dirhodium complexes.28,29 Presented is a kinetic analysis of the 
process that sheds light on the equilibrium and kinetic parameters involved 
in reaction with phosphite ligands. 
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Dirhodium metallopeptides are kinetically inert coordination 
complexes that are readily synthesized by direct metalation of a fully 
deprotected peptide ligand28 and adopt discrete secondary structures that are 
stabilized by chelate binding to the dirhodium center.29 While in a typical 
catalyst four molecules of chiral ligand around the dirhodium center are 
required for asymmetric catalysis, I have been interested in asymmetric 
catalysis with a single chelating bis-carboxylate peptide ligand at a rhodium 
center that also contains two (achiral) acetate ligands. In general, these 
mono-peptide catalysts provide modest stereoselectivity in silane insertion 
reactions (Table 6-1). 
Selectivity is improved in bis-peptide catalysts,27 but the development 
of selective mono-peptide catalysts is desirable for many purposes, including 
screening peptide ligands directly on solid support. 
 
Figure 6-1. Distal ligation and X–H insertion of dirhodium metallocarbene intermediates. 
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Table 6-1. Screen of additives for increased enantioselectivity. 
 
additive % ee 
none 50 
Tris(2,4-di-tert-butylphenyl) phosphite 52 
(PhO)3P 66 
(EtO)3P 50 
(MeO)3P 53 
DMSO 51 
Et2NOH 51 
Pyridine 48 
(i-Pr)2EtN 52 
9-Cyanoanthracene 42 
PhCN 48 
(biphenyl)(tBu)2P 54 
Ad2PhP 53 
(Ph)3P 46 
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6.2. Phosphite additives and enantioselectivity 
Upon initial screening, the complex Rh2(L1)(OAc)2, containing one 
chelating peptide ligand and two achiral acetate groups, catalyzes the silane 
insertion reaction of dimethylphenylsilane and ethyl phenyldiazoacetate with 
50% ee (Table 6-1). I examined additives that might bind to the dirhodium 
core and affect enantioselectivity. Although most additives had a negligible 
or negative effect on enantioselectivity, the addition of triphenylphosphite 
improved the product ee to 66%. 
The beneficial effect on product ee was general across a variety of 
peptide ligands; the addition of 10 equiv, relative to dirhodium, produced 
modest increases (5–18%) in ee across catalysts with a variety of peptide 
sequences (Table 6-2). The best results were observed with catalyst 
Rh2(L2)(OAc)2, which afforded the product in 88% ee, and the best 
enhancement in ee was observed with the Rh2(L1)(OAc)2 catalyst. 
6.3. Kinetics 
To shed light on the effect of phosphite on enantioselective dirhodium 
catalysis, a kinetic analysis of the process was performed. The loss of 
dinitrogen to form a metallocarbene is irreversible and turnover limiting, so 
that the kinetics of the reaction can be expressed as a function of two ligand 
association constants (Ki1 and Ki2), a rate constant for reaction in the absence 
of phosphite (k1), and a constant (!) that describes the catalytic power of the 
phosphite complex relative to the free catalyst, as shown in Figure 6-4. The 
association constants were determined by fitting UV-vis absorption spectra 
as a function of phosphite concentration (Figure 6-2 and Figure 6-3).30-33 For 
Rh2(L1)(OAc)2, logKi1 and logKi2 are 5.38 and 3.31, respectively (Table 6-
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2). These values are consistent with negative cooperativity binding typical of 
dirhodium complexes.30-33 
 
Figure 6-2. Fitting of UV-vis data for (L1)Rh2(OAc)2. Absorbance at 323 nm and 295 
nm correspond to the complexes with a one and two axial ligands respectively. 
 
Figure 6-3. Fitting of UV-vis data for Rh2(OAc)4. Absorbance at 323 nm and 295 nm 
correspond to the complexes with a one and two axial ligands respectively. 
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Table 6-2. Triphenylphosphite as an additive for enantioselective dirhodium reactions at 
0 °C. a Scaled up reaction afforded 84% yield. 
ligand sequence 
ee, % 
no additive P(OPh)3 
L1 KZADAALDAKZ 40 58 
L2 KZTDAAIDAKZ 77 88a 
L3 KZTDGATDAKZ 61 76 
L4 KZNDAAIDAKZ 82 87 
The values for Rh2(L1)(OAc)2 are somewhat lower than those for the 
parent compound, Rh2(OAc)4 (6.09 and 3.96), indicating that the bulky 
peptide ligand disfavors axial ligation. The rate constant kc can be measured 
for reactions without phosphite or fit numerically. The relationship between 
phosphine concentration and reaction rate provides a plot of concentration 
vs. 1/rate that allows determination of the reactivity ratio, !. Disappearance 
of the diazo substrate was monitored by HPLC and/or UV absorption at 
varying concentrations of phosphite. Individual reactions displayed linear 
plots of –log([diazo]/[diazo]0)  vs. time, indicative of clean kinetics that are 
first-order in substrate (Figure 6-14). The constant ! was obtained by fitting 
the rate constants to the kinetic data using a least-squares fitting method 
(Figure 6-5).34 A value of 0.013 was obtained for ! (Table 6-3). 
Table 6-3. Experimentally determined kinetic and thermodynamic parameters. 
log Ki1  (M-1) 5.38  
log Ki1  (M-1) 3.31 
kc   (M-1s-1) 5.46  
! 0.013 
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Figure 6-4. Mechanism of dual-path enantioselective catalysis. 
6.4. Discussion 
It is not apparent that ligand additives should be a successful strategy 
for altering selectivity in dirhodium catalysis. Each metal center contains a 
single open coordination site, so that ligand-bound rhodium atoms are 
necessarily catalytically inactive. In addition, the two axial sites of the 
dirhodium core point in opposite directions, projecting into very different 
regions of space. Finally, a previous kinetic study of dirhodium catalysis in 
nonpolar solvent in the presence of weak ligands (such as THF) concluded 
that ligand-bound catalysts (Figure 6-4 B) are unreactive.5,6 Nonetheless, it is 
clear that triphenylphosphite provides an enhancement in enantioselectivity 
with the dirhodium metallopeptide catalysts described here. The basis for 
this additive effect is difficult to establish. In the presence of a single peptide 
ligand, there is no symmetry in the complex and the two dirhodium sites are 
chemically nonequivalent. Part of the initial rationale for the use of added 
ligand was the belief that axial ligands might bind and change the site of 
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catalysis. However, the difference between two association constants Ki1 and 
Ki2 are comparable to the observed with dirhodium tetraacetate, implying 
that the two non-equivalent rhodium atoms bind phosphite with similar 
affinity. Alternatively, electronic or steric effects of distal ligand binding 
may alter selectivity. 
The acquired kinetic data is inconsistent with !=0, as would be the case if 
ligand-bound catalysts (Figure 6-4, B) are not kinetically competent in diazo 
decomposition reactions. Least-squares fitting of the kinetic data provides a 
measured ! of 1.3% (Figure 6-5). Fitting the data in Figure 6-5 under the 
alternative assumption that !=0 provides a model that is inconsistent with 
the obtained data (Figure 6-5, dashed curve). Indeed, the apparent linear 
relationship in Figure 6-5 requires either that !=0 and Ki2=0 reducing the 
system to simple, single-site inhibition, or else that both ! and Ki2 are non-
zero. This differs from a previous report, which determined that !=0 for a 
series of weak oxygen donor ligands.5,6 Despite the fact that ligand-bound 
 
Figure 6-5. Plot of kinetic data and fit for the reactivity ratio, !. 
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Figure 6-6. Experimental measurement of partitioning between phosphite-bound and 
unligated catalyst for the two steps of the reaction, diazo decomposition and silane 
insertion. Diazo partition determined from kinetic data; metallocarbene partition 
determined from product ee. 
catalysts are less reactive (!<1), ligand-bound intermediates (B,E) can still 
be the predominant pathway in catalytic reactions. For example, in the 
reaction described in the Table 6-1, ligand-bound intermediates (B,E) are on 
the predominant catalytic pathway (i.e., partition>0.5, see Figure 6-6) for 
phosphite concentrations ,6 mol %.  
Changes in product enantioselectivity as a function of phosphite 
concentration require that triphenylphosphite is involved in the enantio-
determining step. Because the turnover-limiting step in dirhodium–catalyzed 
diazo reactions is irreversible diazo decomposition to afford the 
metallocarbene, it is difficult to use kinetic methods to probe the subsequent 
steps that determine product selectivity. Gleaning information about steps 
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after the formation of the metallocarbene requires creative substrate design 
to derive kinetic and mechanistic information from product ratios.11,12 
Assuming two reactive metallocarbenes are involved in catalysis—a 
(less selective) free metallocarbene and a (more selective) phosphite-bound 
metallocarbene—it is possible to define a metallocarbene partition, the 
percentage of silane insertion that occurs though the ligand-bound 
metallocarbene (Figure 6-4, E). Examining the product ee as a function of 
ligand concentration provides a measure of this metallocarbene partition 
(Figure 6-6). The measurement of reaction kinetics was used to define a 
diazo partition—a function of catalyst and ligand concentration—that 
defines the percentage of diazo decomposition through the ligand-bound 
catalyst (Figure 6-4, B). In a general sense, these two partitions will be 
rigorously identical only if silane insertion is faster than ligand exchange of 
the metallocarbene intermediate. However, coincidental overlapping 
partition curves is possible for individual reactions, even if insertion is not 
faster than ligand exchange, based on the rates of metallocarbene 
interconversion and product formation. As shown in the Figure 6-6, the 
diazo partition, derived from kinetics experiments, is identical to the 
metallocarbene partition. In other words, the fraction of substrate following 
the bottom path (Figure 6-4) during diazo decomposition is the same as that 
during product formation. This observation implies that metallocarbene 
intermediates do not interconvert through ligand exchange, subject to the 
caveat of possible coincidental overlap described above. Future work with 
other substrates may enable to address this possibility. The presented 
analysis carries with it a number of assumptions that could affect the results. 
The mono-ligated species (Figure 6-4, B), as well as both metallocarbene 
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intermediates, represent a mixture of ligand isomers. Because kinetic 
analysis is based on the steady-state approximation, the ratio of these species 
must remain constant during a reaction and thus the existence of these 
isomers does not affect the kinetic results described here. This analysis also 
ignores ligation to the axial sites by solvent molecules. Although 
trifluoroethanol certainly does bind to the axial sites, this binding is weak 
and transient and is accounted for under steady-state assumptions. Finally, a 
previous study modeled the diazo decomposition process as a combination 
of substrate binding and dinitrogen expulsion steps. This approach is 
compatible with the analysis presented here, and the reactivity ratio ! is 
equivalent to the ratio of two constants, "/#, used in that approach.5,6 
6.5. Conclusion 
This work demonstrates the potential of axial ligands as a control 
element in dirhodium-catalysis. In the present context, a phosphite additive 
enables synthetically useful enantioselectivity in a dirhodium mono-peptide 
complex. In the absence of phosphite additives, achieving synthetically 
useful levels of enantioselectivity required the use of bis-peptide complexes, 
which require chromatographic separation of the two isomers that differ in 
the orientation of the ligated peptides (parallel and antiparallel in the respect 
to the N and C termini).27,29 Because axial ligands inherently inhibit catalysis 
through both competitive and non-competitive mechanisms, it may be 
possible to build carboxylate ligands with a single pendant axial ligand to 
achieve improved selectivity with minimal sacrifice of reactivity. 
Axial-bound dirhodium centers have been proposed in a few 
circumstances, beyond enantioselectivity questions, to play a role in 
chemoselectivity and reaction efficiency. However, it has been difficult to 
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establish the role of added ligand and its presence on the catalytic pathway. 
In providing the first nonzero measurement of the reactivity ratio, !, this 
paper provides a framework for investigating other instances of ligand 
effects and provides a foundation for the use of ligands to alter other 
selectivity types in dirhodium catalysis. 
6.6. Experimental Section 
6.6.1. General information 
Peptide synthesis. All peptides were synthesized with an Advanced 
ChemTech APEX 396 Automated Multipeptide Synthesizer using standard 
solid-phase Fmoc protocols. The peptides are acetylated at N-termini and 
amides at the C-termini. All lysine side chains are capped with 
carboxybenzyl protecting group (Z) and remain unprotected. The 
purification was accomplished by reverse-phase HPLC with gradients of 
water-acetonitrile containing 0.1% trifluoroacetic acid, and peptides were 
isolated by lyophilization. Analysis and purity assessment was attained by 
mass spectrometry and analytical HPLC. 
HPLC analysis and purification. HPLC was performed on a 
Shimadzu CBM-20A instrument with Phenomenex Jupiter 4* Proteo 90A 
(250 ( 15 mm preparative) and Phenomenex Jupiter 4* Proteo 90A (250 ( 
4.6 mm analytical) columns. Flow rates of 8 mL/min and 1 mL/min were 
used for preparative and analytical columns, respectively. Analytical and 
preparative HPLC were performed with gradient of acetonitrile in water. 
Both solvents contained 0.1% trifluoroacetic acid (TFA) unless otherwise 
noted. Two wavelengths — 220 nm and 300 nm — were used to allow for 
independent analysis of peptides and dirhodium complexes.  
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Mass Spectrometry. MALDI-MS and MS/MS analyses were 
performed on a Bruker Daltonics Autoflex MALDI- TOF/TOF mass 
spectrometer with CHCA matrix (10 mg/mL, Thermo Scientific Pierce). 
ESI-MS was performed on Bruker Daltonics micrOTOF instrument. 
NMR Spectroscopy. 1D Spectra were measured with Bruker 500 
UltraSield™ (500 MHz) spectrometer or Oxford (400 MHz) spectrometer. 
1H NMR are reported in units of part per million (ppm). Standard 
abbreviations are used to indicate signal multiplicity: s, singlet; d, doublet; t, 
triplet; q, quartet; m, multiplet. Coupling constant are reported as J value in 
Hertz (Hz). nH describes the number of protons (n) from integration. 
6.6.2. Synthetic procedures 
Phenyl diazo acetate was prepared according to the published 
procedure.35 
General procedure for the synthesis of dirhodium metallopeptides 
from cis-Rh2(tfa)2(OAc)2. Peptide (1 equiv) and cis-Rh2(tfa)2(OAc)2 (1 
equiv) were dissolved in TFE  (calculated for 1.0 mM peptide 
concentration). The reaction was heated to 50 °C for 3 h and monitored by 
HPLC. Purification of the metallopeptides was performed by direct injection 
of the reaction mixture on a preparative RP-HPLC column. All complexes 
were isolated as a green solid upon lyophilization: (L1)Rh2(OAc)2 (2.3 mg, 
60% yield), (L2)Rh2(OAc)2 (1.7 mg, 67% yield), (L3)Rh2(OAc)2 (1.4 mg, 
50% yield), (L4)Rh2(OAc)2 (2.2 mg, 70% yield). 
  153 
6.6.3. Analytical data 
 
 
Figure 6-7. HPLC trace and ESI-MS of the (L1)Rh2(OAc)2 metallopeptide. Calculated 
mass [M+Na]+: 1555.5; found: 1555.5. 
 
 
Figure 6-8. HPLC trace and ESI-MS of the (L2)Rh2(OAc)2 metallopeptide. Calculated 
mass [M+Na]+: 1585.5; found: 1585.4. 
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Figure 6-9. HPLC trace and ESI-MS of the (L3)Rh2(OAc)2 metallopeptide. Calculated 
mass [M+Na]+: 1559.4; found: 1559.4. 
 
 
Figure 6-10. HPLC trace and ESI-MS of the (L4)Rh2(OAc)2 metallopeptide. Calculated 
mass [M+Na]+: 1598.5; found: 1598.4. 
 
Minutes
12 14 16 18 20 22 24 26 28 30
SPD-20A Ch1-220nm
AZ5-179-1
AZ5-179-1.dat
Minutes
10 12 14 16 18 20 22 24 26 28 30
SPD-20A Ch1-220nm
AZ5-184-1
AZ5-184-1.dat
  155 
6.6.4. Ligand screening 
General procedure for enantioselective silane insertion with 
phosphite additives. Methyl phenyldiazoacetate (1 equiv, 7.8 *mol) was 
mixed with silane (2 equiv, 15.6 *mol) in trifluoroethanol (200 *L ) and 
equilibrated to -30 °C in Neslab CB-80 cold bath; peptide catalyst (0.5 %, 39 
nmol) is dissolved and trifluoroethanol (100 *L) and ligand (5 %, 390 nmol) 
was added in DCM solution (200 *L).  After equilibration of the catalyst 
solution to -30 °C, the mixture of starting materials was added and reaction 
proceeded overnight. The reactions were moved to ice (0 °C) and allowed to 
warm up to rt. The crude mixtures were dried under nitrogen jet and the 
product was isolated by silica-gel column, eluting with ether/hexanes (1:99). 
Enantioselectivity was determined by chiral HPLC (Phenomenex Lux 5*, 
eluent: isopropanol-hexanes (10:90). Analytical data for the product (S)-
Methyl 2-dimethylphenylsilyl-2-phenylacetate can be found in the previous 
work.27  
6.6.5. Equilibrium constants.  
The equilibrium constants, Ki1 and Ki2, were determined from UV-vis 
titration experiments according to the method of Bear.8 Measurments were 
taken on Jasco spectropolarimeter at 0 °C. The sample of dirhodium 
complex in 3:2 mixture of trifluoroethanol/DCM (78 *M, 4 mL) and 
solution of triphenyl phosphite in DCM (6.24 mM) were equilibrated at 0 
°C. The dirhodium solution was titrated with phosphite and UV-vis spectra 
were acquired at each increment. The absorbtion data at 295 nm and 323 nm 
(Equation 6-1) were fitted using least-square procedure to three-state 
equilibrium model (Figure 6-2 and Figure 6-3) using method implemented in 
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Equation 6-1. Absorption values at each wavelength are compound of contribution from 
CL and CL2 species. 
Acalc (295)  = ! 295
CL ! CL[ ]+ ! 295
CL2 ! CL2[ ]
Acalc (323)  = ! 323
CL ! CL[ ]+ ! 323
CL2 ! CL2[ ]
 
Excel.11. The fitting parameters are equilibrium constants Ki1 and Ki2, 
extinction coefficients of CL and CL2 complexes at both 295 nm and 323 
nm. 
Determining the concentration of free phosphite, [L], requires solving 
the third-degree polynomial obtained upon solving the equilibrium 
expressions in Equation 6-2:  
Equation 6-2. Third-degree polynomial describing the equilibrium in Figure 6-4. 
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for [C]0 = total metallopeptide concentration and [L]0 = total phosphite 
concentration. Solving this equation was accomplished with an add-in for 
Excel.36 
Concentrations of free metallopepitde, [C]; the monophosphite 
complex, [CL]; and the bis-phosphite complex, [CL2], were determined from 
the Equation 6-3 (Figure 6-13). 
Equation 6-3. Equilibrium concentrations of the dirhodium species. 
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Figure 6-11. Raw UV-vis data for (L1)Rh2(OAc)2. 
 
Figure 6-12. Raw UV-vis data for Rh2(OAc)4. 
  158 
 
Figure 6-13. Concentrations of the dirhodium species and the ligand. 
6.6.6. Rate measurements.  
Methyl phenyldiazoacetate (1 equiv, 6.2 *mol) was mixed with silane 
(2 equiv, 12.4 *mol) in trifluoroethanol (160 *L) and cooled to 0 °C. In a 
separate vial, solid Rh2(L1)(OAc)2 (0.5 %, 31 nmol) was dissolved in 
trifluoroethanol (80 *L) and ligand (variable amounts) was added in CH2Cl2 
(160 *L). After cooling to 0 °C, the solution of starting materials was added. 
Aliquots (10 *L) were taken from the reaction mixture at various times and 
quenched with acetonitrile (90 *L). The conversion of the reaction was 
determined by analytical HPLC (Phenomenex Kinetex 2.6*, water-
acetonitrile gradient). Graphs of –log([diazo]/[diazo]0) vs. time were linear, 
indicating clean first-order kinetics (Figure 6-14). 
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The reactivity ratio, !, was fit using the least-squares method 
referenced above, according to the rate law,  
Equation 6-4. Overall rate of the reaction. 
][][ CLkCkrate cc !+=  
where kc = rate constant measured in the absence of phosphite and [C] and 
[CL] were determined from the equilibrium constants measured above. 
 
Figure 6-14. Linear relationship between –log([diazo]/[diazo]0) and time at various 
concentrations of triphenyl phosphite. 
  160 
 
Figure 6-15. 1H NMR of (L1)Rh2(OAc)2 (top) compared with 1H NMR of 
(L1)Rh2(OAc)2 with 1 equiv of triphenylphosphite (bottom). Spectra were taken in 
MeOD at 2.6 mM concentration of metallopeptide. 
 
Figure 6-16. 1H NMR in the region 2.3-5.2 ppm. 
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Figure 6-17. 1H NMR  in the region 0.7-2.3 ppm. 
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Chapter 7 
Dirhodium metallopeptide as MDM2 ligands  
7.1. Introduction 
Multi-functional therapeutic and probe agents are increasingly 
important for the future of chemical biology and drug design. Different 
regions of a biologically active molecule may serve complementary roles, as 
in fragment-based drug design,1 or probes may include differing functions, 
incorporating binding and chemical function in a single unit.2 
Metallopeptides are attractive targets to be developed as biological probes. 
As hybrid structures of a metal complex and a polypeptide, they 
conveniently combine biochemical properties of peptides as protein ligands 
and various functions of metal that now can be directed to the protein 
interface. A transition-metal center may serve diverse roles, including 
stabilizing ligand secondary structure,3-5 increasing potency through 
secondary binding interactions,6 serving as spectroscopic handles,7 or 
facilitating electron transfer8-10 or catalytic activity.11-13  
As described in Chapter 4 and in the examples reported by others, 
metalation of a peptide can be used as a means of enforcing peptide helical 
conformation.3-5 Stabilization of the peptide secondary structure has the 
potential for improving activity of the peptide-based therapeutic agents. A 
large number of proteins utilize helical domains in protein-protein 
interactions that are often transient in nature and involved in signal 
transduction pathways.14-16 Targeting protein-protein interactions is an 
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important goal of today’s medicinal chemistry.17 Inhibition of these proteins 
with small-molecule drugs however is quite challenging due to a shallow 
binding interface, a fact that led to their label as “undruggable.”18 As a 
result, there is a growing interest in peptide- and protein- based therapeutics 
because of the benefits such as larger interaction surface and higher 
specificity. A success with peptide “stapling” methodology, where helical 
peptide structure is stabilized by a hydrocarbon tether, encourages 
development of other techniques that influence peptide conformation.19-22 
Interaction of metal chaperon proteins is mediated by metal binding to 
both of the interaction partners.6 The fact that metal ligation can provide a 
thermodynamic force for interaction in these systems suggests that a similar 
concept could be utilized in metallopeptide-protein interactions. Again, the 
idea would be highly beneficial for targeting proteins with weak affinities. 
Cooperative binding of the peptide ligand and the attached metal will 
provide both selectivity and an enhanced affinity that could lead to a more 
potent therapeutic (Figure 7-1, A). Protein domains are categorized into the 
families based on their structure and interacting partners. High similarity of 
the binding domains between many proteins creates a selectivity issue when 
only an individual protein needs to be targeted. These domains however may 
vary in position and distribution of the residues that are preferential for 
metal ligation, such as Lewis-basic residues histidine, cysteine and 
methionine. Thus improved selectivity can be attained with metallopeptide 
that spatially positions metal in the proximity to the ligating residue and 
ensures their interaction. 
Dirhodium has several advantages over other metal centers. Unlike 
many metal-ion–peptide interactions,23,24 dirhodium metalation of 
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Figure 7-1. Conceptual scheme depicting (A) cooperative interaction of a peptide and a 
dirhodium center with a protein’s biding pocket and (B) site-specific labeling of a protein 
catalyzed by the proximal dirhodium. 
 side chains yields kinetically inert coordination complexes, enabling 
purification and isolation.3 The covalent-like character of a dirhodium bond 
to the equatorial carboxylates ensures irreversible attachment of metal center 
to the peptide. The unique structure of the dirhodium core separates the 
equatorial sites that provide a robust connection to the peptide from the 
Lewis-acidic axial sites that are capable of reversible binding to electron-
donor ligands. Though complete studies of dirhodium metallopeptide 
biocompatibility, stability in biological environment, and cell permeability 
are yet to come, initial results demonstrate reasonable stability in cellular 
media and low toxicity.3  
In addition, dirhodium has useful catalytic, redox,25,26 and medicinal 
properties.27,28 Exciting results demonstrating utility of dirhodium 
metallopeptides for site-specific labeling of interacting partners has recently 
been presented from our lab.29-31 Coiled-coil assembly that serves as a model 
of protein-protein interaction was used to bring a dirhodium center on one 
peptide into the proximity to the amino-acid side chains on the 
complimentary peptide. Treatment of the assembly with a diazo reagent 
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leads to the catalytic decomposition of the reagent at the dirhodium to form a 
reactive metallocarbene intermediate. This intermediate undergoes an 
insertion reaction with the local amino acid on the complimentary peptide 
resulting in the covalent modification of the peptide substrate.30,31  The diazo 
reagent was further designed to carry a biotin affinity probe or a fluorophore. 
This technology can be potentially extended to enable protein 
functionalization by localizing a dirhodium core at the binding interface of 
the protein of interest (Figure 7-1, B). Targeting specific proteins with a 
dirhodium metallopeptide can be used to exploit and improve dirhodium’s 
ability for small-molecule sensing32 and DNA binding33 in the biological 
context. 
7.2. MDM2 protein 
The protein MDM2 is well studied, owing to its role in oncogenesis.34 
MDM2 regulates the p53 protein, which controls cell cycle and cellular 
responses to various stress factors (Figure 7-2). It is estimated that MDM2 is 
overexpressed in 50 % of cancers , resulting in suppression of p53 activity 
and survival of the tumor cells.35 Inhibition of the MDM2-p53 interaction is 
a validated approach to restore p53 function and activate natural cancer-
defense mechanisms.36 Significant efforts were made to invent potent 
inhibitors of MDM2, including small molecule, peptide and peptidomimetic 
structures (Figure 7-3).37,38 The binding domain of the p53 protein adopts an 
!-helical conformation and binds into the exposed hydrophobic pocket of 
MDM2 (Figure 7-4, A).39 A peptide fragment derived from the p53 domain 
displays reasonable affinity for MDM2 that was significantly improved by 
sequence optimization and utilization of unnatural amino acids.40-43 
Stabilization of the helical conformation by bridging peptide side chains is 
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another approach to improve ligand potency, as in the example of “stapled” 
peptides, and the metallopeptides presented here were designed according to 
this concept.22,44  
 
Figure 7-2. Defense function of the p53 protein and its regulation by the MDM2. 
Overexpression of MDM2 in cancers results in suppression of p53 activity. 
 
Figure 7-3. Peptide based on the wild type p53 sequence (top) and a few examples 
peptide and small molecule inhibitors of the MDM2. 
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7.3. Dirhodium metallopeptide design 
Four metallopeptides were designed that are based on the wild-type 
sequence of the MDM2 binding domain. The natural sequence contains three 
carboxylate residues that can contribute to protein-protein interaction. 
Aspartate and glutamate residues often play crucial role for binding, such as 
in the example of highly conserved aspartate of BH3-Bcl2 interactions.45 To 
evaluate importance of the acidic residues in this case, two peptides (P2-
Rh2(OAc)2 and P4-Rh2(OAc)2) were made using an orthogonal protection 
scheme described in Chapter 4, preserving one or both of the native 
glutamate residues (Table 7-1). In addition, two other metallopeptides (P6-
Rh2(OAc)2 and P7-Rh2(OAc)2) were synthesized with the sequence derived 
from an alternative peptide (P5) with improved affinity (Table 7-1).46 Two 
glutamate residues were positioned in the i, i+4 arrangement to provide 
ligand sites for metalation with bidentate cis-Rh2(tfa)2(OAc)2 precursor. Two  
 
Figure 7-4. (A) MDM2 protein with bound p53 helical peptide. Annotated residues 
(based on the sequence in the Table 7-1 are positioned on the exposed side of the helix 
and were chosen as the dirhodium metalation sites. (B) Model of the metallopeptide P7-
Rh2(OAc)2 bound to the MDM2. The model is created using Spartan, starting from a 
reported MDM2–peptide structure (PDB ID: 1YCR).  
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Table 7-1. Peptide sequences and MDM2 affinity (Kd) obtained by a fluorescence 
polarization assay. [Rh2] stands for bridging Rh2(OAc)2 metallocenter and * indicates that 
metallopeptides are functionalized with fluorescein bound through "-alanine linker.  
 
registers of metalation were tested, with the dirhodium bridging residues in 
positions 4 and 8 or 8 and 12 (Figure 7-4, A). The positions of glutamate 
residues were chosen based on the previous structural data to ensure the 
metal core is directed away from the binding interface, thus avoiding steric 
clashes with the protein surface (Figure 7-4, B).39 Peptides were synthesized 
with N-terminal "-alanine amino acid as a linker to a fluorescein moiety that 
is necessary for the fluorescence polarization studies. 
7.4. Fluorescence polarization affinity measurements 
Affinities for MDM2 were assessed by fluorescence polarization 
anisotropy (Figure 7-5).47 The p53-binding region of MDM2, residues 5–
109, was prepared using a published method for high-yielding protein 
expression.48 In our hands, MDM2 [5–109] binds the wild-type sequence 
entry 
*LSQETFSDLWKLLPEN 
*QSQETFSELWRLLPQN 
*QSQETFSELWRLLPEN 
*QSQQTFSELWRELPQN 
*QSQETFSELWRELPEN 
   *LTFSDYWAQLTS 
   *ETFSEYWAQLTS 
   *LTFSEYWAELTS 
name sequence 
1 
2 
3 
4 
5 
6 
7 
8 
WT 
P1-Rh2(OAc)2  
P2-Rh2(OAc)2 
P3-Rh2(OAc)2 
P4-Rh2(OAc)2 
P5 
P6-Rh2(OAc)2 
P7-Rh2(OAc)2   
[Rh2] 
[Rh2] 
[Rh2] 
[Rh2] 
[Rh2] 
[Rh2] 
1.9±0.3 
3.0±0.5 
2.0±0.7 
7.0±1.0 
9.0±1.2 
0.066±0.013 
0.77±0.020 
0.131±0.030 
Kd(µM) 
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(WT) with Kd = 1.9 *M, consistent with a previous report for the MDM2 
peptide-binding domain without N-terminal truncation.47,49 For 
metallopeptide variants based on p53-WT, the register of metalation has an 
impact on binding affinity, despite the fact that both registers should position 
the dirhodium core away from the binding interface (Figure 7-4, A). 
Dirhodium chelation at residues 4 and 8 (P1-Rh2(OAc)2 and P2-Rh2(OAc)2) 
provides affinity comparable to the wild-type sequence, while chelation at 
residues 8 and 12 (P3-Rh2(OAc)2 and P4-Rh2(OAc)2)  provides considerably
 
 
 
Figure 7-5. Fluorescence polarization assays with FITC-dirhodium peptides and MDM2 
[5-109] protein.  
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weaker affinity. This trend between metal-binding registers is mirrored in 
two other metallopeptides (P6-Rh2(OAc)2 and P7-Rh2(OAc)2)  based on a 
previously reported sequence (P5) with improved affinity.50 The peptide P5 
bound MDM2 with Kd = 66 nM. The corresponding metallopeptide with the 
N-terminal binding register (P6-Rh2(OAc)2) demonstrated comparable 
affinity (77 nM), while that with the C-terminal binding register (P7-
Rh2(OAc)2) exhibited decreased affinity. Although register does impact 
affinity significantly, peptide charge and the free carboxylate side chains 
have a surprisingly minimal effect, especially given the close proximity of 
E4 and E15 to the binding interface.  
7.5. Conclusions 
This chapter describes multifunctional MDM2 ligands that 
incorporate a peptide binding sequence, an organic dye molecule, and a 
catalytically active transition-metal center. The designed metallopeptides 
were demonstrated to retain high affinity to the MDM2 protein with bridging 
metalation not interfering with binding. The chelated metallopeptides 
employed here were in part designed to stabilize helical secondary 
structure.3,22,51 However the examined metallopeptides do not exhibit 
increased affinity compared to corresponding free peptides. Evidence 
indicates that the benefits of helix stabilization go beyond simple affinity 
concerns. In Verdine’s work stapling non-natural alkenyl side chains in the 
MDM2-p53 system, a modest increase in Kd (from 100 to 55 nM over an 
unstapled control) led to a large improvement in apoptosis reactivation, 
suggesting that stapling offers other benefits such as cell permeability, 
degradative stability, and/or target specificity. 
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The ability to produce a complex dirhodium metallopeptide that bind 
to natural protein targets provides a foundation for various applications, such 
as development of stable hybrid inorganic-organic structures as therapeutic 
agents and dirhodium-catalyzed site-specific functionalization with diazo 
reagents.31  It also offers tools to localize dirhodium centers for applications 
as diverse as electron-transfer, small molecule sensing,32 and UV-vis 
spectroscopy.  
7.6. Experimental section 
7.6.1. General considerations 
Peptide synthesis. All peptides were synthesized with an Advanced 
ChemTech APEX 396 Automated Multipeptide Synthesizer using standard 
solid-phase Fmoc protocols. The purification was accomplished by reverse-
phase HPLC with gradients of water-acetonitrile containing 0.1% 
trifluoroacetic acid, and peptides were isolated by lyophilization. Analysis 
and purity assessment was attained by mass spectrometry and analytical 
HPLC. Peptides were prepared using Rink amide MBHA resin (AAPPTEC) 
to afford the C-terminal amide.   
HPLC. HPLC was performed on a Shimadzu CBM-20A instrument 
with Phenomenex Jupiter 4* Proteo 90A (250 ( 15 mm preparative) and 
Phenomenex Jupiter 4* Proteo 90A (250 ( 4.6 mm analytical) columns. 
Flow rates of 8 mL/min and 1 mL/min were used for preparative and 
analytical columns, respectively. Analytical and preparative HPLC were 
performed with gradient of acetonitrile in water. Both solvents contained 
0.1% trifluoroacetic acid (TFA) unless otherwise noted. Spectra were 
obtained using UV-vis detection at 220 nm and 300 nm.  
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Mass Spectrometry. MALDI-MS and MS/MS were performed on a 
Bruker Daltonics Autoflex MALDI- TOF/TOF mass spectrometer with 
CHCA matrix (10 mg/mL, Thermo Scientific Pierce) for peptide analyses 
and DHAP matrix (10 mg/mL) for protein analyses. ESI-MS was performed 
on Bruker Daltonics micrOTOF instrument.  
7.6.2. Experimental Procedures 
General procedure for metallopeptide synthesis. Peptide (1 equiv) 
and cis-Rh2(tfa)2(OAc)2 precursor (1 equiv) were dissolved in MES buffer 
(0.1 M, volume calculated for 1 mM concentration of peptide) and pH 
adjusted to 4.5 with NaOH (0.1 M) if necessary. The reaction was heated to 
50 °C for 3 h and monitored by HPLC. Purification of the metallopeptides 
was performed by direct injection of the reaction mixture on a preparative 
RP-HPLC column. All complexes were isolated as a green solid upon 
lyophilization. 
General procedure for palladium deprotection.  Allyl deprotection 
was performed directly on the crude metalation reaction (1 mM in MES 
buffer, pH 4.5). A solution of Pd(PPh3)4 (0.5 equiv) and morpholine (10 
equiv) in tetrahydrofuran (volume is equivalent to the volume of buffer 
solution in the preceding reaction, i.e. 50/50 THF:water final solution) were 
added to the crude metalation reaction and the pH was adjusted to 7.0 with 
KOH (0.1 M aq solution).52 The reaction was monitored by HPLC, reaching 
completion after 0.5–1.5 h. Metallopeptides were purified by RP-HPLC, 
isolated by lyophilization, and characterized by ESI–MS. Using this general 
procedure P4 peptide (1.80 mg) was converted to the unlabeled P4-
Rh2(OAc)2 metallopeptide (1.06 mg, 53%). (note: deprotection can be 
performed on isolated metallopeptide as well) 
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General procedure for labeling with fluorescein. Solution of 
fluorescein isothiocyanate (FITC) (1.5 equiv) in DMSO (volume is 
calculated for a final 0.1 mM concentration of metallopeptide) was added to 
a lyophilized metallopeptide (typically 0.1-0.2 mg), followed by addition of 
diisopropylethylamine (5 equiv). The reaction mixture was quenched with 
methanol (5x rxn volume), diluted with water (5x rxn volume), purified by 
RP-HPLC (without TFA in the eluent) and characterized by ESI–MS. 
Lyophilized labeled metallopeptides were dissolved in DMSO (50 *L) and 
concentrations of these solutions were determined by absorbance at 492 nm 
(. = 83000 M-1cm-1) after dilution in Tris buffer (20 mM Tris pH 8, 200 mM 
NaCl) to achieve 0.2-1.0 absorbance values.50 Using this general procedure 
P3-Rh2(OAc)2  unlabeled metallopeptide (0.64 mg) was converted to the 
fluorescein-P3-Rh2(OAc)2 metallopeptide (0.49 mg, 68%). 
Protein expression. The protein MDM2 [5–109] was expressed in 
BL21 E. coli (Rosetta) cells as a fusion with its interaction partner, the p53 
transactivation peptide, which has been shown to afford dramatically higher 
yields.48 The MDM2 plasmid was purchased from Genscript in pET15b 
vector. After expression, cells were lysed by freezing at /80 °C. Due to 
instability of the protein, subsequent steps should be performed in minimal 
time. The lysate was purified on Ni-NTA affinity column with stepwise 
increase in concentration of imidazole in the eluent buffer 50 mM/ 100 mM/ 
300 mM (Figure 7-26). After analysis by SDS-PAGE gel, most concentrated 
and clean fractions were combined and dialyzed. His-tag and the fusion 
peptide were cleaved with 100 U/mg TEV protease at rt overnight or 4 °C 
for 48 h (Figure 7-27). MDM2 protein was purified by a second Ni-column 
and used immediately in binding measurements. Concentration of the 
protein was determined by absorbance at 280 nm (. = 8960 M-1cm-1) 
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Fluorescence polarization. Fluorescence polarization data were 
acquired on Nanolog (Horiba Jobin Yvon) Spectrometer with 16.5F-Q-10 
quartz cells (1 cm path length). 200-nM stock solutions of the labeled 
metallopeptides in DMSO were prepared. Samples were made by adding 4 
*L of metallopeptide solution (10 nM final concentration) to 76 *L of 
MDM2 solution of various concentrations in Tris buffer (20 mM Tris pH 
8.0, 200 mM NaCl, 2 *M mercaptoethanol) and incubation for 30 min at rt. 
Measurements were obtained by excitation at 485 nm with 6 nm slit width 
and emission detection at 512 nm with 6 nm slit width. 10 data points each 
integrated over 3 seconds were collected. Binding curves and Kd values were 
generated in Excel using a non-linear least-squares fit to the equation53:  
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where L0 is the concentration of the peptide, P0 is the concentration of 
the protein, Kd is the dissociation constant, FPmin is the low limit of the curve 
and FPmax is the high limit of the curve.22 Kd, FPmin and FPmax were all 
floating parameters during the non-linear least-squares fitting. 
MDM2 model (Figure 7-4). Model structure was prepared based on 
PDB coordinates 1YCR of p53-wild type peptide and N-terminal binding 
domain MDM2 [17-125]. The coordinates for p53 peptide were manually 
extracted into a separate file (pdb) and the structure was altered in Spartan to 
represent P1-Rh2(OAc)2. The complete assembly was “frozen” and only the 
side chains of glutamates that are bound to the dirhodium core were released 
for molecular mechanic (MMFF) optimization. The optimized P1-
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Rh2(OAc)2 structure was exported in PDB format and overlaid with MDM2 
in PyMOL.   
7.6.3. Analytical data 
 
Figure 7-6. HPLC trace and MS data for isolated P1 peptide. 
 
Figure 7-7! HPLC trace of crudes of metalation reaction (top) and fluorescein labeling 
with FITC (bottom) for P1-Rh2(OAc)2 metallopeptide synthesis. 
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Figure 7-8. HPLC trace and MS data of purified product for P1-Rh2(OAc)2 
metallopeptide synthesis before (top) and after (bottom) fluorescein labeling with FITC. 
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Figure 7-9%&HPLC trace and MS data for isolated P2 peptide. 
"
 
Figure 7-10%& HPLC trace of crudes of metalation reaction (top), in-situ palladium 
deprotection (center) and fluorescein labeling with FITC (bottom) for P2-Rh2(OAc)2 
metallopeptide synthesis. 
!"#$%&'
( ) *+ ** *, *- *. */ *0 *1 *(
SPD-20A Ch2-300nm
AZ7-82-pf4''
AZ7-82-pf4''.dat
!"#$%&'
( ) * + , -( -) -* -+ -, )(
!"#$%&'
( ) * + , -( -) -* -+ -, )(
!"#$%&'
( ) * + , -( -) -* -+ -, )(
SPD-20A Ch2-300nm
AZ7-19-1
AZ7-19-1.dat
  180 
 
 
Figure 7-11. HPLC trace and MS data of purified product for P2-Rh2(OAc)2 
metallopeptide synthesis before (top) and after (bottom) fluorescein labeling with FITC. 
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Figure 7-12. HPLC trace and MS data for isolated P3 peptide. 
 
Figure 7-13%&HPLC trace of crudes of metalation reaction (top) and fluorescein labeling 
with FITC (bottom) for P3-Rh2(OAc)2 metallopeptide synthesis. 
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Figure 7-14. HPLC trace and MS data of purified product for P3-Rh2(OAc)2 
metallopeptide synthesis before (top) and after (bottom) fluorescein labeling with FITC. 
 
 
!"#$%&'
( ) *+ ** *, *- *. */ *0 *1 *(
SPD-20A Ch2-300nm
AZ7-82-pf5Rh
AZ7-82-pf5Rh.dat
!"#$%&'
( ) *+ ** *, *- *. */ *0 *1 *(
SPD-20A Ch2-300nm
AZ7-70-test-F5Rh
AZ7-70-test-F5Rh.dat
  183 
 
Figure 7-15%&HPLC trace and MS data for isolated P4 peptide. 
 
"
 
 
Figure 7-16%& HPLC trace of crudes of metalation reaction (top), in-situ palladium 
deprotection (center) and fluorescein labeling with FITC (bottom) for P4-Rh2(OAc)2 
metallopeptide synthesis. 
!"#$%&'
( ) *+ ** *, *- *. */ *0 *1 *(
SPD-20A Ch2-300nm
AZ7-82-pf6all
AZ7-82-pf6all.dat
!"#$%&'
( ) * + , -( -) -* -+ -, )(
!"#$%&'
( ) * + , -( -) -* -+ -, )(
!"#$%&'
( ) * + , -( -) -* -+ -, )(
SPD-20A Ch2-300nm
AZ7-97-F6Rh-1
AZ7-97-F6Rh-1.dat
  184 
 
 
Figure 7-17. HPLC trace and MS data of purified product for P4-Rh2(OAc)2 
metallopeptide synthesis before (top) and after (bottom) fluorescein labeling with FITC. 
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Figure 7-18%&HPLC trace and MS data for isolated P6 peptide. 
"
 
Figure 7-19%&HPLC trace of crudes of metalation reaction (top) and fluorescein labeling 
with FITC (bottom) for P6-Rh2(OAc)2 metallopeptide synthesis. 
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Figure 7-20. HPLC trace and MS data of purified product for P6-Rh2(OAc)2 
metallopeptide synthesis before (top) and after (bottom) fluorescein labeling with FITC. 
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Figure 7-21%&HPLC trace and MS data for isolated P7 peptide. 
"
 
Figure 7-22%&HPLC trace of crudes of metalation reaction (top) and fluorescein labeling 
with FITC (bottom) for P7-Rh2(OAc)2 metallopeptide synthesis. 
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Figure 7-23. HPLC trace and MS data of purified product for P7-Rh2(OAc)2 
metallopeptide synthesis before (top) and after (bottom) fluorescein labeling with FITC. 
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Figure 7-24%&HPLC trace and MS data for isolated fluorescein-p53-WT peptide. 
 
Figure 7-25%&HPLC trace and MS data for isolated fluorescein-P5 peptide. 
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Figure 7-26. SDS-page gel of MDM2 protein purification by Ni-NTA affinity column 
with gradient concentration of imidazole (wash 2 and 3 – 20 mM, elute 1 – 50 nM, elute 
2 and 3 – 100 mM, elute 4-7 – 300 mM). 
 
Figure 7-27. MALDI (at 4 °C (top) and rt (bottom) after 12 h rxn) and SDS-page gel for 
TEV protease cleavage of the His-tag and auxiliary peptide from the MDM2 protein. 
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